
<html lang="en"     class="pb-page"  data-request-id="19068a15-7088-44c5-a8f0-7fa2408d86f5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-7;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c02161;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC)" /></meta><meta name="dc.Creator" content="Kuojun  Zhang" /></meta><meta name="dc.Creator" content="Zhiyi  Liu" /></meta><meta name="dc.Creator" content="Yiwu  Yao" /></meta><meta name="dc.Creator" content="Yatao  Qiu" /></meta><meta name="dc.Creator" content="Feng  Li" /></meta><meta name="dc.Creator" content="Dong  Chen" /></meta><meta name="dc.Creator" content="Dale J.  Hamilton" /></meta><meta name="dc.Creator" content="Zheng  Li" /></meta><meta name="dc.Creator" content="Sheng  Jiang" /></meta><meta name="dc.Description" content="Abnormally high levels of class I histone deacetylases (HDACs) are associated with triple-negative breast cancer (TNBC) proliferation, malignant transformation, and poor prognosis of patients. Here..." /></meta><meta name="Description" content="Abnormally high levels of class I histone deacetylases (HDACs) are associated with triple-negative breast cancer (TNBC) proliferation, malignant transformation, and poor prognosis of patients. Here..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 22, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02161" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02161" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02161" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02161" /></link>
        
    
    

<title>Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02161" /></meta><meta property="og:title" content="Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0013.jpeg" /></meta><meta property="og:description" content="Abnormally high levels of class I histone deacetylases (HDACs) are associated with triple-negative breast cancer (TNBC) proliferation, malignant transformation, and poor prognosis of patients. Herein, we report a near-infrared imaging probe for TNBC detection via visualizing class I HDACs. Conjugating Cy5.5 to a cyclic depsipeptide inhibitor, we obtained the probe (20-Cy5.5) that retained desirable class I HDAC affinity and selectivity. Then, this probe could visualize epigenetic changes by class I HDACs in TNBC MDA-MB-231 cells and in xenograft tumor models in real time. Treatment with suberoylanilide hydroxamic acid (SAHA) significantly reduced the uptake of the probe in tumors, suggesting its potential use in evaluation of therapeutic responses of HDACi-mediated therapy. Moreover, 20-Cy5.5 could detect class I HDAC expression in TNBC lung metastasis. This novel NIR probe that achieves tumor class I HDAC imaging not only leads to a better understanding of epigenetic regulation in tumors but also has great potential for improving the TNBC diagnosis and treatment." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02161"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02161">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02161&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02161&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02161&amp;href=/doi/10.1021/acs.jmedchem.0c02161" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 4020-4033</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02157" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c02170" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC)</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Kuojun Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kuojun Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kuojun++Zhang">Kuojun Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhiyi Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhiyi Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Bioenergetics, Houston Methodist Research Institute, 6670 Bertner, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhiyi++Liu">Zhiyi Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yiwu Yao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yiwu Yao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yiwu++Yao">Yiwu Yao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yatao Qiu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yatao Qiu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yatao++Qiu">Yatao Qiu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Feng Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Feng Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Bioenergetics, Houston Methodist Research Institute, 6670 Bertner, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Feng++Li">Feng Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dong Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dong Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dong++Chen">Dong Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dale J. Hamilton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dale J. Hamilton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Bioenergetics, Houston Methodist Research Institute, 6670 Bertner, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dale+J.++Hamilton">Dale J. Hamilton</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zheng Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zheng Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Bioenergetics, Houston Methodist Research Institute, 6670 Bertner, Houston, Texas 77030, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#1d6771745d5572686e697273507869757279746e6933726f7a"><span class="__cf_email__" data-cfemail="52283e3b121a3d2721263d3c1f37263a3d363b21267c3d2035">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zheng++Li">Zheng Li</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Sheng Jiang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sheng Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#96fcfff7f8f1e5feafd6f1fbf7fffab8f5f9fb"><span class="__cf_email__" data-cfemail="4b21222a252c3823720b2c262a222765282426">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sheng++Jiang">Sheng Jiang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4550-5024" title="Orcid link">http://orcid.org/0000-0002-4550-5024</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02161&amp;href=/doi/10.1021%2Facs.jmedchem.0c02161" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 4020–4033</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 22, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 December 2020</li><li><span class="item_label"><b>Published</b> online</span>22 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 April 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02161" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02161</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4020%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DKuojun%2BZhang%252C%2BZhiyi%2BLiu%252C%2BYiwu%2BYao%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D7%26contentID%3Dacs.jmedchem.0c02161%26title%3DStructure-Based%2BDesign%2Bof%2Ba%2BSelective%2BClass%2BI%2BHistone%2BDeacetylase%2B%2528HDAC%2529%2BNear-Infrared%2B%2528NIR%2529%2BProbe%2Bfor%2BEpigenetic%2BRegulation%2BDetection%2Bin%2BTriple-Negative%2BBreast%2BCancer%2B%2528TNBC%2529%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4033%26publicationDate%3DApril%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02161"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1103</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02161" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Kuojun&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Zhiyi&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Yiwu&quot;,&quot;last_name&quot;:&quot;Yao&quot;},{&quot;first_name&quot;:&quot;Yatao&quot;,&quot;last_name&quot;:&quot;Qiu&quot;},{&quot;first_name&quot;:&quot;Feng&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Dong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Dale&quot;,&quot;last_name&quot;:&quot;J. Hamilton&quot;},{&quot;first_name&quot;:&quot;Zheng&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Sheng&quot;,&quot;last_name&quot;:&quot;Jiang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;4020-4033&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02161&quot;},&quot;abstract&quot;:&quot;Abnormally high levels of class I histone deacetylases (HDACs) are associated with triple-negative breast cancer (TNBC) proliferation, malignant transformation, and poor prognosis of patients. Herein, we report a near-infrared imaging probe for TNBC detection via visualizing class I HDACs. Conjugating Cy5.5 to a cyclic depsipeptide inhibitor, we obtained the probe (20-Cy5.5) that retained desirable class I HDAC affinity and selectivity. Then, this probe could visualize epigenetic changes by class I HDACs in TNBC MDA-MB-231 cells and in xenograft tumor models in real time. Treatment with suberoylanilide hydroxamic acid (SAHA) significantly reduced the uptake of the probe in tumors, suggesting its potential use in evaluation of therapeutic responses of HDACi-mediated therapy. Moreover, 20-Cy5.5 could detect class I HDAC expression in TNBC lung metastasis. This novel NIR probe that achieves tumor class I HDAC imaging not only leads to a better understanding of epigenetic regulation in tumors but also has great p&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02161&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02161" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02161&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02161" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02161&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02161" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02161&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02161&amp;href=/doi/10.1021/acs.jmedchem.0c02161" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02161" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02161" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02161%26sid%3Dliteratum%253Aachs%26pmid%3D33745280%26genre%3Darticle%26aulast%3DZhang%26date%3D2021%26atitle%3DStructure-Based%2BDesign%2Bof%2Ba%2BSelective%2BClass%2BI%2BHistone%2BDeacetylase%2B%2528HDAC%2529%2BNear-Infrared%2B%2528NIR%2529%2BProbe%2Bfor%2BEpigenetic%2BRegulation%2BDetection%2Bin%2BTriple-Negative%2BBreast%2BCancer%2B%2528TNBC%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D7%26spage%3D4020%26epage%3D4033%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291400" title="Fluorescence imaging">Fluorescence imaging</a>,</li><li><a href="/action/doSearch?ConceptID=290997" title="Biological imaging">Biological imaging</a>,</li><li><a href="/action/doSearch?ConceptID=292601" title="Probes">Probes</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/jmcmar.2021.64.issue-7/20210408/jmcmar.2021.64.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Abnormally high levels of class I histone deacetylases (HDACs) are associated with triple-negative breast cancer (TNBC) proliferation, malignant transformation, and poor prognosis of patients. Herein, we report a near-infrared imaging probe for TNBC detection via visualizing class I HDACs. Conjugating Cy5.5 to a cyclic depsipeptide inhibitor, we obtained the probe (<b>20</b>-Cy5.5) that retained desirable class I HDAC affinity and selectivity. Then, this probe could visualize epigenetic changes by class I HDACs in TNBC MDA-MB-231 cells and in xenograft tumor models in real time. Treatment with suberoylanilide hydroxamic acid (SAHA) significantly reduced the uptake of the probe in tumors, suggesting its potential use in evaluation of therapeutic responses of HDACi-mediated therapy. Moreover, <b>20</b>-Cy5.5 could detect class I HDAC expression in TNBC lung metastasis. This novel NIR probe that achieves tumor class I HDAC imaging not only leads to a better understanding of epigenetic regulation in tumors but also has great potential for improving the TNBC diagnosis and treatment.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Breast cancer is one of the main causes of death among women worldwide. Clinical staging and subtyping of breast cancers is very important for selecting suitable therapies.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Clinically, tumors that are immunohistochemically diagnosed as the lack of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) are classified as triple-negative breast cancer (TNBC), which account for about 10–20% of breast cancers.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> Compared with other subtypes, TNBC has higher recurrence, metastasis, and mortality rates.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> This subtype of breast cancers is not susceptive to hormone therapy and lacks targeted treatments.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Consequently, there is an urgent need to discover a biomarker for TNBC, to find methods of improving the diagnosis and staging, and to develop innovative therapies that can effectively control and manage TNBC.</div><div class="NLM_p">Histone deacetylases (HDACs) catalyze the removal of lysine residues’ acetyl group from histones and other cellular proteins, causing chromatin contraction and transcription repression.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Till now, there are 18 human HDACs having been found that are divided into four subclasses.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Among them, nuclear localized class I HDACs, especially HDACs <b>1</b>, <b>2</b>, and <b>3</b>, are abnormally upregulated in multiple tumor cells and play an important role in modulating gene expressions implicated in carcinogenesis.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Overexpressed class I HDACs correlate with poor prognosis of cancer patients including those with TNBC.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13">(9−13)</a> Moreover, selective class I HDAC inhibitors (HDACis) have been shown to trigger ER expression and attenuate TNBC tumor progression and metastasis.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18">(14−18)</a> Recently, studies revealed that class I HDACis can enhance tumor immunogenicity and sensitize TNBC to PD1-blockade.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> Class I HDACs thus represent a promising diagnostic and therapeutic biomarker for TNBC. Accordingly, imaging agents that selectively target class I HDACs are ideal pharmacological tools to visualize the dynamics of class I HDACs during carcinogenesis. This will contribute to the validation of the roles they play in carcinogenesis and definition of the underlying molecular mechanisms and may further advance the development of personalized HDAC-targeted cancer therapy. However, the sequences of HDAC isoforms in the active site are highly similar, which makes the development of class- or isoform-selective HDAC-targeted agents remain challenging.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><div class="NLM_p">To date, multiple HDACis have been reported and four, vorinostat (<b>1</b>),<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> romidepsin (<b>2</b>),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> belinostat (<b>3</b>),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and panobinostat (<b>4</b>)<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), were already on the market for clinical application. Currently, most of the known HDACis in clinical evaluations are pan-inhibitors.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> In addition to the reported HDAC imaging agents (<b>5</b>–<b>11</b>),<a onclick="showRef(event, 'ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35 ref36">(28−36)</a> limited noninvasive agents have been applied to cancer diagnosis as well as target occupancy of HDACis, most of which are based on pan-HDACi and are incapable of selectively labeling specific isoforms (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). For neuroimaging, HDAC class-selective positron emission tomography (PET) imaging agents, such as [<sup>11</sup>C]Martinostat (<b>12</b>),<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> [<sup>18</sup>F]MSG3 (<b>13</b>),<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and [<sup>18</sup>F]Bavarostat (<b>14</b>),<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> have been used in the central nervous system (CNS) to measure target occupancy but have not been applied to cancer diagnosis. Besides these affinity-based fluorescent inhibitors, some activity-based fluorescent probes produced by incorporating HDAC substrates into fluorescent dyes, such as compounds <b>15</b>–<b>18</b>, have also been reported. These probes cannot selectively label HDAC isoforms and were mainly investigated <i>in vitro</i> as chemical tools for the evaluation of HDAC activity.<a onclick="showRef(event, 'ref40 ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42 ref43">(40−43)</a> Therefore, discovery of class I HDAC-targeted imaging agents, particularly in TNBC where ER- and HER2-targeted imaging is not feasible, is highly desirable. This will contribute to the validation of the roles they play in carcinogenesis and the definition of the molecular mechanisms underlying cancer initiation and progression and further advance cancer diagnosis and HDAC-based personalized therapy. On the other hand, small molecules like HDACis have advantages superior to other ligands (like antibody-based ligands) in delivering the imaging moiety to tumors owing to their satisfactory pharmacokinetics, low immunogenicity, and the ease of their chemical modification.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selected HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Selected HDAC imaging agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0003.jpeg jm0c02161_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A near-infrared (NIR) fluorescence imaging probe is a robust tool for molecularly imaging diseases <i>in situ</i> since it is performed safer and easier without using ionizing radiation.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Also, it has some other significant advantages, including low tissue autofluorescence, low cost, and high sensitivity, where the minimum detectability is picomolar or even femtomolar concentrations of imaging agents.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> NIR imaging contributes to labeling of tumor biomarkers, therapeutic response evaluation, and target validation in preclinical stage. Herein, since the most reported probes suffer from a lack of selectivity among the HDAC isoforms, we report the rational design, chemical synthesis, and biological investigation of a novel optical probe for selective imaging of class I HDACs in TNBC tumors. The NIR probe (<b>20</b>-Cy5.5) that combines a targeting moiety (<b>20</b>) and an NIR fluorophore (Cy5.5) was developed for imaging of tumor class I HDACs in cell culture and in the TNBC orthotropic xenograft model, and for therapeutic evaluation of HDACis in the xenograft model. Most breast cancer deaths result from metastasis, which leads to the failure of major organs, and preventive diagnosis and early detection of the breast tumors, at either the primary or metastatic sites, will greatly reduce the mortality rate. We demonstrated the detection of TNBC lung metastatic lesions with <b>20-</b>Cy5.5. This work confirms our knowledge of the molecular design of class-specific HDAC-targeted agents/probes and may illuminate ways to clarify the function and mechanism of epigenetic processes in breast carcinogenesis, leading to the development of new TNBC treatment strategies.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87561" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87561" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Rational Design, Chemical Synthesis, and Biological Profiling of New Class I HDAC Inhibitors</h3><div class="NLM_p">To build an efficient fluorescent probe, we first designed an effective and specific HDAC-targeting moiety following the conjugation of the NIR fluorophore. We started with a macrocyclic HDACi structure because such inhibitors usually have complex capping groups, which can interact variously with the outer region of the HDAC enzyme exhibiting outstanding affinity and class- or isoform selectivity toward HDACs. In our previous study, we successfully identified a novel cyclic depsipeptide (<b>19</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) that selectively targets class I HDAC enzymes.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> From the perspective of SARs, the valine moiety in <b>19</b> is tolerated and could be replaced with amino acid residues of similar shape and size with minimal loss of potency toward HDACs.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> To introduce a functional group that could easily be connected to various fluorophores, we replaced the valine residue of <b>19</b> with a lysine residue that has an amino group bearing a long side chain. In addition, considering that the thiol ester present in <b>19</b> aimed at protecting the sulfhydryl is actually vulnerable to hydrolysis by extensively expressed esterases, we substituted the thiol ester of <b>19</b> with a disulfide bond that is more stable and cleaved by thiols that are relatively abundant in the tumor, such as glutathione (GSH).<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> Ultimately, the compound <b>20</b> containing a lysine residue and a disulfide bond was designed (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). Given that compounds <b>19</b> and <b>20</b> are actually prodrugs and that thiols are their active forms, we docked the thiols related to <b>19</b> and <b>20</b> to HDAC <b>1</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX">4BKX</a>), respectively.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> From the superposition of structures (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B), <b>19</b> and <b>20</b> adopt similar poses in the active site of HDAC1, and their thiol groups chelated to Zn<sup>2+</sup> within the enzyme active site coincide well. The thiazole moiety of <b>20</b> interacts with the aromatic ring of Phe205 through π–π stacking identical to that in <b>19</b>. In addition, the side chain of valine moiety in <b>19</b> occupies a shallow cleft formed by Leu271, His178, and Tyr204 in HDAC1, and the hydrophobic section of lysine side chain in <b>20</b> is located exactly in this cleft. The terminal amine of the lysine side chain in <b>20</b> is extended toward the solvent and has no direct interactions with the protein. It is conceivable that the amino group does not affect the binding affinity against HDAC1. Taken together, these observations suggest that compound <b>20</b> should retain the affinity and selectivity.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure-based design of class I HDACi. (A) Chemical structures of compounds <b>19</b> and <b>20</b>. (B) Overlay of docking poses of <b>19</b> and <b>20</b> thiols to HDAC1 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX">4BKX</a>). The <b>19</b>-thiol is shown in green and the <b>20</b>-thiol in violet. Zn<sup>2+</sup> is shown in indigo. The yellow arrow indicates the thiol moiety of <b>19</b> and <b>20</b> thiols. The green arrow indicates the valine of <b>19</b>-thiol, and the violet arrow indicates the lysine of <b>20</b>-thiol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of the targeting moiety (<b>20</b>) is depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Condensation of <b>21</b> with Boc-lys(Fmoc)-OH with the aid of EDCI at room temperature afforded compound <b>22</b>, followed by the removal of the Boc protecting group through treatment with TFA. Then, the deprotected intermediate was directly coupled with the acid (<b>26</b>) under the condition of HATU/HOAT/DIPEA furnishing the intermediate (<b>23</b>). The protecting group Trt of <b>23</b> was removed by the treatment with TES and TFA, and then the deprotected compound was reacted with <b>27</b> under the base of TEA to give cyclization precursor (<b>24</b>). The removal of the Boc and 2-(trimethylsilyl)ethoxy groups by TFA, macrolactamization, and subsequent piperidine-mediated removal of Fmoc protecting group yielded the desired compound (<b>20</b>).</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0011.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Targeting Moiety <b>20</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Conjugate <b>20-</b>Cy5.5</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>20</b> was tested for its inhibitory activity against HDAC isoforms <b>1</b>–<b>11</b> using the fluorescence resonance energy transfer (FRET) assay,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> with suberoylanilide hydroxamic acid (SAHA) (<b>1</b>) as the positive control. Before the assays, the compounds <b>19</b> and <b>20</b> were subjected to hydrolysis to release the corresponding <b>19</b> and <b>20</b> thiols. Consistent with the docking results, compound <b>20</b> retained the inhibitory activity and selectivity against HDACs 1, 2, and 3 (IC<sub>50</sub> = 5.8, 7.5, and 10.3 nM, respectively), with IC<sub>50</sub> values against classes II, III, and IV > 10 μM (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). We evaluated the antiproliferative activity of compound <b>20</b> against TNBC MDA-MB-231 cells and human normal fibroblast-like fetal lung Wi38 cells with a Cell Counting Kit-8 (CCK8) assay. The activity exhibited by compound <b>20</b> toward MDA-MB-231 cells was comparable to that of compound <b>19</b> (GI<sub>50</sub> = 11.9 and 11.3 nM, respectively), while <b>20</b> showed a dramatic increase in selectivity between cancer and normal cells (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibitory Activity (IC<sub>50</sub>) against HDAC Isoforms <b>1–11</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center"> </th><th class="rowsep1 colsep0" colspan="11" align="center" char="±">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="4" align="center" char="±">class I</th><th class="rowsep1 colsep0" colspan="4" align="center">class IIa</th><th class="rowsep1 colsep0" colspan="2" align="center">class IIb</th><th class="rowsep1 colsep0" align="center">class IV</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">HDAC1</th><th class="colsep0 rowsep0" align="center" char="±">HDAC2</th><th class="colsep0 rowsep0" align="center" char="±">HDAC3</th><th class="colsep0 rowsep0" align="center">HDAC8</th><th class="colsep0 rowsep0" align="center">HDAC4</th><th class="colsep0 rowsep0" align="center">HDAC5</th><th class="colsep0 rowsep0" align="center">HDAC7</th><th class="colsep0 rowsep0" align="center">HDAC9</th><th class="colsep0 rowsep0" align="center">HDAC6</th><th class="colsep0 rowsep0" align="center">HDAC10</th><th class="colsep0 rowsep0" align="center">HDAC11</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b>-thiol</td><td class="colsep0 rowsep0" align="char" char="±">5.8 ± 0.52</td><td class="colsep0 rowsep0" align="char" char="±">7.5 ± 0.81</td><td class="colsep0 rowsep0" align="char" char="±">10.3 ± 1.1</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b>-thiol</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.28</td><td class="colsep0 rowsep0" align="char" char="±">5.3 ± 0.69</td><td class="colsep0 rowsep0" align="char" char="±">8.9 ± 1.3</td><td class="colsep0 rowsep0" align="left">3960 ± 391</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">1810 ± 43.2</td><td class="colsep0 rowsep0" align="left">37 ± 3.5</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAHA</td><td class="colsep0 rowsep0" align="char" char="±">80.0 ± 12</td><td class="colsep0 rowsep0" align="char" char="±">230 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">90.0 ± 25</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">SAHA (<b>1</b>) is the positive control. Values are a mean ± standard error (SE) of three independent experiments, and the SE was generally lower than 10%.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">ND: not determined.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. <i>In Vitro</i> Assay of Antiproliferative Activity (GI<sub>50</sub>)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">GI<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">MDA-MB-231</th><th class="colsep0 rowsep0" align="center" char="±">Wi38</th><th class="colsep0 rowsep0" align="center">selectivity (Wi38/MDA-MB-231)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="char" char="±">11.9 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">2316.0 ± 210.3</td><td class="colsep0 rowsep0" align="left">194</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="char" char="±">11.3 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">363.2 ± 65.6</td><td class="colsep0 rowsep0" align="left">32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char="±">9.7 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">30.1 ± 6.1</td><td class="colsep0 rowsep0" align="left">3.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last"><b>2</b> is the positive control. Antiproliferative activity was evaluated with the CCK8 assay. Values are a mean ± standard error (SE) of three independent experiments, and the SE was generally lower than 20%.</p></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Design and Synthesis of <b>20</b>-Cy5.5</h3><div class="NLM_p">As described above, the targeting moiety (<b>20</b>) shows desired potency and selectivity for class I HADCs, and has good inhibitory potency against MDA-MB-231 cells. In addition, the terminal amino group of its lysine side chain protruded toward the solvent and thus was amenable to the modification at this point probably without affecting the binding affinity for HDAC1. Compound <b>20</b> is, therefore, an ideal targeting moiety for the construction of the NIR probe. The probe <b>20-</b>Cy5.5 was obtained by coupling Cy5.5 NHS ester to the terminal amine in the lysine side chain of <b>20</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) and subsequent purification through semipreparative HPLC, whose structure was confirmed by mass spectrometry (MS).</div><div class="NLM_p">The biochemical activity of <b>20</b>-Cy5.5 was evaluated against HDAC1, HDAC6, and a mixture of HDACs obtained from HeLa nuclear extracts using the FRET-based assay. As expected, the IC<sub>50</sub> value of <b>20</b>-Cy5.5 for HDAC1 was about 100-fold less than that of the HDAC-rich HeLa nuclear extracts (IC<sub>50</sub> = 8 and 824 nM, respectively), as depicted in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. In addition, the inhibition of HDAC6 by <b>20-</b>Cy5.5 (IC<sub>50</sub> = 70 nM) was not as potent as the inhibition of HDAC1 (IC<sub>50</sub> = 8 nM), suggesting that <b>20-</b>Cy5.5 selectively targets HDAC1. The fluorescent moiety did not affect the affinity of compound <b>20</b> for its targets, since <b>20-</b>Cy5.5 (IC<sub>50</sub> = 8 nM) showed comparable inhibitory potency toward HADC1 to that of unlabeled <b>20</b> (IC<sub>50</sub> = 5.8 nM).</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Concentration-dependent inhibition of HDAC enzyme activity by <b>20-Cy5.5</b>. Each point is a mean ± SD of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> <i>In Vitro</i> Imaging in TNBC MDA-MB-231 Cells</h3><div class="NLM_p">The <i>in vitro</i> binding of <b>20</b>-Cy5.5 was evaluated by incubation of the probe with TNBC MDA-MB-231 cells in which class I HDACs are overexpressed,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and its intracellular distribution was recorded by a confocal fluorescence microscope. The majority of the probe accumulated in the nucleus as indicated by the colocalization of the Cy5.5 signal (red) and the DAPI-stained nuclear signal (blue), which is the subcellular localization of class I HDACs (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Excess amount (∼100×) of unlabeled <b>20</b> could completely block the cellular uptake of <b>20</b>-Cy5.5 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) showing a highly specific uptake. Combined with the results from the <i>in vitro</i> binding assay, we concluded that <b>20</b>-Cy5.5 specifically targeted class I HDACs in cells.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Imaging of <b>20</b>-Cy5.5 binding to HDACs in MDA-MB-231 cells by confocal laser microscopy at 600× magnification. The cells were incubated with <b>20</b>-Cy5.5 alone (imaging group) or pretreated with excess amount (∼100×) of unlabeled <b>20</b> (blocking group). Blue indicates DAPI-stained nuclei, and red indicates NIR fluorescence of <b>20</b>-Cy5.5. The scale bar represents 10 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> <i>In Vivo</i> Fluorescence Imaging in the TNBC MDA-MB-231 Xenograft Model and <i>Ex Vivo</i> Biodistribution</h3><div class="NLM_p">After demonstrating that <b>20</b>-Cy5.5 exhibited selective HDAC targeting, we examined whether <b>20</b>-Cy5.5 can detect tumor class I HDACs <i>in vivo</i> by employing an MDA-MB-231 tumor xenograft model. Three nanomoles of the probe <b>20</b>-Cy5.5 was injected intravenously to nude mice implanted with MDA-MB-231 cells, and NIR fluorescence imaging at various time points was performed. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A, the tumor uptake of the probe can be visualized at 4 h post-injection (pi) and the signal continued to be enriched <i>in situ</i> throughout the remainder of the imaging process, as measured by the radiant efficiency of epifluorescence. The ratios of radiant efficiency of the fluorescence signals in tumor to normal tissues were plotted against time and are shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C, which displays the dynamics of probe enrichment in the tumor. In the imaging group, the tumor to normal tissue ratios peaked at 24 h pi and remained high until 48 h pi, and significant clearance of the background signal was observed at 48 h pi.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Imaging of <b>20</b>-Cy5.5 binding to HDACs in the MDA-MB-231 xenograft model. (A) NIR images of mice treated with the probe <b>20</b>-Cy5.5 (imaging group) alone or in the presence of unlabeled <b>20</b> (blocking group) at different time points. The white arrows indicate the tumors. (B) <i>In vivo</i> imaging for therapeutic response evaluation of HDACi at different time points. The mice were treated with SAHA (15 mg/kg, 3 days) followed by <b>20</b>-Cy5.5 imaging studies. The white arrows indicate the tumors. (C) Region of interest (ROI) study of tumor to normal tissue ratio of the probe <b>20</b>-Cy5.5. Each point is a mean ± SD of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Blocking studies were performed to further validate the <i>in vivo</i> specific binding of <b>20</b>-Cy5.5 by pretreatment of unlabeled <b>20</b> (15 mg/kg). It was clearly observed that the tumor uptake of the probe was decreased in the blocking group by unlabeled <b>20</b> throughout the entire time course of the study (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). In the blocking group, the tumor to normal tissue ratios are reduced by about 70% compared to the imaging group (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C, <i>p</i> < 0.01, unpaired Student’s <i>t</i> test).</div><div class="NLM_p">Next, we determined whether <b>20</b>-Cy5.5 can convey the diagnostic assessment upon the treatment of breast tumors by SAHA, a clinically used HDACi. SAHA (15 mg/kg/day) was administered to mice bearing MDA-MB-231 xenograft tumors for 3 days before the <b>20</b>-Cy5.5 imaging study. Interestingly, SAHA treatment significantly reduced the tumor uptake of the probe, as evidenced by the epifluorescence images (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B) and the quantification of the enrichment dynamics (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C, <i>p</i> < 0.01, unpaired Student’s <i>t</i> test), indicating that SAHA treatment reduced or blocked HDACs <i>in vivo</i>, thereby decreasing the uptake of <b>20</b>-Cy5.5 by the xenograft tumors. Thus, the probe <b>20</b>-Cy5.5 represents a promising tool for the measurement of target participation and evaluation of therapeutic response in HDACi-mediated cancer therapy.</div><div class="NLM_p">At 48 h pi, epifluorescence of major organs was <i>ex vivo</i> imaged (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A) and quantified (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B) to further confirm the <i>in vivo</i> specificity. Correlated with the <i>in vivo</i> results, the average radiant efficiency in tumors was significantly reduced in both the blocking group (<i>p</i> < 0.01, <i>n</i> = 3) and the SAHA treatment group (<i>p</i> < 0.01, <i>n</i> = 3). The tumor fluorescence intensities were calculated as (3.13 ± 0.70) × 10<sup>9</sup> photons/(s cm<sup>2</sup> sr) in the imaging group, (1.95 ± 0.16) × 10<sup>9</sup> photons/(s cm<sup>2</sup> sr) in the blocking group, and (1.33 ± 0.28) × 10<sup>9</sup> photons/(s cm<sup>2</sup> sr) in the SAHA treatment group. In addition, we observed robust fluorescence in the kidney in the imaging group ((3.06 ± 0.74) × 10<sup>9</sup> photons/(s cm<sup>2</sup> sr)), demonstrating <i>in vivo</i> renal excretion of the probe <b>20</b>-Cy5.5. With the exception of the muscle and gastrointestinal (GI) tract, other organs in the blocking group share a similar fluorescence intensity to that of the imaging group. Together, these results confirm that <b>20</b>-Cy5.5 could specifically image class I HDACs that are upregulated in TNBC.</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0009.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Biodistribution of <b>20</b>-Cy5.5 in the MDA-MB-231 xenograft model. (A) <i>Ex vivo</i> NIR images of organs collected from imaging, blocking, and SAHA-treated groups at 48 h pi. (B) Quantitative analysis of epifluorescence in the imaging group compared to the blocking and SAHA-treated groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> <i>In Vivo</i> Fluorescence Imaging in a Metastatic TNBC MDA-MB-231 Xenograft Model</h3><div class="NLM_p">It is well known that tumor metastasis is the most prominent problem in clinical treatment of TNBC, and it is urgent to find an effective method of indicating tumor metastasis at an earlier stage. Class I HDACs have been reported to be closely associated with tumor metastasis. Inspired by the promising results from the cellular and mouse studies, we further examined whether this probe can be used to indicate tumor metastasis. TNBC tumors preferentially metastasize to the brain or the lung (70%), rather than bone or liver (30%).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> We injected 3 nmol of the probe <b>20</b>-Cy5.5 intravenously to TNBC tumor-bearing NOD-SCID mice and at 24 h pi examined the lung metastatic lesion by <i>ex vivo</i> imaging. In the metastatic tumor model, the primary tumor cells were observed to metastasize to the lung, and this was confirmed by the presence of the green fluorescent protein (GFP) signals in the lung (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). Interestingly, the NIR signals were colocalized with the green fluorescence in the metastatic lung, whereas the normal lung did not show any NIR signals or green fluorescence (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). The enrichment of the probe was significantly higher in the metastatic lung than in the normal lung (8.0 ± 1.3 <i>vs</i> 2.2 ± 0.5, <i>p</i> < 0.01, Student’s <i>t</i> test, <i>n</i> = 3) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B). Immunohistochemistry (IHC) staining confirmed the high HDAC1 levels in the MDA-MB-231 xenograft tumors. Hematoxylin and eosin (H&E) staining of metastatic lung sections was performed to evaluate the morphology of the tumor cells (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C). Together, these results demonstrated the potential of the probe <b>20</b>-Cy5.5 imaging to assess TNBC metastasis.</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0010.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <i>Ex vivo</i> NIR fluorescence imaging with <b>20</b>-Cy5.5 for metastatic MDA-MB-231 xenograft tumors. (A) NIR imaging of lungs harvested from the mice treated with <b>20</b>-Cy5.5 at 24 h pi. NIR signals (red) were colocalized with metastatic tumor cells in the lung (green), but normal lung did not show any NIR signals or green fluorescence. The scale bar represents 1 cm. (B) Quantification of accumulation of <b>20</b>-Cy5.5 in normal and metastatic lungs. Error bars represent SD of triplicate measurements for ROI in lungs and background tissues. (C) IHC staining for HDAC1 in metastatic lungs and H&E staining for the physiological changes of metastatic lungs. The images were acquired by a 40× objective lens.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66150" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66150" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">NIR optical imaging for specific biomarkers has emerged as a powerful noninvasive technology for molecularly visualizing the disease <i>in vivo</i>. Given overexpressed HDACs, especially class I subtype, in breast cancers, a HDAC-targeted imaging probe is highly desirable for cancer detection and therapeutic response evaluation, particularly for TNBC where traditional imaging is not feasible. In this study, we successfully developed a first selective class I NIR imaging probe, <b>20</b>-Cy5.5, through the SAR study. Our results demonstrated that <b>20</b>-Cy5.5 is highly potent and specific and can noninvasively visualize class I HDAC expression in real time in TNBC primary tumor and lung metastasis. We also showed that the probe successfully detects dynamic changes during HDACi treatment. The ability to selectively detect isoform HDAC dynamics <i>in vivo</i> can greatly enhance our understanding of the critical roles of the HDAC epigenetic function in initiation, promotion, and regulation of TNBC. This NIR probe has great potential for accurate TNBC staging and HDAC therapy efficacy monitoring.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77365" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77365" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General Methods</h3><div class="NLM_p">All chemicals and reagents were purchased from commercial suppliers and used without further purification. Anhydrous dichloromethane (DCM) was freshly distilled from calcium hydride and tetrahydrofuran (THF) over sodium wire with benzophenone as an indicator. All other solvents were of reagent grade. All moisture-sensitive reactions were carried out in a flame-dried flask under an argon atmosphere. The progress of all reactions was monitored by TLC using ethyl acetate/n-hexane as the solvent system, and spots were visualized by irradiation with ultraviolet light (254 nm) or staining with phosphomolybdic acid. Flash chromatography was performed using silica gel (300–400 mesh). <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance ARX-400, ARX-500, or ARX-600. Chemical shifts δ are reported in ppm, and multiplicity of signals are denoted as follows: s = singlet, d = doublet, t = triplet, and m = multiplet. Low- or high-resolution ESIMS was recorded on an Agilent 1200 HPLC-MSD mass spectrometer or an Applied Biosystems Q-STAR Elite ESI-LC-MS/MS mass spectrometer. The purity of the final compounds was determined by liquid chromatography–mass spectrometry (LC-MS), which was recorded on a Shimadzu LC-2020 system (DUIS-ESI) under the following conditions: the solvents were programmed to run at gradient starting from 20% CH<sub>3</sub>CN in water to 80% during an 8.5 min run, with monitoring between 190 and 800 nm. A flow rate of 1.0 mL/min was used. The retention time was reported as <i>t</i><sub>R</sub> (min). The purity of final compounds was >95%.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 2-(Trimethylsilyl)ethyl(<i>S</i>,<i>E</i>)-3-((<i>N</i><sup>6</sup>-(((9<i>H</i>-fluoren-9-yl)methoxy)carbonyl)-<i>N</i><sup>2</sup>-(<i>tert</i>-butoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-lysyl)oxy)-7-(tritylthio)hept-4-enoate (<b>22</b>)</h4><div class="NLM_p last">To a solution of <b>21</b> (1 g, 1.93 mmol) and Boc-Lys(Fmoc)-OH (2.71 g, 5.79 mmol) in anhydrous DCM (5 mL) at 0 °C, EDCI (1.11 g, 5.79 mmol), DIPEA (1.03 mL, 5.79 mmol), and DMAP (50 mg, 0.39 mmol) were added successively. The mixture was stirred at room temperature until TLC showed disappearance of the reactant. Aqueous NH<sub>4</sub>Cl was added to the mixture, and the organic phase was separated, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated under reduced pressure, and purified by chromatography to afford compound <b>22</b> as a white foam solid (1.63 g, 87%). [α]<sub class="stack">D</sub><sup class="stack">23</sup> −8.0 (c 0.1, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.77 (d, <i>J</i> = 7.5 Hz, 2H), 7.61 (d, <i>J</i> = 7.3 Hz, 2H), 7.46–7.36 (m, 8H), 7.35–7.24 (m, 8H), 7.24–7.17 (m, 3H), 5.73–5.55 (m, 2H), 5.37 (dd, <i>J</i> = 7.3, 15.4 Hz, 1H), 5.06 (d, <i>J</i> = 8.0 Hz, 1H), 4.94–4.81 (m, 1H), 4.41 (d, <i>J</i> = 6.9 Hz, 2H), 4.30–4.19 (m, 2H), 4.16 (t, <i>J</i> = 6.8 Hz, 2H), 3.13 (q, <i>J</i> = 6.1 Hz, 2H), 2.68 (dd, <i>J</i> = 8.0, 15.8 Hz, 1H), 2.55 (dd, <i>J</i> = 5.5, 15.8 Hz, 1H), 2.19 (t, <i>J</i> = 6.8 Hz, 2H), 2.11–2.01 (m, 2H), 1.82–1.69 (m, 1H), 1.64–1.53 (m, 1H), 1.44 (s, 9H), 1.42–1.15 (m, 4H), 0.97 (t, <i>J</i> = 6.8 Hz, 2H), 0.04 (s, 9H). <sup>13</sup>C NMR (100 MHz, chloroform-<i>d</i>) δ 171.6, 169.8, 156.5, 155.5, 144.9, 144.1, 141.4, 133.7, 129.7, 128.0, 127.8, 127.8, 127.1, 126.7, 125.1, 120.1, 79.9, 71.8, 66.7, 66.6, 63.2, 53.2, 47.4, 40.8, 39.7, 32.5, 31.4, 31.2, 29.3, 28.4, 22.4, 17.4, −1.4. HRMS (ESI) calcd <i>m</i>/<i>z</i> for C<sub>57</sub>H<sub>69</sub>N<sub>2</sub>O<sub>8</sub>SSi [M + H]<sup>+</sup> 969.4544, found 969.4543.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 2-(Trimethylsilyl)ethyl(<i>S</i>,<i>E</i>)-3-((<i>N</i><sup>6</sup>-(((9<i>H</i>-fluoren-9-yl)methoxy)carbonyl)-<i>N</i><sup>2</sup>-((<i>Z</i>)-2-(2-(((<i>tert</i>-butoxycarbonyl)amino)methyl)thiazole-4-carboxamido)but-2-enoyl)-<span class="smallcaps smallerCapital">l</span>-lysyl)oxy)-7-(tritylthio)hept-4-enoate (<b>23</b>)</h4><div class="NLM_p">To a stirred solution of <b>22</b> (1.25 g, 1.29 mmol) in anhydrous DCM (15 mL) at 0 °C, trifluoroacetic acid (1.5 mL) was added. After stirring for 30 min at 0 °C, the reaction mixture was concentrated under reduced pressure to afford the amine for the next step.</div><div class="NLM_p last">To the solution of acid <b>26</b> (0.44 g, 1.42 mmol) in DCM (10 mL) cooled to 0 °C, HATU (0.35 g, 2.58 mmol), HOAt (0.63 g, 4.6 mmol) followed by addition of the amine mentioned above in DCM (5 mL), and DIPEA (0.92 mL, 5.16 mmol) were added. The reaction mixture was allowed to warm to room temperature and stirred for 12 h. Aqueous NH<sub>4</sub>Cl was added to the mixture, and the organic phase was separated, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated under reduced pressure, and purified by chromatography to afford a colorless viscous compound <b>23</b> (1.03 g, 86%). [α]<sub class="stack">D</sub><sup class="stack">23</sup> −0.4 (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.59 (s, 1H), 8.11 (s, 1H), 7.74 (d, <i>J</i> = 7.5 Hz, 2H), 7.59 (d, <i>J</i> = 7.4 Hz, 2H), 7.42–7.32 (m, 8H), 7.29–7.23 (m, 8H), 7.22–7.15 (m, 3H), 6.67 (d, <i>J</i> = 8.1 Hz, 1H), 6.55 (q, <i>J</i> = 6.8 Hz, 1H), 5.72–5.53 (m, 3H), 5.36 (dd, <i>J</i> = 7.3, 15.4 Hz, 2H), 4.66 (q, <i>J</i> = 7.4 Hz, 1H), 4.55 (d, <i>J</i> = 6.2 Hz, 2H), 4.43–4.25 (m, 2H), 4.24–4.08 (m, 3H), 3.27–3.00 (m, 2H), 2.67 (dd, <i>J</i> = 8.0, 15.9 Hz, 1H), 2.53 (dd, <i>J</i> = 5.5, 15.9 Hz, 1H), 2.17 (t, <i>J</i> = 6.8 Hz, 2H), 2.09–1.98 (m, 2H), 1.97–1.87 (m, 1H), 1.79 (d, <i>J</i> = 7.0 Hz, 3H), 1.69–1.53 (m, 1H), 1.46 (s, 9H), 1.45–1.20 (m, 4H), 0.95 (t, <i>J</i> = 6.8 Hz, 2H), 0.02 (s, 9H). <sup>13</sup>C NMR (100 MHz, chloroform-<i>d</i>) δ 171.3, 169.8, 164.3, 159.7, 156.7, 155.7, 148.7, 144.9, 144.1, 144.1, 141.3, 133.8, 129.8, 129.6, 128.8, 128.0, 127.7, 127.1, 127.1, 126.7, 125.3, 120.0, 80.6, 72.0, 66.7, 66.7, 63.3, 52.1, 47.4, 42.4, 40.5, 39.7, 32.0, 31.4, 31.2, 29.0, 28.4, 22.0, 17.4, 13.7, −1.4. HRMS (ESI) calcd <i>m</i>/<i>z</i> for C<sub>66</sub>H<sub>78</sub>N<sub>5</sub>O<sub>10</sub>S<sub>2</sub>Si [M + H]<sup>+</sup> 1192.4959, found 1192.4956.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 2-(Trimethylsilyl)ethyl(<i>S</i>,<i>E</i>)-3-((<i>N</i><sup>6</sup>-(((9<i>H</i>-fluoren-9-yl)methoxy)carbonyl)-<i>N</i><sup>2</sup>-((<i>Z</i>)-2-(2-(((<i>tert</i>-butoxycarbonyl)amino)methyl)thiazole-4-carboxamido)but-2-enoyl)-<span class="smallcaps smallerCapital">l</span>-lysyl)oxy)-7-(heptyldisulfaneyl)hept-4-enoate (<b>24</b>)</h4><div class="NLM_p last">To a stirred solution of <b>23</b> (1.95 g, 1.64 mmol) in DCM (12 mL) at 0 °C, TES (0.4 mL, 3.28 mmol) and TFA (1.2 mL, 16.4 mmol) were added. After stirring for 2 h at 0 °C, the reaction mixture was concentrated under reduced pressure to afford the residue, which was redissolved in DCM (15 mL). To the stirred mixture at 0 °C, compound <b>27</b> (0.57 g, 3.3 mmol) and TEA (0.42 mL, 3.0 mmol) were added. The reaction mixture was allowed to warm to room temperature and stirred for 4 h. Saturated aqueous NaCl was added to the mixture, and the organic phase was separated, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated under reduced pressure, and purified by chromatography to afford compound <b>24</b> as a white foam solid (0.93 g, 58%). [α]<sub class="stack">D</sub><sup class="stack">23</sup> −4.4 (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.62 (s, 1H), 8.13 (s, 1H), 7.74 (d, <i>J</i> = 7.4 Hz, 2H), 7.59 (d, <i>J</i> = 7.4 Hz, 2H), 7.37 (t, <i>J</i> = 7.4 Hz, 2H), 7.31–7.22 (m, 2H), 6.73 (d, <i>J</i> = 7.9 Hz, 1H), 6.57 (q, <i>J</i> = 6.7 Hz, 1H), 5.87–5.75 (m, 1H), 5.74–5.67 (m, 1H), 5.67–5.59 (m, 1H), 5.57–5.47 (m, 1H), 5.41 (s, 1H), 4.75–4.62 (m, 1H), 4.57 (d, <i>J</i> = 5.5 Hz, 2H), 4.42–4.26 (m, 2H), 4.25–4.08 (m, 3H), 3.30–3.06 (m, 2H), 2.77–2.51 (m, 6H), 2.48–2.34 (m, 2H), 2.04–1.88 (m, 1H), 1.80 (d, <i>J</i> = 7.0 Hz, 3H), 1.70–1.59 (m, 3H), 1.59–1.49 (m, 2H), 1.46 (s, 9H), 1.41–1.20 (m, 10H), 0.97 (t, <i>J</i> = 6.8 Hz, 2H), 0.88 (t, <i>J</i> = 6.6 Hz, 3H), 0.04 (s, 9H). <sup>13</sup>C NMR (100 MHz, chloroform-<i>d</i>) δ 171.3, 170.0, 169.8, 164.4, 159.7, 156.7, 155.7, 148.7, 144.1, 144.1, 141.3, 133.3, 129.8, 129.0, 128.2, 127.7, 127.1, 125.3, 120.0, 80.6, 72.0, 66.7, 63.3, 52.2, 47.4, 42.4, 40.5, 39.7, 39.1, 37.7, 31.9, 31.8, 31.7, 29.3, 29.1, 29.0, 28.5, 28.4, 22.7, 22.0, 17.4, 14.2, 13.7, −1.4. HRMS (ESI) calcd <i>m</i>/<i>z</i> for C<sub>54</sub>H<sub>78</sub>N<sub>5</sub>O<sub>10</sub>S<sub>3</sub>Si [M + H]<sup>+</sup> 1080.4680, found 1080.4676.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> (9<i>H</i>-Fluoren-9-yl)methyl(4-((12<i>Z</i>,4<i>Z</i>,7<i>S</i>,10<i>S</i>)-4-ethylidene-10-((<i>E</i>)-4-(heptyldisulfaneyl)but-1-en-1-yl)-2,5,8,12-tetraoxo-9-oxa-3,6,13-triaza-1(4,2)-thiazolacyclotetradecaphane-7-yl)butyl)carbamate (<b>25</b>)</h4><div class="NLM_p last">In a round-bottom flask, compound <b>24</b> (1.1 g, 1.0 mmol) was dissolved in DCM (20 mL), then trifluoroacetic acid (TFA) (4 mL) was added to the solution at 0 °C, and the reaction mixture was warmed to room temperature and then stirred for 12 h. The solvent was evaporated under reduced pressure to obtain a brown residue, which was further dissolved in DCM (100 mL). HATU (1.15 g, 3.0 mmol), HOAt (408 mg, 3.0 mmol), and DIPEA (776 mg, 6.0 mmol) were added successively to the reaction mixture. After stirring for 2 days at room temperature, the solvent was evaporated under reduced pressure. The crude product was extracted with ethyl acetate (20 mL × 3) and washed with sat. aq. NaHCO<sub>3</sub>, brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and then concentrated under reduced pressure. The resulting residue was loaded onto a silica gel column in hexane, and the column was eluted with hexane, EtOAc, and MeOH (10:10:1) to obtain compound <b>25</b> as a white solid (172 mg, 20%). [α]<sub class="stack">D</sub><sup class="stack">23</sup> 12.94 (c 0.34, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.59 (s, 1H), 8.07 (s, 1H), 7.75 (d, <i>J</i> = 7.5 Hz, 2H), 7.64–7.49 (m, 2H), 7.39 (t, <i>J</i> = 7.4 Hz, 2H), 7.30 (t, <i>J</i> = 7.4 Hz, 2H), 6.99 (q, <i>J</i> = 7.1 Hz, 1H), 6.81 (d, <i>J</i> = 9.6 Hz, 1H), 6.66–6.48 (m, 1H), 5.85–5.67 (m, 2H), 5.54 (dd, <i>J</i> = 6.9, 15.5 Hz, 1H), 5.38 (t, <i>J</i> = 5.2 Hz, 1H), 5.05 (dd, <i>J</i> = 7.3, 17.3 Hz, 1H), 4.91–4.77 (m, 1H), 4.41–4.25 (m, 3H), 4.20 (t, <i>J</i> = 6.9 Hz, 1H), 3.18–3.02 (m, 1H), 3.01–2.85 (m, 1H), 2.81–2.53 (m, 6H), 2.50–2.31 (m, 2H), 1.90 (s, 1H), 1.85 (d, <i>J</i> = 7.2 Hz, 3H), 1.75–1.57 (m, 3H), 1.40–1.31 (m, 3H), 1.31–1.14 (m, 9H), 0.87 (t, <i>J</i> = 6.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, chloroform-<i>d</i>) δ 170.2, 169.5, 167.3, 163.6, 158.4, 156.6, 148.2, 144.2, 144.1, 141.4, 134.3, 132.8, 128.4, 127.8, 127.2, 127.0, 125.3, 124.6, 120.0, 71.8, 66.6, 52.0, 47.4, 41.1, 40.9, 40.3, 39.3, 39.1, 37.6, 32.0, 31.8, 31.6, 29.3, 29.0, 28.6, 22.7, 22.3, 15.1, 14.2. HRMS (ESI) calcd <i>m</i>/<i>z</i> for C<sub>44</sub>H<sub>56</sub>N<sub>5</sub>O<sub>7</sub>S<sub>3</sub> [M + H]<sup>+</sup> 862.3342, found 862.3346.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> (1<sup>2</sup><i>Z</i>,4<i>Z</i>,7<i>S</i>,10<i>S</i>)-7-(4-Aminobutyl)-4-ethylidene-10-((<i>E</i>)-4-(heptyldisulfaneyl)but-1-en-1-yl)-9-oxa-3,6,13-triaza-1(4,2)-thiazolacyclotetradecaphane-2,5,8,12-tetraone (<b>20</b>)</h4><div class="NLM_p last">To a stirred solution of compound <b>25</b> (40 mg, 0.046 mmol) in MeCN (10 mL) at room temperature, piperidine (0.2 mL) was added. After stirring for 3 h at room temperature, the reaction mixture was concentrated under reduce pressure and purified by HPLC to afford compound <b>20</b> as a white solid (12 mg, 41%). [α]<sub class="stack">D</sub><sup class="stack">23</sup> 19.8 (c 0.1, MeOH); <sup>1</sup>H NMR (DMSO<i>-d</i><sub>6</sub>, 500 MHz), δ 9.08 (s, 1H), 8.43 (br, 1H), 8.28 (s, 1H), 8.07 (d, 1H, <i>J</i> = 9.0 Hz), 6.47 (m, 1H), 5.66–5.55 (m, 3H), 5.00–4.95 (m, 1H), 4.55–4.53 (m, 1H), 4.36–4.32 (m, 1H), 2.87–2.81 (m, 1H), 2.74–2.68 (m, 7H), 2.55 (m, 2H), 2.35 (m, 2H), 1.86–1.20 (m, 19H), 0.86 (m, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 173.6, 171.7, 168.8, 166.3, 160.9, 149.0, 133.9, 133.6, 129.9, 129.1, 125.8, 73.1, 53.3, 42.2, 40.6, 39.9, 39.7, 38.7, 32.9, 32.7, 32.4, 30.2, 30.0, 29.4, 28.1, 23.7, 23.5, 14.9, 14.4. HRMS (ESI) calcd <i>m</i>/<i>z</i> for C<sub>29</sub>H<sub>46</sub>N<sub>5</sub>O<sub>5</sub>S<sub>3</sub> [M + H]<sup>+</sup> 640.2661, found 640.2663. The purity of products was characterized by LC-MS, which was recorded on a Shimadzu LC-2020 system (DUIS-ESI). The solvents were programmed to run at gradient starting 20% CH<sub>3</sub>CN in water to 80% during 8.5 min run. HPLC analysis: 97.1% in purity.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Synthesis of the <b>20-</b>Cy5.5 Conjugate</h3><div class="NLM_p last">Compound <b>20</b> in dry dimethyl sulfoxide (DMSO) solution (0.2 mL, 10 μmol/mL, 2 μmol) and TEA (0.5 mL) was mixed with Cy5.5 mono NHS ester (2.5 mg, 2.2 μmol) in DMSO in the dark at ambient temperature. After stirring overnight in the dark at room temperature, the reaction was quenched by addition of 200 μL trifluoroacetic acid (TFA). The purification of the crude product was carried out on a semipreparative reversed-phase high-performance liquid chromatography (HPLC) system (Agilent 1200 series). Purification was performed on a Phenomenex Luna C18(2) column 100R (250 × 10.00 mm<sup>2</sup>). The flow was 4 mL/min, with the mobile phase starting from 70% solvent A (0.05 M ammonia acetate in water) and 30% solvent B (acetonitrile) to 50% solvent A and 50% solvent B at 20 min. The peak containing the <b>20</b>-Cy5.5 conjugate was collected, dissolved in dimethyl sulfoxide (DMSO) at a concentration of 10 μmol/mL, and stored in the dark at −20 °C until use. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.07 (s, 1H), 9.00 (dd, <i>J</i> = 9.2, 4.4 Hz, 1H), 8.52–8.37 (m, 4H), 8.33–8.17 (m, 3H), 8.06 (d, <i>J</i> = 9.1 Hz, 1H), 7.75 (dd, <i>J</i> = 9.4, 3.7 Hz, 2H), 7.70–7.66 (m, 1H), 7.24 (s, 1H), 6.64 (t, <i>J</i> = 12.8 Hz, 1H), 6.44 (q, <i>J</i> = 7.1 Hz, 1H), 6.36 (d, <i>J</i> = 13.8 Hz, 2H), 5.75–5.46 (m, 3H), 5.32 (t, <i>J</i> = 4.8 Hz, 1H), 4.95 (dd, <i>J</i> = 17.7, 8.3 Hz, 1H), 4.56–4.46 (m, 1H), 4.33–4.17 (m, 3H), 2.93–2.88 (m, 2H), 2.89–2.75 (m, 1H), 2.76–2.59 (m, 4H), 2.32 (q, <i>J</i> = 6.5 Hz, 2H), 2.15–1.87 (m, 12H), 1.85–1.73 (m, 2H), 1.69 (d, <i>J</i> = 7.1 Hz, 3H), 1.62–1.51 (m, 4H), 1.54–0.89 (m, 24H), 0.92–0.83 (m, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 174.32, 173.65, 173.21, 171.64, 170.42, 169.04, 167.57, 163.79, 157.52, 153.21, 147.57, 145.67, 145.47, 139.73, 139.34, 133.58, 133.47, 130.14, 129.76, 129.67, 129.61, 129.38, 128.79, 128.06, 127.58, 127.52, 126.85, 126.81, 125.42, 124.10, 123.86, 121.62, 118.97, 116.81, 114.87, 111.46, 111.22, 102.76, 102.42, 71.26, 51.52, 50.75, 50.71, 48.62, 41.40, 38.26, 37.83, 37.01, 35.21, 35.13, 34.38, 31.31, 31.17, 29.10, 29.05, 28.85, 28.72, 28.51, 28.26, 27.68, 27.09, 26.57, 25.85, 25.13, 25.02, 22.12, 22.04, 14.62, 13.96, 12.47. MS (ESI) calcd <i>m</i>/<i>z</i> for C<sub>70</sub>H<sub>87</sub>N<sub>7</sub>O<sub>18</sub>S<sub>7</sub> [M + H<sup>+</sup>] 1538.4, found 1538.4. The analytic HPLC method was performed with the same gradient system but with a Phenomenex Luna C18(2) column 100R (250 × 4.6 mm<sup>2</sup>), and the flow rate was 1 mL/min. The absorbance was monitored at 675 nm. HPLC analysis: 95.5% in purity.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Molecular Modeling</h3><div class="NLM_p last">The X-ray structure of HDAC1 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX">4BKX</a>) reported by Millard et al. was employed in the docking calculation. Since there is no ligand in the active site of HDAC1, we incorporated SAHA by superimposing the crystal structure of HDAC1 with a crystal structure of HDAC2 bound with SAHA. The protein and the ligand were, respectively, prepared using the protein preparation wizard and ligprep modules of the Schrodinger Suite 2009. Glide SP was used for the docking calculation. The docked poses were evaluated by GlideScore.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> HDAC Inhibition Assay by Cyclic Depsipeptides and <b>20</b>-Cy5.5</h3><div class="NLM_p last">HDAC bioassays were based on principles of fluorometric measurement. The inhibitory activities of <b>20</b> and <b>20</b>-Cy5.5 on HeLa nuclear HDAC mixtures (Enzo Life Sciences, NY) or purified, recombinant HDAC1-11 (BPS Bioscience, CA) were measured according to the protocols supplied by the manufacturers. Trichostatin A was used as a positive control. Briefly, a serial dilution of tested compounds and <b>20</b>-Cy5.5 was mixed with the HDAC fluorometric substrates. The deacetylation reactions were initiated by addition of the HDAC enzymes and allowed to proceed for 60 min at 37 °C. At the end of incubation, a developer was added to the mixture and incubated for another 20 min. Finally, the fluorescence intensities of the samples were recorded by a microtiter-plate reading fluorimeter (FLUOstar OPTIMA, Durham, NC) with excitation at 360 nm and emission at 460 nm. The IC<sub>50</sub> values were calculated by nonlinear regression analysis using GraphPad Prism software (Graph-Pad Software, Inc., San Diego, CA). The error bars represent the standard deviations (SDs) of the triplicate measurements.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Cell Culture and Antiproliferation Assay</h3><div class="NLM_p last">MDA-MB-231 cells and Wi38 cells were purchased from Shanghai Cell Bank, Chinese Academy of Sciences. MDA-MB-231 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin, while Wi38 cells were grown in MEM without antibiotics. After subconfluent growth, cells were grown into the logarithmic phase, harvested, and seeded at a density of 800–1000 cells/well in 384-well plates. The plates were incubated in a Thermo/Forma Scientific CO<sub>2</sub> Water-Jacketed Incubator with 5% CO<sub>2</sub> in air at 37 °C for 24 h. Cell proliferation assay was determined by the CCK8 (DOjinDo, Japan) assay. Then, the cells were treated with either various concentrations of target compounds or the solvent control. After 72 h of incubation, the CCK8 reagent was added, and absorbance was measured at 450 nm using an Envision 2104 multilabel Reader (Perkin Elmer). Dose–response curves were plotted to determine the IC<sub>50</sub> values using Prism 5.0 (GraphPad Software Inc.).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Breast Tumor Xenograft and Metastatic Tumor Model</h3><div class="NLM_p last">All animal procedures were performed according to a protocol approved by the Houston Methodist Research Institute Animal Care and Use Committee. For the mouse xenograft model of breast cancer, 5 × 10<sup>6</sup> MDA-MB-231 cells were suspended in 200 μL of phosphate-buffered saline (PBS) and injected orthotopically into the mammary fat pad of 4–6-week-old female athymic nude mouse (Charles River). Mice were subjected to the <i>in vivo</i> imaging studies when tumors reached 4–6 mm in diameter. For the mouse model of metastatic breast cancer, 2 × 10<sup>6</sup> luciferase-labeled MDA-MB-231 cells were injected into the fat pads (<i>i.e</i>., the primary tumor site) of NOD-SCID immunodeficient mice (Charles River). Metastasis of MDA-MB-231 cells in the lungs was monitored and confirmed by noninvasive bioluminescence imaging (IVIS200 System, Xenogen, CA).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>In Vitro</i> Fluorescence Microscopic Studies</h3><div class="NLM_p last">MDA-MB-231 cells (1 × 10<sup>4</sup>) were seeded on an 8-well Nunc Lab-Tek II Chamber Slide System (Thermo Scientific, MA). After 24 h, cells were washed with PBS and incubated in <b>20</b>-Cy5.5 (1.5 μM in FBS-free DMEM) with and without 100-fold excess compound <b>20</b> (150 μM in FBS-free DMEM) as a blocking agent at 37 °C for 60 min, respectively. Following incubation, the cells were washed three times with ice-cold PBS and mounted with a ProLong Gold antifade reagent containing DAPI (Invitrogen, CA). The fluorescence signal was recorded using a FluoView 1000 laser scanning confocal microscope (Olympus).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>In Vivo</i> and <i>Ex Vivo</i> Optical Imaging Studies</h3><div class="NLM_p last">Optical fluorescence imaging was performed on an IVIS200 imaging system (Xenogen, CA). Epifluorescence was quantified by Living Imaging 4.2 (Xenogen, CA). For <i>in vivo</i> imaging studies, each tumor-bearing mouse was injected intravenously at the tail vein with 3 nmol of the probe <b>20</b>-Cy5.5 (in 100 μL of PBS). Fluorescence images were acquired at the time points indicated in the experiments. For blocking studies, unlabeled <b>20</b> (in 33% Tween 20, %v/v) was used as the blocking agent and was administered intraperitoneally at a dose of 15 mg/kg, followed by injection of <b>20</b>-Cy5.5 (3 nmol). Regions of interest (ROI) were drawn over the tumor and background tissue to provide the tumor/normal tissue ratio. At the end of <i>in vivo</i> imaging studies, each mouse was euthanized and dissected. Major organs along with the tumors were excised and subjected to <i>ex vivo</i> image acquisition. For direct comparison of the images obtained from different treatments, both the <i>in vivo</i> and <i>ex vivo</i> images were scaled to the same color gauges indicated in the respective experiments.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Immunohistochemistry</h3><div class="NLM_p last">Tumors were fixed in 10% (w/v) neutral buffered formalin. The fixed tissues were embedded in paraffin from which continuous 4 μm sections were prepared. Hematoxylin and eosin (H&E) staining was performed according to the standard protocol. For immunohistochemistry, heat-induced antigen retrieval was performed in sodium citrate buffer (pH 6.0). A rabbit polyclonal anti-HDAC1 antibody (Cat. ab7028, Abcam) was used at a 1:100 dilution.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Therapeutic Evaluation Study</h3><div class="NLM_p last">SAHA (dissolved in 10% DMSO, 45% PEG400, and 45% PBS) was intraperitoneally injected to MDA-MB-231 tumor-bearing mice (<i>n</i> = 3) at a dose of 15 mg/kg for 3 days, followed by injection of <b>20</b>-Cy5.5 (3 nmol). Imaging was acquired at 2, 6, 24, and 48 h post-injection. All images were scaled to the same maximum intensity for direct comparisons.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Statistical Analysis</h3><div class="NLM_p last">Results are presented as mean ± standard deviation (SD). Statistical significance was examined with Student’s <i>t</i> test and nonlinear curve fitting with GraphPad Prism 6: *<i>p</i> < 0.05, **<i>p</i> < 0.01, and ***<i>p</i> < 0.001.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31"><a href="/doi/suppl/10.1021/acs.jmedchem.0c02161" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61277" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61277" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c02161?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02161</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Chemistry and general methods; molecular modeling; HDAC inhibition assay by cyclic depsipeptides and <b>20</b>-Cy5.5; cell culture and antiproliferation assay; breast tumor xenograft and metastatic tumor model; <i>in vitro</i> fluorescence microscopic studies; <i>in vivo</i> and <i>ex vivo</i> optical imaging studies; immunohistochemistry; therapeutic evaluation study; and statistical analysis (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES formula of each tested compound and associated biochemical data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Compound 9 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound 10 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_004.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_001.pdf">jm0c02161_si_001.pdf (1.49 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_002.csv">jm0c02161_si_002.csv (0.7 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_003.pdb">jm0c02161_si_003.pdb (300.35 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_004.pdb">jm0c02161_si_004.pdb (300.96 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02161" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25827" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25827" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zheng Li</span> - <span class="hlFld-Affiliation affiliation">Center
for Bioenergetics, Houston Methodist Research
Institute, 6670 Bertner, Houston, Texas 77030, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a8d2c4c1e8e0c7dddbdcc7c6e5cddcc0c7ccc1dbdc86c7dacf"><span class="__cf_email__" data-cfemail="eb918782aba3849e989f8485a68e9f83848f82989fc584998c">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheng Jiang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, and Department of Medicinal Chemistry,
School of Pharmacy, China Pharmaceutical
University, Nanjing 210009, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4550-5024" title="Orcid link">http://orcid.org/0000-0002-4550-5024</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9ff5f6fef1f8ecf7a6dff8f2fef6f3b1fcf0f2"><span class="__cf_email__" data-cfemail="315b58505f5642590871565c50585d1f525e5c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kuojun Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, and Department of Medicinal Chemistry,
School of Pharmacy, China Pharmaceutical
University, Nanjing 210009, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhiyi Liu</span> - <span class="hlFld-Affiliation affiliation">Center
for Bioenergetics, Houston Methodist Research
Institute, 6670 Bertner, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yiwu Yao</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, and Department of Medicinal Chemistry,
School of Pharmacy, China Pharmaceutical
University, Nanjing 210009, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yatao Qiu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, and Department of Medicinal Chemistry,
School of Pharmacy, China Pharmaceutical
University, Nanjing 210009, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feng Li</span> - <span class="hlFld-Affiliation affiliation">Center
for Bioenergetics, Houston Methodist Research
Institute, 6670 Bertner, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dong Chen</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, and Department of Medicinal Chemistry,
School of Pharmacy, China Pharmaceutical
University, Nanjing 210009, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dale J. Hamilton</span> - <span class="hlFld-Affiliation affiliation">Center
for Bioenergetics, Houston Methodist Research
Institute, 6670 Bertner, Houston, Texas 77030, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>K.Z., Z.L., and Y.Y. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e2297-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35316" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35316" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Natural Science Foundation (81773559, 21807114) and the Double First-Class University Project (CPU2018GY03) (S.J.). This work was also supported by the Houston Methodist Research Institute (HMRI) and foundation (Z.L., D.J.H.).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">CCK8</td><td class="NLM_def"><p class="first last">Cell Counting Kit-8</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">EMT</td><td class="NLM_def"><p class="first last">epithelial–mesenchymal transition</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">FRET</td><td class="NLM_def"><p class="first last">fluorescence resonance energy transfer</p></td></tr><tr><td class="NLM_term">GFP</td><td class="NLM_def"><p class="first last">fluorescent protein</p></td></tr><tr><td class="NLM_term">GI</td><td class="NLM_def"><p class="first last">gastrointestinal</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">HDACs</td><td class="NLM_def"><p class="first last">histone deacetylases</p></td></tr><tr><td class="NLM_term">HDACi</td><td class="NLM_def"><p class="first last">HDAC inhibitor</p></td></tr><tr><td class="NLM_term">H&E</td><td class="NLM_def"><p class="first last">hematoxylin and eosin</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">IHC</td><td class="NLM_def"><p class="first last">immunohistochemistry</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectrometry</p></td></tr><tr><td class="NLM_term">NIR</td><td class="NLM_def"><p class="first last">near-infrared</p></td></tr><tr><td class="NLM_term">pi</td><td class="NLM_def"><p class="first last">post-injection</p></td></tr><tr><td class="NLM_term">PR</td><td class="NLM_def"><p class="first last">progesterone receptor</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancer</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64837" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64837" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 53 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gradishar, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balassanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burstein, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elias, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrar, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isakoff, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcom, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Regan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzberg, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitapati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soliman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somlo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shead, D. A.</span></span> <span> </span><span class="NLM_article-title">Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology</span>. <i>J. Natl. Compr. Cancer Network</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">310</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.6004/jnccn.2018.0012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.6004%2Fjnccn.2018.0012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=29523670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A280%3ADC%252BC1MrpsFyjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=310-320&author=W.+J.+Gradisharauthor=B.+O.+Andersonauthor=R.+Balassanianauthor=S.+L.+Blairauthor=H.+J.+Bursteinauthor=A.+Cyrauthor=A.+D.+Eliasauthor=W.+B.+Farrarauthor=A.+Foreroauthor=S.+H.+Giordanoauthor=M.+P.+Goetzauthor=L.+J.+Goldsteinauthor=S.+J.+Isakoffauthor=J.+Lyonsauthor=P.+K.+Marcomauthor=I.+A.+Mayerauthor=B.+McCormickauthor=M.+S.+Moranauthor=R.+M.+O%E2%80%99Reganauthor=S.+A.+Patelauthor=L.+J.+Pierceauthor=E.+C.+Reedauthor=K.+E.+Salernoauthor=L.+S.+Schwartzbergauthor=A.+Sitapatiauthor=K.+L.+Smithauthor=M.+L.+Smithauthor=H.+Solimanauthor=G.+Somloauthor=M.+L.+Telliauthor=J.+H.+Wardauthor=R.+Kumarauthor=D.+A.+Shead&title=Breast+cancer%2C+version+4.2017%2C+NCCN+clinical+practice+guidelines+in+oncology&doi=10.6004%2Fjnccn.2018.0012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology</span></div><div class="casAuthors">Gradishar William J; Anderson Benjamin O; Balassanian Ron; Blair Sarah L; Burstein Harold J; Cyr Amy; Elias Anthony D; Farrar William B; Forero Andres; Giordano Sharon H; Goetz Matthew P; Goldstein Lori J; Isakoff Steven J; Lyons Janice; Marcom P Kelly; Mayer Ingrid A; McCormick Beryl; Moran Meena S; O'Regan Ruth M; Patel Sameer A; Pierce Lori J; Reed Elizabeth C; Salerno Kilian E; Schwartzberg Lee S; Sitapati Amy; Smith Karen Lisa; Smith Mary Lou; Soliman Hatem; Somlo George; Telli Melinda L; Ward John H; Kumar Rashmi; Shead Dorothy A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Comprehensive Cancer Network : JNCCN</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">310-320</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of neoplastic lesions in the breast ducts.  The goal for management of DCIS is to prevent the development of invasive breast cancer.  This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAACZdsi8QiVm8bhe6roZYfW6udTcc2ebDwD7A1j9ry7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrpsFyjug%253D%253D&md5=7d3686a5eefb430f13fea8565b05cc7e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.6004%2Fjnccn.2018.0012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.6004%252Fjnccn.2018.0012%26sid%3Dliteratum%253Aachs%26aulast%3DGradishar%26aufirst%3DW.%2BJ.%26aulast%3DAnderson%26aufirst%3DB.%2BO.%26aulast%3DBalassanian%26aufirst%3DR.%26aulast%3DBlair%26aufirst%3DS.%2BL.%26aulast%3DBurstein%26aufirst%3DH.%2BJ.%26aulast%3DCyr%26aufirst%3DA.%26aulast%3DElias%26aufirst%3DA.%2BD.%26aulast%3DFarrar%26aufirst%3DW.%2BB.%26aulast%3DForero%26aufirst%3DA.%26aulast%3DGiordano%26aufirst%3DS.%2BH.%26aulast%3DGoetz%26aufirst%3DM.%2BP.%26aulast%3DGoldstein%26aufirst%3DL.%2BJ.%26aulast%3DIsakoff%26aufirst%3DS.%2BJ.%26aulast%3DLyons%26aufirst%3DJ.%26aulast%3DMarcom%26aufirst%3DP.%2BK.%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DMcCormick%26aufirst%3DB.%26aulast%3DMoran%26aufirst%3DM.%2BS.%26aulast%3DO%25E2%2580%2599Regan%26aufirst%3DR.%2BM.%26aulast%3DPatel%26aufirst%3DS.%2BA.%26aulast%3DPierce%26aufirst%3DL.%2BJ.%26aulast%3DReed%26aufirst%3DE.%2BC.%26aulast%3DSalerno%26aufirst%3DK.%2BE.%26aulast%3DSchwartzberg%26aufirst%3DL.%2BS.%26aulast%3DSitapati%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DK.%2BL.%26aulast%3DSmith%26aufirst%3DM.%2BL.%26aulast%3DSoliman%26aufirst%3DH.%26aulast%3DSomlo%26aufirst%3DG.%26aulast%3DTelli%26aufirst%3DM.%2BL.%26aulast%3DWard%26aufirst%3DJ.%2BH.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DShead%26aufirst%3DD.%2BA.%26atitle%3DBreast%2520cancer%252C%2520version%25204.2017%252C%2520NCCN%2520clinical%2520practice%2520guidelines%2520in%2520oncology%26jtitle%3DJ.%2520Natl.%2520Compr.%2520Cancer%2520Network%26date%3D2018%26volume%3D16%26spage%3D310%26epage%3D320%26doi%3D10.6004%2Fjnccn.2018.0012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertucci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervera, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esterni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermitte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, D.</span></span> <span> </span><span class="NLM_article-title">How basal are triple-negative breast cancers?</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1002/ijc.23518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1002%2Fijc.23518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=18398844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtlantbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2008&pages=236-240&author=F.+Bertucciauthor=P.+Finettiauthor=N.+Cerveraauthor=B.+Esterniauthor=F.+Hermitteauthor=P.+Viensauthor=D.+Birnbaum&title=How+basal+are+triple-negative+breast+cancers%3F&doi=10.1002%2Fijc.23518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">How basal are triple-negative breast cancers?</span></div><div class="casAuthors">Bertucci, Francois; Finetti, Pascal; Cervera, Nathalie; Esterni, Benjamin; Hermitte, Fabienne; Viens, Patrice; Birnbaum, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">236-240</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The basal mol. subtype of breast cancer (BC) is defined by the mRNA expression pattern of an intrinsic ∼500-gene set.  It is the most homogeneous subtype in transcriptional terms, and one of the most aggressive in prognostic terms.  Clin. trials testing new systemic therapeutic strategies have been launched in basal BCs.  Although no proof of evidence has yet been reported, basal tumors are currently assimilated to and selected as triple-neg. (TN) BCs in these trials because of their frequent immunohistochem. (IHC) negativity for hormone and ERBB2 receptors.  Here, we have assessed the degree of correlation and of homogeneity of the TN phenotype (IHC-based definition) and the basal subtype (gene expression-based definition).  We analyzed 172 TN BCs defined by gene expression profile as basal (123 cases) and nonbasal (49 cases).  Conversely, 160 tumors were defined as basal by their gene expression profile and included 123 TN and 37 non-TN samples.  Uni- and multivariate analyses revealed that TN BCs represent a more heterogeneous group than basal BCs, including basal and nonbasal tumors very different both at the histoclin. and mol. level, notably for mRNA expression of mols. targeted by specific therapies under evaluation in clin. trials.  These results call for caution in the interpretation of ongoing trials and selection of patients in future trials.  They also warrant the identification of mol. markers for basal BCs more clin. applicable than gene expression profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxVpoZP512JLVg90H21EOLACvtfcHk0lj1eIvp0T4J-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtlantbg%253D&md5=6ca7cc86ff3ec14c508fe11e3226ca8a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fijc.23518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.23518%26sid%3Dliteratum%253Aachs%26aulast%3DBertucci%26aufirst%3DF.%26aulast%3DFinetti%26aufirst%3DP.%26aulast%3DCervera%26aufirst%3DN.%26aulast%3DEsterni%26aufirst%3DB.%26aulast%3DHermitte%26aufirst%3DF.%26aulast%3DViens%26aufirst%3DP.%26aulast%3DBirnbaum%26aufirst%3DD.%26atitle%3DHow%2520basal%2520are%2520triple-negative%2520breast%2520cancers%253F%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2008%26volume%3D123%26spage%3D236%26epage%3D240%26doi%3D10.1002%2Fijc.23518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fahad
Ullah, M.</span></span> <span> </span><span class="NLM_article-title">Breast Cancer: Current perspectives on the disease status</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1152</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1007/978-3-030-20301-6_4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1007%2F978-3-030-20301-6_4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=31456179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvFSrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1152&publication_year=2019&pages=51-64&author=M.+Fahad%0AUllah&title=Breast+Cancer%3A+Current+perspectives+on+the+disease+status&doi=10.1007%2F978-3-030-20301-6_4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Breast Cancer: Current Perspectives on the Disease Status</span></div><div class="casAuthors">Fahad Ullah, Mohammad</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1152</span>
        (<span class="NLM_cas:issue">Breast Cancer Metastasis and Drug Resistance</span>),
    <span class="NLM_cas:pages">51-64</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Breast cancer is the most frequently diagnosed cancer in women and ranks second among causes for cancer related death in women.  Evidence in literature has shown that the past and ongoing research has an enormous implication in improving the clin. outcome in breast cancer.  This has been attributed to the progress made in the realm of screening, diagnosis and therapeutic strategies engaged in breast cancer management.  However, poor prognosis in TNBC and drug resistance presents major inhibitions which are also current challenges for contg. the disease.  Similarly, a focal point of concern is the rising rate of breast cancer incidence and mortality among the population of under developed world.  In this chapter, an overview of the current practices for the diagnosis and treatment of breast cancer and assocd. impediments has been provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtaZOdy8Tx97Vg90H21EOLACvtfcHk0lhY_rzo3MRrIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvFSrt7k%253D&md5=bc1efba9b3a0478f10a1df8b89b4d2ac</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2F978-3-030-20301-6_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-030-20301-6_4%26sid%3Dliteratum%253Aachs%26aulast%3DFahad%2BUllah%26aufirst%3DM.%26atitle%3DBreast%2520Cancer%253A%2520Current%2520perspectives%2520on%2520the%2520disease%2520status%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2019%26volume%3D1152%26spage%3D51%26epage%3D64%26doi%3D10.1007%2F978-3-030-20301-6_4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garrido-Castro, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, N. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyak, K.</span></span> <span> </span><span class="NLM_article-title">Insights into molecular classifications of triple-negative breast cancer: Improving patient selection for treatment</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">176</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-1177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1158%2F2159-8290.CD-18-1177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=30679171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlGrsbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=176-198&author=A.+C.+Garrido-Castroauthor=N.+U.+Linauthor=K.+Polyak&title=Insights+into+molecular+classifications+of+triple-negative+breast+cancer%3A+Improving+patient+selection+for+treatment&doi=10.1158%2F2159-8290.CD-18-1177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment</span></div><div class="casAuthors">Garrido-Castro, Ana C.; Lin, Nancy U.; Polyak, Kornelia</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">176-198</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) remains the most challenging breast cancer subtype to treat.  To date, therapies directed to specific mol. targets have rarely achieved clin. meaningful improvements in outcomes of patients with TNBC, and chemotherapy remains the std. of care.  Here, we seek to review the most recent efforts to classify TNBC based on the comprehensive profiling of tumors for cellular compn. and mol. features.  Technol. advances allow for tumor characterization at ever-increasing depth, generating data that, if integrated with clin.-pathol. features, may help improve risk stratification of patients, guide treatment decisions and surveillance, and help identify new targets for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb4mfay-pxrbVg90H21EOLACvtfcHk0lhY_rzo3MRrIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlGrsbbJ&md5=823d8658319e5d9d19cdae93b776c4b4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-1177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-1177%26sid%3Dliteratum%253Aachs%26aulast%3DGarrido-Castro%26aufirst%3DA.%2BC.%26aulast%3DLin%26aufirst%3DN.%2BU.%26aulast%3DPolyak%26aufirst%3DK.%26atitle%3DInsights%2520into%2520molecular%2520classifications%2520of%2520triple-negative%2520breast%2520cancer%253A%2520Improving%2520patient%2520selection%2520for%2520treatment%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26spage%3D176%26epage%3D198%26doi%3D10.1158%2F2159-8290.CD-18-1177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianni, L.</span></span> <span> </span><span class="NLM_article-title">Triple-negative breast cancer: an unmet medical need</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2011-S1-01</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1634%2Ftheoncologist.2011-S1-01" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=21278435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A280%3ADC%252BC3M7nslaiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=1-11&author=C.+A.+Hudisauthor=L.+Gianni&title=Triple-negative+breast+cancer%3A+an+unmet+medical+need&doi=10.1634%2Ftheoncologist.2011-S1-01"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer: an unmet medical need</span></div><div class="casAuthors">Hudis Clifford A; Gianni Luca</div><div class="citationInfo"><span class="NLM_cas:title">The oncologist</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16 Suppl 1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer, characterized by tumors that do not express estrogen receptor (ER), progesterone receptor (PR), or HER-2 genes, represents an important clinical challenge because these cancers do not respond to endocrine therapy or other available targeted agents.  The metastatic potential in triple-negative breast cancer is similar to that of other breast cancer subtypes, but these tumors are associated with a shorter median time to relapse and death.  One important goal is therefore the identification of prognostic factors and markers to reliably select high and low risk subsets of patients with triple-negative disease for different treatment approaches of subtypes with differential responsiveness to specific agents.  However, a reliable prognostic marker has been elusive, and markers have been inconsistently useful.  For example, epidermal growth factor receptor (EGFR) has been studied, but there is still a lack of agreement on a standard assay or cutoff for EGFR expression levels with respect to prognosis.  Similarly, because triple-negative status is sometimes used as a surrogate for basal-like breast cancer, specific basal markers have been explored.  Indeed, trials designed to accrue patients with basal-like breast cancer using ER/PR and HER-2 negativity may provide only an approximation of the triple-negative population and are sometimes reanalyzed using more specific indicators like CK 5/6, EGFR status, and others, again marred by discordances.  Chemotherapy remains the mainstay of treatment of triple-negative breast cancer, but important limitations still need to be overcome in the next few years if any significant clinical strides are to be made.  Current treatment strategies for triple-negative disease include anthracyclines, taxanes, ixabepilone, platinum agents, and biologic agents.  More recently, EGFR inhibition has been proposed as a therapeutic mechanism in triple-negative breast cancer, again with mixed results.  Agents that target poly(ADP-ribose) polymerase and androgen receptors have also been proposed in these patients or subsets of them, and ongoing trials should result in definitive guidance with respect to the value of these agents in triple-negative disease.  Triple-negative breast cancer is clearly a distinct clinical subtype, from the perspective of both ER and HER-2 expression, but further subclassification is needed.  At present, there is not a clear, proven effective single agent that targets a defining vulnerability in triple-negative breast cancer.  This article will review the clinical problem of triple-negative disease, potential prognostic factors, demonstrated efficacy of currently available therapeutic options, and new potential therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOPZpUZEYLnfx2phytoz6_fW6udTcc2eYNhotsCWe647ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7nslaiuw%253D%253D&md5=9a57cf464e3da0253820b7828c5bc76e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2011-S1-01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2011-S1-01%26sid%3Dliteratum%253Aachs%26aulast%3DHudis%26aufirst%3DC.%2BA.%26aulast%3DGianni%26aufirst%3DL.%26atitle%3DTriple-negative%2520breast%2520cancer%253A%2520an%2520unmet%2520medical%2520need%26jtitle%3DOncologist%26date%3D2011%26volume%3D16%26spage%3D1%26epage%3D11%26doi%3D10.1634%2Ftheoncologist.2011-S1-01" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haberland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. N.</span></span> <span> </span><span class="NLM_article-title">The many roles of histone deacetylases in development and physiology: implications for disease and therapy</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1038/nrg2485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1038%2Fnrg2485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=19065135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWis7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=32-42&author=M.+Haberlandauthor=R.+L.+Montgomeryauthor=E.+N.+Olson&title=The+many+roles+of+histone+deacetylases+in+development+and+physiology%3A+implications+for+disease+and+therapy&doi=10.1038%2Fnrg2485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The many roles of histone deacetylases in development and physiology: implications for disease and therapy</span></div><div class="casAuthors">Haberland, Michael; Montgomery, Rusty L.; Olson, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The expression of many histone deacetylase (HDAC) isoforms in eukaryotic cells raises questions regarding their specificity and the programs of gene expression that they control.  HDAC knockout mice are a powerful tool for addressing these questions and have revealed that individual HDACs have specific functions in development and disease.  Histone deacetylases (HDACs) are part of a vast family of enzymes that have crucial roles in numerous biol. processes, largely through their repressive influence on transcription.  The expression of many HDAC isoforms in eukaryotic cells raises questions about their possible specificity or redundancy, and whether they control global or specific programs of gene expression.  Recent analyses of HDAC knockout mice have revealed highly specific functions of individual HDACs in development and disease.  Mutant mice lacking individual HDACs are a powerful tool for defining the functions of HDACs in vivo and the mol. targets of HDAC inhibitors in disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMWcIo3mrsM7Vg90H21EOLACvtfcHk0liR4rz4YqRAeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWis7bI&md5=0678d8655e86994cd4f0174c1e9d0eb1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrg2485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg2485%26sid%3Dliteratum%253Aachs%26aulast%3DHaberland%26aufirst%3DM.%26aulast%3DMontgomery%26aufirst%3DR.%2BL.%26aulast%3DOlson%26aufirst%3DE.%2BN.%26atitle%3DThe%2520many%2520roles%2520of%2520histone%2520deacetylases%2520in%2520development%2520and%2520physiology%253A%2520implications%2520for%2520disease%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2009%26volume%3D10%26spage%3D32%26epage%3D42%26doi%3D10.1038%2Fnrg2485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruijter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gennip, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kuilenburg, A. B.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases (HDACs): characterization of the classical HDAC family</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1042/bj20021321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1042%2Fbj20021321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=12429021" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2003&pages=737-749&author=A.+J.+Ruijterauthor=A.+H.+van+Gennipauthor=H.+N.+Caronauthor=S.+Kempauthor=A.+B.+van+Kuilenburg&title=Histone+deacetylases+%28HDACs%29%3A+characterization+of+the+classical+HDAC+family&doi=10.1042%2Fbj20021321"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1042%2Fbj20021321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj20021321%26sid%3Dliteratum%253Aachs%26aulast%3DRuijter%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2BGennip%26aufirst%3DA.%2BH.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26aulast%3DKemp%26aufirst%3DS.%26aulast%3Dvan%2BKuilenburg%26aufirst%3DA.%2BB.%26atitle%3DHistone%2520deacetylases%2520%2528HDACs%2529%253A%2520characterization%2520of%2520the%2520classical%2520HDAC%2520family%26jtitle%3DBiochem.%2520J.%26date%3D2003%26volume%3D370%26spage%3D737%26epage%3D749%26doi%3D10.1042%2Fbj20021321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bountra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span> <span> </span><span class="NLM_article-title">Epigenetic protein families: a new frontier for drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1038/nrd3674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1038%2Fnrd3674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=22498752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFWjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=384-400&author=C.+H.+Arrowsmithauthor=C.+Bountraauthor=P.+V.+Fishauthor=K.+Leeauthor=M.+Schapira&title=Epigenetic+protein+families%3A+a+new+frontier+for+drug+discovery&doi=10.1038%2Fnrd3674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic protein families: a new frontier for drug discovery</span></div><div class="casAuthors">Arrowsmith, Cheryl H.; Bountra, Chas; Fish, Paul V.; Lee, Kevin; Schapira, Matthieu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">384-400</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic regulation of gene expression is a dynamic and reversible process that establishes normal cellular phenotypes but also contributes to human diseases.  At the mol. level, epigenetic regulation involves hierarchical covalent modification of DNA and the proteins that package DNA, such as histones.  Here, we review the key protein families that mediate epigenetic signalling through the acetylation and methylation of histones, including histone deacetylases, protein methyltransferases, lysine demethylases, bromodomain-contg. proteins and proteins that bind to methylated histones.  These protein families are emerging as druggable classes of enzymes and druggable classes of protein-protein interaction domains.  In this article, we discuss the known links with disease, basic mol. mechanisms of action and recent progress in the pharmacol. modulation of each class of proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcD99eCigNtLVg90H21EOLACvtfcHk0liR4rz4YqRAeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFWjsbs%253D&md5=eb82034466a43107aa74a18ccf6d29f5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd3674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3674%26sid%3Dliteratum%253Aachs%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DFish%26aufirst%3DP.%2BV.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DSchapira%26aufirst%3DM.%26atitle%3DEpigenetic%2520protein%2520families%253A%2520a%2520new%2520frontier%2520for%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D384%26epage%3D400%26doi%3D10.1038%2Fnrd3674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weichert, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roske, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niesporek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noske, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckendahl, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gekeler, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denkert, C.</span></span> <span> </span><span class="NLM_article-title">Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1669</span>– <span class="NLM_lpage">1677</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-0990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1158%2F1078-0432.CCR-07-0990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=18347167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtlejt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1669-1677&author=W.+Weichertauthor=A.+Roskeauthor=S.+Niesporekauthor=A.+Noskeauthor=A.+C.+Buckendahlauthor=M.+Dietelauthor=V.+Gekelerauthor=M.+Boehmauthor=T.+Beckersauthor=C.+Denkert&title=Class+I+histone+deacetylase+expression+has+independent+prognostic+impact+in+human+colorectal+cancer%3A+specific+role+of+class+I+histone+deacetylases+in+vitro+and+in+vivo&doi=10.1158%2F1078-0432.CCR-07-0990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo</span></div><div class="casAuthors">Weichert, Wilko; Roeske, Annika; Niesporek, Silvia; Noske, Aurelia; Buckendahl, Ann-Christin; Dietel, Manfred; Gekeler, Volker; Boehm, Markus; Beckers, Thomas; Denkert, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1669-1677</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Recently, several studies reported a strong functional link between histone deacetylases (HDAC) and the development of tumors of the large intestine.  However, despite the importance of these mols., comparably little is known on expression patterns and functions of specific HDAC isoforms in colorectal cancer.  Exptl. Design: We characterized class I HDAC isoform expression patterns in a cohort of 140 colorectal carcinomas by immunohistochem.  In addn., effects of HDAC inhibition by valproic acid and suberoylanilide hydroxamic acid, and specific HDAC isoform knockdown by short interfering RNA, were investigated in a cell culture model.  RESULTS: We found class I HDACs highly expressed in a subset of colorectal carcinomas with positivity for HDAC1 in 36.4%, HDAC2 in 57.9%, and HDAC3 in 72.9% of cases.  Expression was significantly enhanced in strongly proliferating (P = 0.002), dedifferentiated (P = 0.022) tumors.  High HDAC expression levels implicated significantly reduced patient survival (P = 0.001), with HDAC2 expression being an independent survival prognosticator (hazard ratio, 2.6; P = 0.03).  Short interfering RNA-based inhibition of HDAC1 and HDAC2 but not HDAC3 suppressed growth of colon cancer cells in vitro, although to a lesser extent than chem. HDAC inhibitors did.  CONCLUSIONS: The strong prognostic impact of HDAC isoforms in colorectal cancer, the interactions of HDACs with tumor cell proliferation and differentiation in vivo, and our finding that HDACs are differentially expressed in colorectal tumors suggest that the evaluation of HDAC expression in clin. trials for HDAC inhibitors might help to identify a patient subgroup who will exceptionally profit from such a treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQAUfNzjDakrVg90H21EOLACvtfcHk0liR4rz4YqRAeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtlejt7o%253D&md5=f54611c0b65fe4cd8a0cfea3ea143126</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0990%26sid%3Dliteratum%253Aachs%26aulast%3DWeichert%26aufirst%3DW.%26aulast%3DRoske%26aufirst%3DA.%26aulast%3DNiesporek%26aufirst%3DS.%26aulast%3DNoske%26aufirst%3DA.%26aulast%3DBuckendahl%26aufirst%3DA.%2BC.%26aulast%3DDietel%26aufirst%3DM.%26aulast%3DGekeler%26aufirst%3DV.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DBeckers%26aufirst%3DT.%26aulast%3DDenkert%26aufirst%3DC.%26atitle%3DClass%2520I%2520histone%2520deacetylase%2520expression%2520has%2520independent%2520prognostic%2520impact%2520in%2520human%2520colorectal%2520cancer%253A%2520specific%2520role%2520of%2520class%2520I%2520histone%2520deacetylases%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D1669%26epage%3D1677%26doi%3D10.1158%2F1078-0432.CCR-07-0990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinkerneil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deenen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohrer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arent, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niegisch, G.</span></span> <span> </span><span class="NLM_article-title">Inhibition of class I histone deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1158%2F1535-7163.MCT-15-0618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=26772204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVWrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=299-312&author=M.+Pinkerneilauthor=M.+J.+Hoffmannauthor=R.+Deenenauthor=K.+Kohrerauthor=T.+Arentauthor=W.+A.+Schulzauthor=G.+Niegisch&title=Inhibition+of+class+I+histone+deacetylases+1+and+2+promotes+urothelial+carcinoma+cell+death+by+various+mechanisms&doi=10.1158%2F1535-7163.MCT-15-0618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms</span></div><div class="casAuthors">Pinkerneil, Maria; Hoffmann, Michele J.; Deenen, Rene'e; Kohrer, Karl; Arent, Tanja; Schulz, Wolfgang A.; Niegisch, Gunter</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">299-312</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Class I histone deacetylases HDAC1 and HDAC2 contribute to cell proliferation and are commonly upregulated in urothelial carcinoma.  To evaluate whether specific inhibition of these enzymes might serve as an appropriate therapy for urothelial carcinoma, siRNA-mediated knockdown and specific pharmacol. inhibition of HDAC1 and HDAC2 were applied in urothelial carcinoma cell lines (UCC) with distinct HDAC1 and HDAC2 expression profiles.  HDACs and response marker proteins were followed by Western blotting and qRT-PCR.  Effects of class I HDAC suppression on UCCs were analyzed by viability, colony forming, and caspase-3/7 assays; flow cytometry, senescence and lactate dehydrogenase cytotoxicity assays; and immunofluorescence staining.  Whereas single knockdowns of HDAC1 or HDAC2 were impeded by compensatory upregulation of the other isoenzyme, efficient double knockdown of HDAC1 and HDAC2 reduced proliferation by up to 80% and induced apoptosis-like cell death in all UCCs.  Clonogenic growth was cell line- and HDAC-dependently reduced, with double knockdown of HDAC1 and HDAC2 being usually most efficient.  Class I HDAC-specific inhibitors, esp. the more specific HDAC1/2 inhibitors romidepsin and givinostat, significantly reduced proliferation of all UCCs (IC50, 3.36 nmol/L-4.59 μmol/L).  Romidepsin and givinostat also significantly inhibited clonogenic growth of UCCs, with minor effects on nontumorigenic controls.  Intriguingly, these compds. induced primarily S-phase disturbances and nonapoptotic cell death in UCCs.  Thus, although both ways of inhibiting HDAC1/2 share mechanisms and efficaciously inhibit cell proliferation, their modes of action differ substantially.  Regardless, combined inhibition of HDAC1/2 appears to represent a promising strategy for urothelial carcinoma therapy.  Mol Cancer Ther; 15(2); 299-312. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW8MT_AwmqpLVg90H21EOLACvtfcHk0lj5niIkGqk97A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVWrs7o%253D&md5=5be8f0be83930ac9aa564a9afd42d2c5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0618%26sid%3Dliteratum%253Aachs%26aulast%3DPinkerneil%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%2BJ.%26aulast%3DDeenen%26aufirst%3DR.%26aulast%3DKohrer%26aufirst%3DK.%26aulast%3DArent%26aufirst%3DT.%26aulast%3DSchulz%26aufirst%3DW.%2BA.%26aulast%3DNiegisch%26aufirst%3DG.%26atitle%3DInhibition%2520of%2520class%2520I%2520histone%2520deacetylases%25201%2520and%25202%2520promotes%2520urothelial%2520carcinoma%2520cell%2520death%2520by%2520various%2520mechanisms%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D299%26epage%3D312%26doi%3D10.1158%2F1535-7163.MCT-15-0618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buurman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gürlevik, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäffer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandbothe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreipe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegelberger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kühnel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skawran, B.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">811</span>– <span class="NLM_lpage">820</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2012.05.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1053%2Fj.gastro.2012.05.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=22641068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1KktLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2012&pages=811-820&author=R.+Buurmanauthor=E.+G%C3%BCrlevikauthor=V.+Sch%C3%A4fferauthor=M.+Eilersauthor=M.+Sandbotheauthor=H.+Kreipeauthor=L.+Wilkensauthor=B.+Schlegelbergerauthor=F.+K%C3%BChnelauthor=B.+Skawran&title=Histone+deacetylases+activate+hepatocyte+growth+factor+signaling+by+repressing+microRNA-449+in+hepatocellular+carcinoma+cells&doi=10.1053%2Fj.gastro.2012.05.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylases Activate Hepatocyte Growth Factor Signaling by Repressing MicroRNA-449 in Hepatocellular Carcinoma Cells</span></div><div class="casAuthors">Buurman, Reena; Guerlevik, Engin; Schaeffer, Vera; Eilers, Marlies; Sandbothe, Maria; Kreipe, Hans; Wilkens, Ludwig; Schlegelberger, Brigitte; Kuehnel, Florian; Skawran, Britta</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">811-820.e15</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Histone deacetylation regulates chromatin remodeling and transcriptional down-regulation of specific genomic regions; it is altered in many types of cancer cells.  We searched for microRNAs (miRs) that are affected by histone deacetylation and investigated the effects in hepatocellular carcinoma (HCC) cells.  HCC cell lines (HepG2, HLE, HLF, and Huh7) and immortalized liver cell lines (THLE-2 and THLE-3) were incubated with the histone deacetylase inhibitor trichostatin A.  Differentially expressed mRNAs (mRNAs) and miRs were identified by expression profiling.  Small interfering RNAs were used to reduce levels of histone deacetylases (HDAC)1-3, and HCC cell lines were transfected with miR-449.  We evaluated growth of xenograft tumors from modified cells in nude mice.  Cells were analyzed by immunoblot and luciferase reporter assays.  We analyzed HCC samples from 23 patients.  HDAC1-3 were up-regulated in HCC samples from patients.  In cell lines, inhibition of HDAC significantly increased levels of hsa-miR-449a. c-MET mRNA, which encodes the receptor tyrosine kinase for hepatocyte growth factor, is a target of miR-449.  Incubation of HCC cells with trichostatin A or transfection with miR-449 reduced expression of c-MET and phosphorylation of extracellular signal-regulated kinases 1 and 2 (downstream effectors of c-MET), increased apoptosis, and reduced proliferation.  Huh-7 cells transfected with miR-449 formed tumors more slowly in mice than cells expressing control miRs.  HCC samples from patients had lower levels of miR-449 and higher levels of c-MET than human ref.  In HCC cells, up-regulation of HDAC1-3 reduces expression of miR-449. miR-449 binds c-MET mRNA to reduce its levels, promoting apoptosis and reducing proliferation of liver cells.  Expression of miR-449 slows growth of HCC xenograft tumors in mice; this miR might function as a tumor suppressor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5f9Klj5wOXbVg90H21EOLACvtfcHk0lj5niIkGqk97A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1KktLnN&md5=19eb1f004c418205ed713eb9cb47ba85</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2012.05.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2012.05.033%26sid%3Dliteratum%253Aachs%26aulast%3DBuurman%26aufirst%3DR.%26aulast%3DG%25C3%25BCrlevik%26aufirst%3DE.%26aulast%3DSch%25C3%25A4ffer%26aufirst%3DV.%26aulast%3DEilers%26aufirst%3DM.%26aulast%3DSandbothe%26aufirst%3DM.%26aulast%3DKreipe%26aufirst%3DH.%26aulast%3DWilkens%26aufirst%3DL.%26aulast%3DSchlegelberger%26aufirst%3DB.%26aulast%3DK%25C3%25BChnel%26aufirst%3DF.%26aulast%3DSkawran%26aufirst%3DB.%26atitle%3DHistone%2520deacetylases%2520activate%2520hepatocyte%2520growth%2520factor%2520signaling%2520by%2520repressing%2520microRNA-449%2520in%2520hepatocellular%2520carcinoma%2520cells%26jtitle%3DGastroenterology%26date%3D2012%26volume%3D143%26spage%3D811%26epage%3D820%26doi%3D10.1053%2Fj.gastro.2012.05.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krusche, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulfing, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kersting, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vloet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiesel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beier, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfer, J.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1007/s10549-004-1668-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1007%2Fs10549-004-1668-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=15770522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Olur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2005&pages=15-23&author=C.+A.+Kruscheauthor=P.+Wulfingauthor=C.+Kerstingauthor=A.+Vloetauthor=W.+Bockerauthor=L.+Kieselauthor=H.+M.+Beierauthor=J.+Alfer&title=Histone+deacetylase-1+and+-3+protein+expression+in+human+breast+cancer%3A+a+tissue+microarray+analysis&doi=10.1007%2Fs10549-004-1668-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis</span></div><div class="casAuthors">Krusche, Claudia A.; Wuelfing, Pia; Kersting, Christian; Vloet, Anne; Boecker, Werner; Kiesel, Ludwig; Beier, Henning M.; Alfer, Joachim</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-23</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Impaired histone acetylation was recognized to be involved in carcinogenesis.  Furthermore, histone deacetylase (HDAC) inhibitors induce differentiation of breast cancer cells and inhibit tumor growth.  These results prompted us to study HDAC-1 and -3 expression in breast tumors to establish their potential therapeutic and prognostic significance.  HDAC-1 und HDAC-3 protein expression was analyzed immunohistochem. on a tissue microarray (TMA) contg. 600 core biopsies from 200 patients.  HDAC-1 and -3 expression was correlated to steroid hormone receptor-, Her2/neu- and proliferation status of tumors as well as to overall and disease free survival.  Moderate or strong nuclear immunoreactivity for HDAC-1 was obsd. in 39.8% and for HDAC-3 in 43.9% of breast carcinomas.  HDAC-1 and -3 expression correlated significantly with estrogen and progesterone receptor expression (both p< 0.001).  HDAC-1 expression predicted significantly better disease free survival (DFS: p=0.044), in particular, in patients with small tumors of all differentiation types (DFS: p=0.016).  Multivariate anal. demonstrated that HDAC-1 is an independent prognostic marker.  Our data suggest that evaluation of HDAC-1 protein expression enables a more precise assessment of the prognosis of breast cancer patients.  Thus, HDAC-1 expression anal. might be clin. useful to facilitate an individual, risk-directed, adjuvant systemic therapy in breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppl5Ppi20BRbVg90H21EOLACvtfcHk0lj5niIkGqk97A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Olur0%253D&md5=848683aeb8064462b3e269c00db0ce86</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs10549-004-1668-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-004-1668-2%26sid%3Dliteratum%253Aachs%26aulast%3DKrusche%26aufirst%3DC.%2BA.%26aulast%3DWulfing%26aufirst%3DP.%26aulast%3DKersting%26aufirst%3DC.%26aulast%3DVloet%26aufirst%3DA.%26aulast%3DBocker%26aufirst%3DW.%26aulast%3DKiesel%26aufirst%3DL.%26aulast%3DBeier%26aufirst%3DH.%2BM.%26aulast%3DAlfer%26aufirst%3DJ.%26atitle%3DHistone%2520deacetylase-1%2520and%2520-3%2520protein%2520expression%2520in%2520human%2520breast%2520cancer%253A%2520a%2520tissue%2520microarray%2520analysis%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2005%26volume%3D90%26spage%3D15%26epage%3D23%26doi%3D10.1007%2Fs10549-004-1668-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, H.</span></span> <span> </span><span class="NLM_article-title">Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1007/s10549-005-6001-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1007%2Fs10549-005-6001-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=16172792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVyltbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=11-16&author=Z.+Zhangauthor=H.+Yamashitaauthor=T.+Toyamaauthor=H.+Sugiuraauthor=Y.+Andoauthor=K.+Mitaauthor=M.+Hamaguchiauthor=Y.+Haraauthor=S.+Kobayashiauthor=H.+Iwase&title=Quantitation+of+HDAC1+mRNA+expression+in+invasive+carcinoma+of+the+breast*&doi=10.1007%2Fs10549-005-6001-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast</span></div><div class="casAuthors">Zhang, Zhenhuan; Yamashita, Hiroko; Toyama, Tatsuya; Sugiura, Hiroshi; Ando, Yoshiaki; Mita, Keiko; Hamaguchi, Maho; Hara, Yasuo; Kobayashi, Shunzo; Iwase, Hirotaka</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-16</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Estrogen is well-established as a mitogenic factor implicated in the tumorigenesis and progression of breast cancer via its binding to the estrogen receptor α (ERα).  Recent data indicate that chromatin inactivation mediated by histone deacetylation (HDAC) and DNA methylation is a crit. component of ERα silencing in human breast cancer cells.  The aim of this study was to det. the expression of the HDAC1 gene in malignant human breast tissue and to correlate our observations with available clin. information.  In the present study, the level of expression of HDAC1 mRNA was assessed by LightCycler-based quant. real-time reverse transcriptase (RT)-PCR anal. in 162 cases of invasive carcinoma of the breast.  Assocns. between HDAC1 mRNA expression and different clinicopathol. factors were sought.  It was found that HDAC1 mRNA was expressed at significantly higher levels in tumors from patients over 50 years of age and in those tumors without axillary lymph node involvement, that are less than 2 cm, that are of a non-high histol. grade, that are HER2 neg. and that are ERα/PgR pos.  Patients with tumors displaying high levels of HDAC1 mRNA expression tended to have a better prognosis in terms of both disease-free and overall survival.  However, univariate and multivariate anal. did not show HDAC1 mRNA expression level to be an independent prognostic factor for either disease-free or overall survival.  These results imply that HDAC1 mRNA expression could have potential as an endocrine response marker and may have prognostic implications for breast cancer progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXQ0D466PdgrVg90H21EOLACvtfcHk0lhIDf30RZhaJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVyltbjK&md5=2481b26970c84afab7b464d6769014da</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs10549-005-6001-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-005-6001-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DYamashita%26aufirst%3DH.%26aulast%3DToyama%26aufirst%3DT.%26aulast%3DSugiura%26aufirst%3DH.%26aulast%3DAndo%26aufirst%3DY.%26aulast%3DMita%26aufirst%3DK.%26aulast%3DHamaguchi%26aufirst%3DM.%26aulast%3DHara%26aufirst%3DY.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DIwase%26aufirst%3DH.%26atitle%3DQuantitation%2520of%2520HDAC1%2520mRNA%2520expression%2520in%2520invasive%2520carcinoma%2520of%2520the%2520breast%252A%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2005%26volume%3D94%26spage%3D11%26epage%3D16%26doi%3D10.1007%2Fs10549-005-6001-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gau, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, G.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1007/s10549-013-2784-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1007%2Fs10549-013-2784-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=24305977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFKgtbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2014&pages=99-111&author=P.+Shahauthor=Y.+Gauauthor=G.+Sabnis&title=Histone+deacetylase+inhibitor+entinostat+reverses+epithelial+to+mesenchymal+transition+of+breast+cancer+cells+by+reversing+the+repression+of+E-cadherin&doi=10.1007%2Fs10549-013-2784-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin</span></div><div class="casAuthors">Shah, Preeti; Gau, Yael; Sabnis, Gauri</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-111</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Loss of ERα in breast cancer correlates with poor prognosis, increased recurrence rates, and higher incidence of metastasis.  Epigenetic silencing of E-cadherin (loss of which is assocd. with more invasive phenotype) is obsd. in metastatic cell lines and invasive breast cancers.  Here, we are showing that entinostat (ENT) can reverse epithelial to mesenchymal transition (EMT), which is considered to be a first step in the process of metastases formation.  Triple-neg. breast cancer cells such as MDA-MB-231 and Hs578T show a basal phenotype characterized by loss of E-cadherin expression and higher expression of mesenchymal markers such as N-cadherin and vimentin along with transcriptional repressors such as twist and snail.  When MDA-MB-231 and Hs578T cells or tumors were treated with ENT, E-cadherin transcription was increased along with redn. in N-cadherin mRNA expression.  Chromatin immunopptn. assay showed that treatment of MDA-MB-231 and Hs578T cells increased the activation of E-cadherin promoter by reducing the assocn. of twist and snail with the E-cadherin (CDH1) promoter and downregulated both the snail and twist.  ENT also inhibited cell migration in vitro.  In addn., phosphorylation of vimentin was increased, as well as remodeling of vimentin filaments.  ENT treatment also reduced formation of tubulin-based microtentacles, which help floating cells attach to other surfaces.  These findings suggest that ENT can reverse EMT and may reduce the formation of metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3qhRaYzBvB7Vg90H21EOLACvtfcHk0lhIDf30RZhaJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFKgtbrF&md5=0ad48e48edd917a879b3dadb0743e89a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs10549-013-2784-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-013-2784-7%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DP.%26aulast%3DGau%26aufirst%3DY.%26aulast%3DSabnis%26aufirst%3DG.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520entinostat%2520reverses%2520epithelial%2520to%2520mesenchymal%2520transition%2520of%2520breast%2520cancer%2520cells%2520by%2520reversing%2520the%2520repression%2520of%2520E-cadherin%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2014%26volume%3D143%26spage%3D99%26epage%3D111%26doi%3D10.1007%2Fs10549-013-2784-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garmpis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garmpi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalampokas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalampokas, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valsami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontzoglou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiteas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitroulis, D.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases as new therapeutic targets in triple-negative breast cancer: progress and promises</span>. <i>Cancer Genomics Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.21873/CGP.20041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.21873%2FCGP.20041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=28870998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslaisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=299-313&author=N.+Garmpisauthor=D.+Christosauthor=A.+Garmpiauthor=E.+Kalampokasauthor=T.+A.+Kalampokasauthor=S.+Valsamiauthor=M.+Kontosauthor=A.+Nonniauthor=K.+Kontzoglouauthor=D.+Perreaauthor=N.+Nikiteasauthor=D.+Dimitroulis&title=Histone+deacetylases+as+new+therapeutic+targets+in+triple-negative+breast+cancer%3A+progress+and+promises&doi=10.21873%2FCGP.20041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases as new therapeutic targets in triple-negative breast cancer: progress and promises</span></div><div class="casAuthors">Garmpis, Nikolaos; Damaskos, Christos; Garmpi, Anna; Kalampokas, Emmanouil; Kalampokas, Theodoros; Spartalis, Eleftherios; Daskalopoulou, Afrodite; Valsami, Serena; Kontos, Michael; Nonni, Afroditi; Kontzoglou, Konstantinos; Perrea, Despina; Nikiteas, Nikolaos; Dimitroulis, Dimitrios</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Genomics & Proteomics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">299-313</span>CODEN:
                <span class="NLM_cas:coden">CGPAC7</span>;
        ISSN:<span class="NLM_cas:issn">1790-6245</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) lacks expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 gene.  It comprises approx. 15-20% of breast cancers (BCs).  Unfortunately, TNBC's treatment continues to be a clin. problem because of its relatively poor prognosis, its aggressiveness and the lack of targeted therapies, leaving chemotherapy as the mainstay of treatment.  It is essential to find new therapies against TNBC, in order to surpass the resistance and the invasiveness of already existing therapies.  Given the fact that epigenetic processes control both the initiation and progression of TNBC, there is an increasing interest in the mechanisms, mols. and signaling pathways that participate at the epigenetic modulation of genes expressed in carcinogenesis.  The acetylation of histone proteins provokes the transcription of genes involved in cell growth, and the expression of histone deacetylases (HDACs) is frequently up-regulated in many malignancies.  Unfortunately, in the field of BC, HDAC inhibitors have shown limited effect as single agents.  Nevertheless, their use in combination with kinase inhibitors, autophagy inhibitors, ionizing radiation, or two HDAC inhibitors together is currently being evaluated.  HDAC inhibitors such as suberoylanilidehydroxamic acid (SAHA), sodium butyrate, mocetinostat, panobinostat, entinostat, YCW1 and N-2-hydroxyphenyl-2-propylpentanamide have shown promising therapeutic outcomes against TNBC, esp. when they are used in combination with other anticancer agents.  More studies concerning HDAC inhibitors in breast carcinomas along with a more accurate understanding of the TNBC's pathobiol. are required for the possible identification of new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQvJ3B103o-rVg90H21EOLACvtfcHk0lhIDf30RZhaJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslaisw%253D%253D&md5=05740e9bef67109a282ce4ad7399ebb5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.21873%2FCGP.20041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21873%252FCGP.20041%26sid%3Dliteratum%253Aachs%26aulast%3DGarmpis%26aufirst%3DN.%26aulast%3DChristos%26aufirst%3DD.%26aulast%3DGarmpi%26aufirst%3DA.%26aulast%3DKalampokas%26aufirst%3DE.%26aulast%3DKalampokas%26aufirst%3DT.%2BA.%26aulast%3DValsami%26aufirst%3DS.%26aulast%3DKontos%26aufirst%3DM.%26aulast%3DNonni%26aufirst%3DA.%26aulast%3DKontzoglou%26aufirst%3DK.%26aulast%3DPerrea%26aufirst%3DD.%26aulast%3DNikiteas%26aufirst%3DN.%26aulast%3DDimitroulis%26aufirst%3DD.%26atitle%3DHistone%2520deacetylases%2520as%2520new%2520therapeutic%2520targets%2520in%2520triple-negative%2520breast%2520cancer%253A%2520progress%2520and%2520promises%26jtitle%3DCancer%2520Genomics%2520Proteomics%26date%3D2017%26volume%3D14%26spage%3D299%26epage%3D313%26doi%3D10.21873%2FCGP.20041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maiti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hait, N. C.</span></span> <span> </span><span class="NLM_article-title">Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.3892/ijo.2019.4796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.3892%2Fijo.2019.4796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=31059004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1OqtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=116-130&author=A.+Maitiauthor=Q.+Qiauthor=X.+Pengauthor=L.+Yanauthor=K.+Takabeauthor=N.+C.+Hait&title=Class+I+histone+deacetylase+inhibitor+suppresses+vasculogenic+mimicry+by+enhancing+the+expression+of+tumor+suppressor+and+anti-angiogenesis+genes+in+aggressive+human+TNBC+cells&doi=10.3892%2Fijo.2019.4796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells</span></div><div class="casAuthors">Maiti, Aparna; Qi, Qianya; Peng, Xuan; Yan, Li; Takabe, Kazuaki; Hait, Nitai C.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-130</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1791-2423</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) cells form angiogenesis-independent vessel-like structures to survive, known as vasculogenic mimicry (VM), contributing to a poor prognosis for cancer patients.  Nuclear localized class I histone deacetylases (HDACs) enzymes, particularly HDACs 1, 2, 3 deacetylate chromatin histones, are overexpressed in cancers and epigenetically regulate the expression of genes involved in cancer initiation and progression.  The specific HDAC inhibitor, entinostat, has been shown to attenuate tumor progression and metastasis in TNBC.  In this study, we hypothesized that entinostat would enhance the expression of anti-angiogenic and tumor suppressor genes and would thus suppress VM structures in TNBC cells in a 3D Matrigel cell culture preclin. model.  Our data indicated that invasive triple-neg. MDA-MB-231, LM2-4 and BT-549 breast cancer cells, but not poorly invasive luminal MCF-7 cells, efficiently underwent matrix-assocd. VM formation.  Approx. 80% of TNBC cells with the stem cell phenotype potential formed vessel-like structures when mixed with Matrigel and cultured in the low attachment tissue culture plate.  The mol. mechanisms of VM formation are rather complex, while angiogenesis inhibitor genes are downregulated and pro-angiogenesis genes are upregulated in VM-forming cells.  Our data revealed that treatment of the TNBC VM phenotype cells with entinostat epigenetically led to the re-expression of the anti-angiogenic genes, serpin family F member 1 (SERPINF1) and thrombospondin 2 (THBS2), and to that of the tumor suppressor genes, phosphatase and tensin homolog (PTEN) and p21, and reduced VM structures.  We also found that treatment of the TNBC VM phenotype cells with entinostat downregulated the expression of vascular endothelial growth factor A (VEGF-A), and that of the epithelial-mesenchymal transition (EMT)-related genes, Vimentin and β-catenin.  METABIRC and TCGA breast cancer cohort mRNA expression data anal. revealed that a high expression of the anti-angiogenesis-assocd. genes, THBS2, SERPINF1 and serpin family B member 5 (SERPINB5), and of the tumor suppressor gene, PTEN, was assocd. with a better overall survival (OS) of breast cancer patients.  Taken together, the findings of this study demonstrate that HDACs 1, 2, 3 partly contribute to VM formation in TNBC cells; thus, HDACs may be an important therapeutic target for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMD7MoYG5MHbVg90H21EOLACvtfcHk0lgPGZNaVxDArg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1OqtLrM&md5=b1340b7490c73e28379ad785cb33ce14</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.3892%2Fijo.2019.4796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2019.4796%26sid%3Dliteratum%253Aachs%26aulast%3DMaiti%26aufirst%3DA.%26aulast%3DQi%26aufirst%3DQ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DTakabe%26aufirst%3DK.%26aulast%3DHait%26aufirst%3DN.%2BC.%26atitle%3DClass%2520I%2520histone%2520deacetylase%2520inhibitor%2520suppresses%2520vasculogenic%2520mimicry%2520by%2520enhancing%2520the%2520expression%2520of%2520tumor%2520suppressor%2520and%2520anti-angiogenesis%2520genes%2520in%2520aggressive%2520human%2520TNBC%2520cells%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2019%26volume%3D55%26spage%3D116%26epage%3D130%26doi%3D10.3892%2Fijo.2019.4796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanigan, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboukhatwa, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taha, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frasor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petukhov, P. A.</span></span> <span> </span><span class="NLM_article-title">Divergent JNK phosphorylation of HDAC3 in triple-negative breast cancer cells determines HDAC inhibitor binding and selectivity</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1356</span>– <span class="NLM_lpage">13676</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1016%2Fj.chembiol.2017.08.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=28943357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGnsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1356-13676&author=T.+W.+Haniganauthor=S.+M.+Aboukhatwaauthor=T.+Y.+Tahaauthor=J.+Frasorauthor=P.+A.+Petukhov&title=Divergent+JNK+phosphorylation+of+HDAC3+in+triple-negative+breast+cancer+cells+determines+HDAC+inhibitor+binding+and+selectivity&doi=10.1016%2Fj.chembiol.2017.08.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity</span></div><div class="casAuthors">Hanigan, Thomas W.; Aboukhatwa, Shaimaa M.; Taha, Taha Y.; Frasor, Jonna; Petukhov, Pavel A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1356-1367.e8</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) catalytic activity is regulated by formation of co-regulator complexes and post-translational modification.  Whether these mechanisms are transformed in cancer and how this affects the binding and selectivity of HDAC inhibitors (HDACis) is unclear.  In this study, we developed a method that identified a 3- to 16-fold increase in HDACi selectivity for HDAC3 in triple-neg. breast cancer (TNBC) cells in comparison with luminal subtypes that was not predicted by current practice measurements with recombinant proteins.  We found this increase was caused by c-Jun N-terminal kinase (JNK) phosphorylation of HDAC3, was independent of HDAC3 complex compn. or subcellular localization, and was assocd. with a 5-fold increase in HDAC3 enzymic activity.  This study points to HDAC3 and the JNK axes as targets in TNBC, highlights how HDAC phosphorylation affects HDACi binding and selectivity, and outlines a method to identify changes in individual HDAC isoforms catalytic activity, applicable to any disease state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCZU_S5SEOArVg90H21EOLACvtfcHk0lgPGZNaVxDArg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGnsrfF&md5=f63d68cc73cf1175890f39b6a91301bc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DHanigan%26aufirst%3DT.%2BW.%26aulast%3DAboukhatwa%26aufirst%3DS.%2BM.%26aulast%3DTaha%26aufirst%3DT.%2BY.%26aulast%3DFrasor%26aufirst%3DJ.%26aulast%3DPetukhov%26aufirst%3DP.%2BA.%26atitle%3DDivergent%2520JNK%2520phosphorylation%2520of%2520HDAC3%2520in%2520triple-negative%2520breast%2520cancer%2520cells%2520determines%2520HDAC%2520inhibitor%2520binding%2520and%2520selectivity%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D1356%26epage%3D13676%26doi%3D10.1016%2Fj.chembiol.2017.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schech, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, G.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor entinostat inhibits tumor-initiating cells in triple-negative breast cancer cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1848</span>– <span class="NLM_lpage">1857</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1158%2F1535-7163.MCT-14-0778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=26037781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1yrs7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1848-1857&author=A.+Schechauthor=A.+Kaziauthor=S.+Yuauthor=P.+Shahauthor=G.+Sabnis&title=Histone+deacetylase+inhibitor+entinostat+inhibits+tumor-initiating+cells+in+triple-negative+breast+cancer+cells&doi=10.1158%2F1535-7163.MCT-14-0778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells</span></div><div class="casAuthors">Schech, Amanda; Kazi, Armina; Yu, Stephen; Shah, Preeti; Sabnis, Gauri</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1848-1857</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mortality following breast cancer diagnosis is mainly due to the development of distant metastasis.  To escape from the primary site, tumor cells undergo the epithelial-to-mesenchymal transition (EMT), which helps them acquire a more motile and invasive phenotype.  In our previous study, we showed that class I selective HDAC inhibitor entinostat reverses the EMT phenotype through reversal of epigenetic repression of E-cadherin.  Recent evidence suggests that a subset of cells within a breast tumor may drive the metastatic outgrowth following escape from the primary site.  These cells, termed tumor-initiating cells (TIC), represent a great threat to overall prognosis.  They are crit. in terms of drug resistance and tumor initiation at metastatic sites.  Acquisition of EMT traits has also been shown to impart TIC phenotype to the cells, making EMT a "dual-threat" for prognosis.  In the current study, we show that entinostat treatment can reduce the percentage of TIC cells from triple-neg. breast cancer (TNBC) cells.  Entinostat treatment was able to reduce the CD44high/CD24low cell population, ALDH-1 activity, as well as protein and mRNA expression of known TIC markers such as Bmi-1, Nanog, and Oct-4.  Next, we inoculated MDA-MB-231 cells transfected with firefly luciferase (231/Luc) in mammary fat pad of NSG mice.  The mice were then treated with entinostat (2.5 mg/kg/d), and tumor development and formation of metastasis were assessed by bioluminescence imaging.  Treatment with entinostat significantly reduced tumor formation at the primary site as well as lung metastasis.  As such, entinostat may help prevent development of distant metastasis.  Mol Cancer Ther; 14(8); 1848-57. 2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRu0jMR4ckFrVg90H21EOLACvtfcHk0lgPGZNaVxDArg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1yrs7vF&md5=0a68c2c5bdfd03939c216a59987fc8bd</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0778%26sid%3Dliteratum%253Aachs%26aulast%3DSchech%26aufirst%3DA.%26aulast%3DKazi%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DSabnis%26aufirst%3DG.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520entinostat%2520inhibits%2520tumor-initiating%2520cells%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D1848%26epage%3D1857%26doi%3D10.1158%2F1535-7163.MCT-14-0778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terranova-Barberio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowskal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeenah Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krings, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budillon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibition potentiates immunotherapy in triple negative breast cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">114156</span>– <span class="NLM_lpage">114172</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.23169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.18632%2Foncotarget.23169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=29371976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A280%3ADC%252BC1MvksFSrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=114156-114172&author=M.+Terranova-Barberioauthor=S.+Scott+Thomasauthor=N.+Aliauthor=N.+Pawlowskalauthor=J.+Jeenah+Parkauthor=G.+Kringsauthor=M.+D.+Rosenblumauthor=A.+Budillonauthor=P.+N.+Munster&title=HDAC+inhibition+potentiates+immunotherapy+in+triple+negative+breast+cancer&doi=10.18632%2Foncotarget.23169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibition potentiates immunotherapy in triple negative breast cancer</span></div><div class="casAuthors">Terranova-Barberio Manuela; Thomas Scott; Pawlowska Nela; Park Jeenah; Munster Pamela N; Ali Niwa; Rosenblum Michael D; Krings Gregor; Budillon Alfredo</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">69</span>),
    <span class="NLM_cas:pages">114156-114172</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is significant and resistance often follows.  Immunotherapy has shown promising results in various types of cancer, including breast cancer.  Here, we investigated a new combination strategy where histone deacetylase inhibitors (HDACi) are applied with immune checkpoint inhibitors to improve immunotherapy responses in TNBC.  Testing different epigenetic modifiers, we focused on the mechanisms underlying HDACi as priming modulators of immunotherapy.  Tumor cells were co-cultured with human peripheral blood mononuclear cells (PBMCs) and flow cytometric immunophenotyping was performed to define the role of epigenetic priming in promoting tumor antigen presentation and immune cell activation.  We found that HDACi up-regulate PD-L1 mRNA and protein expression in a time-dependent manner in TNBC cells, but not in hormone responsive cells.  Focusing on TNBC, HDACi up-regulated PD-L1 and HLA-DR on tumor cells when co-cultured with PBMCs and down-regulated CD4(+) Foxp3(+) Treg in vitro.  HDACi significantly enhanced the in vivo response to PD-1/CTLA-4 blockade in the triple-negative 4T1 breast cancer mouse model, the only currently available experimental system with functional resemblance to human TNBC.  This resulted in a significant decrease in tumor growth and increased survival, associated with increased T cell tumor infiltration and a reduction in CD4(+) Foxp3(+) T cells in the tumor microenvironment.  Overall, our results suggest a novel role for HDAC inhibition in combination with immune checkpoint inhibitors and identify a promising therapeutic strategy, supporting its further clinical evaluation for TNBC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUq_R8b5qOmiSm0e6ZOaemfW6udTcc2eaugwGAm8VSPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvksFSrsw%253D%253D&md5=c9511d4998918fe6313ea5cdea6dd924</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.23169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.23169%26sid%3Dliteratum%253Aachs%26aulast%3DTerranova-Barberio%26aufirst%3DM.%26aulast%3DScott%2BThomas%26aufirst%3DS.%26aulast%3DAli%26aufirst%3DN.%26aulast%3DPawlowskal%26aufirst%3DN.%26aulast%3DJeenah%2BPark%26aufirst%3DJ.%26aulast%3DKrings%26aufirst%3DG.%26aulast%3DRosenblum%26aufirst%3DM.%2BD.%26aulast%3DBudillon%26aufirst%3DA.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DHDAC%2520inhibition%2520potentiates%2520immunotherapy%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D114156%26epage%3D114172%26doi%3D10.18632%2Foncotarget.23169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waschke, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolaver, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piscopio, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. H.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibition sensitizes PD1 blockade-resistant B-cell lymphomas.</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1318</span>– <span class="NLM_lpage">1331</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-18-0875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1158%2F2326-6066.CIR-18-0875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=31235619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGjs7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=1318-1331&author=X.+Wangauthor=B.+C.+Waschkeauthor=R.+A.+Woolaverauthor=Z.+Chenauthor=G.+Zhangauthor=A.+D.+Piscopioauthor=X.+Liuauthor=J.+H.+Wang&title=Histone+deacetylase+inhibition+sensitizes+PD1+blockade-resistant+B-cell+lymphomas.&doi=10.1158%2F2326-6066.CIR-18-0875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibition sensitizes PD1 blockade-resistant B-cell lymphomas</span></div><div class="casAuthors">Wang, Xiaoguang; Waschke, Brittany C.; Woolaver, Rachel A.; Chen, Zhangguo; Zhang, Gan; Piscopio, Anthony D.; Liu, Xuedong; Wang, Jing H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1318-1331</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PD1 blockade is effective in a subset of patients with B-cell lymphoma (e.g., classical-Hodgkin lymphomas); however, most patients do not respond to anti-PD1 therapy.  To study PD1 resistance, we used an isoform-selective histone deacetylase inhibitor (HDACi; OKI-179), and a mouse mature B-cell lymphoma, G1XP lymphoma, immunosuppressive features of which resemble those of human B-cell lymphomas, including downregulation of MHC class I and II, exhaustion of CD8+ and CD4+ tumor-infiltrating lymphocytes (TIL), and PD1-blockade resistance.  Using two lymphoma models, we show that treatment of B-cell lymphomas refractory to PD1 blockade with both OKI-179 and anti-PD1 inhibited growth; furthermore, sensitivity to single or combined treatment required tumor-derived MHC class I, and pos. correlated with MHC class II expression level.  We conclude that OKI-179 sensitizes lymphomas to PD1-blockade by enhancing tumor immunogenicity.  In addn., we found that different HDACis exhibited distinct effects on tumors and T cells, yet the same HDACi could differentially affect HLA expression on different human B-cell lymphomas.  Our study highlights the immunol. effects of HDACis on antitumor responses and suggests that optimal treatment efficacy requires personalized design and rational combination based on prognostic biomarkers (e.g., MHCs) and the individual profiles of HDACi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYLbxnb5iyHLVg90H21EOLACvtfcHk0ljDH9tE2VsbAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGjs7nM&md5=c1c8a7be8c141e751de4b5c811caf6ba</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-18-0875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-18-0875%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWaschke%26aufirst%3DB.%2BC.%26aulast%3DWoolaver%26aufirst%3DR.%2BA.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DPiscopio%26aufirst%3DA.%2BD.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26atitle%3DHistone%2520deacetylase%2520inhibition%2520sensitizes%2520PD1%2520blockade-resistant%2520B-cell%2520lymphomas.%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2019%26volume%3D7%26spage%3D1318%26epage%3D1331%26doi%3D10.1158%2F2326-6066.CIR-18-0875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bieliauskas, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflum, M. K.</span></span> <span> </span><span class="NLM_article-title">Isoform-selective histone deacetylase inhibitors</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1402</span>– <span class="NLM_lpage">1413</span>, <span class="refDoi"> DOI: 10.1039/b703830p</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1039%2Fb703830p" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=18568166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFejsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2008&pages=1402-1413&author=A.+V.+Bieliauskasauthor=M.+K.+Pflum&title=Isoform-selective+histone+deacetylase+inhibitors&doi=10.1039%2Fb703830p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Isoform-selective histone deacetylase inhibitors</span></div><div class="casAuthors">Bieliauskas, Anton V.; Pflum, Mary Kay H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1402-1413</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) proteins are transcription regulators linked to cancer.  As a result, multiple small mol. HDAC inhibitors are in various phases of clin. trials as anti-cancer drugs.  The majority of HDAC inhibitors non-selectively influence the activities of eleven human HDAC isoforms, which are divided into distinct classes.  This tutorial review focuses on the recent progress toward the identification of class-selective and isoform-selective HDAC inhibitors.  The emerging trends suggest that subtle differences in the active sites of the HDAC isoforms can be exploited to dictate selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXOB_YFWaeZrVg90H21EOLACvtfcHk0ljDH9tE2VsbAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFejsbs%253D&md5=326e20da0623a00114f43e5c459c9920</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1039%2Fb703830p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb703830p%26sid%3Dliteratum%253Aachs%26aulast%3DBieliauskas%26aufirst%3DA.%2BV.%26aulast%3DPflum%26aufirst%3DM.%2BK.%26atitle%3DIsoform-selective%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2008%26volume%3D37%26spage%3D1402%26epage%3D1413%26doi%3D10.1039%2Fb703830p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span> <span> </span><span class="NLM_article-title">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1038/nbt1272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1038%2Fnbt1272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=17211407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=84-90&author=P.+A.+Marksauthor=R.+Breslow&title=Dimethyl+sulfoxide+to+vorinostat%3A+development+of+this+histone+deacetylase+inhibitor+as+an+anticancer+drug&doi=10.1038%2Fnbt1272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span></div><div class="casAuthors">Marks, Paul A.; Breslow, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-90</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In our quest to understand why DMSO (DMSO) can cause growth arrest and terminal differentiation of transformed cells, we followed a path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a histone deacetylase inhibitor.  SAHA reacts with and blocks the catalytic site of these enzymes.  Extensive structure-activity studies were done along the path from DMSO to SAHA.  SAHA can cause growth arrest and death of a broad variety of transformed cells both in vitro and in tumor-bearing animals at concns. not toxic to normal cells.  SAHA has many protein targets whose structure and function are altered by acetylation, including chromatin-assocd. histones, nonhistone gene transcription factors and proteins involved in regulation of cell proliferation, migration and death.  In clin. trials, SAHA has shown significant anticancer activity against both hematol. and solid tumors at doses well tolerated by patients.  A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma.  More potent analogs of SAHA have shown unacceptable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK3endE54rQ7Vg90H21EOLACvtfcHk0ljH4s9UnJGkDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D&md5=cc2a39d80d5d5bea0a1377bdf48a957d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnbt1272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1272%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26atitle%3DDimethyl%2520sulfoxide%2520to%2520vorinostat%253A%2520development%2520of%2520this%2520histone%2520deacetylase%2520inhibitor%2520as%2520an%2520anticancer%2520drug%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D84%26epage%3D90%26doi%3D10.1038%2Fnbt1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smolewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span> <span> </span><span class="NLM_article-title">The discovery and development of romidepsin for the treatment of T-cell lymphoma</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">859</span>– <span class="NLM_lpage">873</span>, <span class="refDoi"> DOI: 10.1080/17460441.2017.1341487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1080%2F17460441.2017.1341487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=28641053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFaksbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=859-873&author=P.+Smolewskiauthor=T.+Robak&title=The+discovery+and+development+of+romidepsin+for+the+treatment+of+T-cell+lymphoma&doi=10.1080%2F17460441.2017.1341487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and development of romidepsin for the treatment of T-cell lymphoma</span></div><div class="casAuthors">Smolewski, Piotr; Robak, Tadeusz</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">859-873</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Romidepsin is a potent and selective inhibitor of histone deacetylases (HDCAi).  It is also the only bicyclic inhibitor to undergo clin. assessment and is considered a promising drug for the treatment of T-cell lymphomas.  The cellular action of romidepsin results in enhanced histone acetylation, as well as the acetylation of other nuclear or cytoplasmic proteins, influencing cell cycle, apoptosis, and angiogenesis.  In phase II studies involving patients with relapsed or refractory of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), romidepsin produced overall response rates (ORR) of 34-35% and 25-38%, with complete response (CR) rates of 6% and 15-18%, resp.: This review summarizes the development of romidepsin, the mechanisms behind its antineoplastic action and its pharmacol.  It also covers its pharmacokinetic and pharmacodynamic properties, as well as the preclin. and clin. data on its activity in T-cell lymphoma.: Since there are only few effective therapies available for T-cell lymphomas, romidepsin is a valuable option for relapsed/refractory patients with both CTCL and PTCL.  It's also generally well tolerated, and gives potentially durable responses for patients with advanced and symptomatic disease.  Combinations of romidepsin with other antineoplastic agents may also further improve drug response and outcomes in T-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsigr0TqPjabVg90H21EOLACvtfcHk0ljH4s9UnJGkDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFaksbbM&md5=663c00630892ded87486e8ca6f406b13</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1080%2F17460441.2017.1341487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2017.1341487%26sid%3Dliteratum%253Aachs%26aulast%3DSmolewski%26aufirst%3DP.%26aulast%3DRobak%26aufirst%3DT.%26atitle%3DThe%2520discovery%2520and%2520development%2520of%2520romidepsin%2520for%2520the%2520treatment%2520of%2520T-cell%2520lymphoma%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2017%26volume%3D12%26spage%3D859%26epage%3D873%26doi%3D10.1080%2F17460441.2017.1341487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwitkowski, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Valle, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habtemariam, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomquist, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehrotra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlab, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminskas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2666</span>– <span class="NLM_lpage">2670</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-3119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1158%2F1078-0432.CCR-14-3119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=25802282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2666-2670&author=H.+Z.+Leeauthor=V.+E.+Kwitkowskiauthor=P.+L.+Del+Valleauthor=M.+S.+Ricciauthor=H.+Saberauthor=B.+A.+Habtemariamauthor=J.+Bullockauthor=E.+Bloomquistauthor=Y.+Li+Shenauthor=X.+H.+Chenauthor=J.+Brownauthor=N.+Mehrotraauthor=S.+Dorffauthor=R.+Charlabauthor=R.+C.+Kaneauthor=E.+Kaminskasauthor=R.+Justiceauthor=A.+T.+Farrellauthor=R.+Pazdur&title=FDA+approval%3A+Belinostat+for+the+treatment+of+patients+with+relapsed+or+refractory+peripheral+T-cell+lymphoma&doi=10.1158%2F1078-0432.CCR-14-3119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma</span></div><div class="casAuthors">Lee, Hyon-Zu; Kwitkowski, Virginia E.; Del Valle, Pedro L.; Ricci, M. Stacey; Saber, Haleh; Habtemariam, Bahru A.; Bullock, Julie; Bloomquist, Erik; Shen, Yuan Li; Chen, Xiao-Hong; Brown, Janice; Mehrotra, Nitin; Dorff, Sarah; Charlab, Rosane; Kane, Robert C.; Kaminskas, Edvardas; Justice, Robert; Farrell, Ann T.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2666-2670</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On July 3, 2014, the FDA granted accelerated approval for belinostat (Beleodaq; Spectrum Pharmaceuticals, Inc.), a histone deacetylase inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).  A single-arm, open-label, multicenter, international trial in the indicated patient population was submitted in support of the application.  Belinostat was administered i.v. at a dose of 1000 mg/m2 over 30 min once daily on days 1 to 5 of a 21-day cycle.  The primary efficacy endpoint was overall response rate (ORR) based on central radiol. readings by an independent review committee.  The ORR was 25.8% [95% confidence interval (CI), 18.3-34.6] in 120 patients that had confirmed diagnoses of PTCL by the Central Pathol. Review Group.  The complete and partial response rates were 10.8% (95% CI, 5.9-17.8) and 15.0% (95% CI, 9.1-22.7), resp.  The median duration of response, the key secondary efficacy endpoint, was 8.4 mo (95% CI, 4.5-29.4).  The most common adverse reactions (>25%) were nausea, fatigue, pyrexia, anemia, and vomiting.  Grade 3/4 toxicities (≥5.0%) included anemia, thrombocytopenia, dyspnea, neutropenia, fatigue, and pneumonia.  Belinostat is the third drug to receive accelerated approval for the treatment of relapsed or refractory PTCL.  Clin Cancer Res; 21(12); 2666-70. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1RbkvuHSk6rVg90H21EOLACvtfcHk0ljH4s9UnJGkDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfM&md5=c1e64c9d01d18272d25ad03001e7041a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-3119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-3119%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BZ.%26aulast%3DKwitkowski%26aufirst%3DV.%2BE.%26aulast%3DDel%2BValle%26aufirst%3DP.%2BL.%26aulast%3DRicci%26aufirst%3DM.%2BS.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DHabtemariam%26aufirst%3DB.%2BA.%26aulast%3DBullock%26aufirst%3DJ.%26aulast%3DBloomquist%26aufirst%3DE.%26aulast%3DLi%2BShen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DMehrotra%26aufirst%3DN.%26aulast%3DDorff%26aufirst%3DS.%26aulast%3DCharlab%26aufirst%3DR.%26aulast%3DKane%26aufirst%3DR.%2BC.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%253A%2520Belinostat%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520relapsed%2520or%2520refractory%2520peripheral%2520T-cell%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2666%26epage%3D2670%26doi%3D10.1158%2F1078-0432.CCR-14-3119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Veggel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamberg, P.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics and pharmacodynamics of panobinostat</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1007/s40262-017-0565-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1007%2Fs40262-017-0565-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=28667459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCrsrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=21-29&author=M.+Van%0AVeggelauthor=E.+Westermanauthor=P.+Hamberg&title=Clinical+pharmacokinetics+and+pharmacodynamics+of+panobinostat&doi=10.1007%2Fs40262-017-0565-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat</span></div><div class="casAuthors">Van Veggel, Mathilde; Westerman, Elsbeth; Hamberg, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-29</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors cause an increase in acetylation that leads to an increase in DNA transcription and accumulation of different proteins, reducing cell proliferation and inducing cell death.  Panobinostat is a first-in-line HDAC inhibitor approved for treating multiple myeloma in combination with bortezomib and dexamethasone.  It is a pan-deacetylase inhibitor and therefore inhibits not only HDAC but also other deacetylases.  The main mechanism of action of panobinostat is to inhibit HDAC, which causes cell cycle arrest and apoptosis, leading to it being an antineoplastic drug.  Pooled data of multiple-dose studies show that an oral dose of panobinostat 20 mg resulted in a max. plasma concn. (Cmax) of 21.6 ng/mL approx. 1 h after administration, while doses between 10 and 30 mg resulted in dose proportional plasma levels.  The abs. bioavailability of panobinostat is 21.4%, and it is moderately bound to plasma proteins.  Renal impairment does not influence the intrinsic pharmacokinetics of panobinostat, however hepatic impairment causes an increase in the plasma concns. of this drug.  Therefore, starting treatment at lower doses could be considered in patients with mild to moderate hepatic impairment.  Different ethnic backgrounds have an influence on the pharmacokinetics of panobinostat; however, due to major interindividual variability, no dose adjustment is recommended.  The area under the concn.-time curve of panobinostat changes significantly under cytochrome P 450 (CYP) 3A4 inhibitors, CYP3A4 and CYP2D6 inducers, and P-glycoprotein inhibitors.  Panobinostat itself is a CYP2D6 inhibitor, which influences the plasma levels of the CYP2D6 substrate dexamethasone.  The main side effects of panobinostat are diarrhea, peripheral neuropathy, asthenia and fatigue; hematol. side effects include neutropenia, thrombocytopenia, and lymphocytopenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-2XvQp0m2jLVg90H21EOLACvtfcHk0lgMcgmqkv8kcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCrsrnI&md5=1459e8401b5682d9ed56899da8f7b6db</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs40262-017-0565-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-017-0565-x%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BVeggel%26aufirst%3DM.%26aulast%3DWesterman%26aufirst%3DE.%26aulast%3DHamberg%26aufirst%3DP.%26atitle%3DClinical%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520panobinostat%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2018%26volume%3D57%26spage%3D21%26epage%3D29%26doi%3D10.1007%2Fs40262-017-0565-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span> <span> </span><span class="NLM_article-title">Selective histone deacetylase small molecule inhibitors: recent progress and perspectives</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">636</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1276565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1080%2F13543776.2017.1276565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=28033734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVym" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=621-636&author=H.+T.+Qinauthor=H.+Q.+Liauthor=F.+Liu&title=Selective+histone+deacetylase+small+molecule+inhibitors%3A+recent+progress+and+perspectives&doi=10.1080%2F13543776.2017.1276565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Selective histone deacetylase small molecule inhibitors: recent progress and perspectives</span></div><div class="casAuthors">Qin, Hai-Tao; Li, Huan-Qiu; Liu, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">621-636</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Since the first pan-HDAC inhibitor SAHA was approved by U.  S. FDA 10 years ago, HDACs including SIRT1-7 have received significant attention due to the fact that aberrant histone deacetylase activity has been implicated in a variety of human diseases, such as cancers, virus infection, and neurodegenerative diseases.  During the past years, a considerable achievement of development of isoform- or class-selective HDAC inhibitors has been made, yielding many drug candidates for further clin. studies, which represents a state-of-the-art technol. in the drug discovery arena.  This review covers new patents and articles about isoform- or class-selective HDAC inhibitors during the last four years, as well as the therapeutic potential of these compds.  HDACs represent one of the most promising therapeutic targets, particularly for tumor therapy though their roles in cancer are still blurry.  From 2012 to present, along with the advances of structural biol. and homol. models, lots of isoform- or class-selective HDAC inhibitors, such as hydroxamic acids and benzamides with various capping groups were found, providing a promising way to circumvent drug toxicity and side-effect issues, as well as providing chem. probes for further better understanding of the biol. process related to specific isoform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwnI5I_UhbmLVg90H21EOLACvtfcHk0lgMcgmqkv8kcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVym&md5=2984f0a32f64aa8d2a33174ed053da10</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1276565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1276565%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DH.%2BT.%26aulast%3DLi%26aufirst%3DH.%2BQ.%26aulast%3DLiu%26aufirst%3DF.%26atitle%3DSelective%2520histone%2520deacetylase%2520small%2520molecule%2520inhibitors%253A%2520recent%2520progress%2520and%2520perspectives%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D621%26epage%3D636%26doi%3D10.1080%2F13543776.2017.1276565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kollar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frecer, V.</span></span> <span> </span><span class="NLM_article-title">Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1472</span>– <span class="NLM_lpage">1502</span>, <span class="refDoi"> DOI: 10.2174/1381612820666141110164604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.2174%2F1381612820666141110164604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=25382430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslyhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1472-1502&author=J.+Kollarauthor=V.+Frecer&title=Selective+inhibitors+of+zinc-dependent+histone+deacetylases.+Therapeutic+targets+relevant+to+cancer&doi=10.2174%2F1381612820666141110164604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer</span></div><div class="casAuthors">Kollar, Jakub; Frecer, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1472-1502</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs), which act on acetylated histones and/or other non-histone protein substrates, represent validated epigenetic targets for the treatment of cancer and other human diseases.  The inhibition of HDAC activity was shown to induce cell cycle arrest, differentiation, apoptosis as well as a decrease in proliferation, angiogenesis, migration, and cell resistance to chemotherapy.  Targeting single HDAC isoforms with selective inhibitors will help to reveal the role of individual HDACs in cancer development or uncover further biol. consequences of protein acetylation.  This review focuses on conventional zinc-contg. HDACs.  In its first part, the biol. role of individual HDACs in various types of cancer is summarized.  In the second part, promising HDAC inhibitors showing activity both in enzymic and cell-based assays are surveyed with an emphasis on the inhibitors selective to the individual HDACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruWmnPURx9OrVg90H21EOLACvtfcHk0lgMcgmqkv8kcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslyhtL8%253D&md5=a9d5af3a36841338b76423db1c849468</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F1381612820666141110164604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612820666141110164604%26sid%3Dliteratum%253Aachs%26aulast%3DKollar%26aufirst%3DJ.%26aulast%3DFrecer%26aufirst%3DV.%26atitle%3DSelective%2520inhibitors%2520of%2520zinc-dependent%2520histone%2520deacetylases.%2520Therapeutic%2520targets%2520relevant%2520to%2520cancer%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2015%26volume%3D21%26spage%3D1472%26epage%3D1502%26doi%3D10.2174%2F1381612820666141110164604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishii, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhopadhyay, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soghomonyan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volgin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alauddin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelovani, J.</span></span> <span> </span><span class="NLM_article-title">Non-invasive imaging of histone deacetylase activity in human breast carcinoma xenografts in rats using positron emission tomography (PET) with [18F]-FAHA</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">34P</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=34P&author=R.+Nishiiauthor=U.+Mukhopadhyayauthor=H.+Yehauthor=S.+Soghomonyanauthor=A.+Volginauthor=M.+Alauddinauthor=W.+Tongauthor=J.+Gelovani&title=Non-invasive+imaging+of+histone+deacetylase+activity+in+human+breast+carcinoma+xenografts+in+rats+using+positron+emission+tomography+%28PET%29+with+%5B18F%5D-FAHA"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNishii%26aufirst%3DR.%26aulast%3DMukhopadhyay%26aufirst%3DU.%26aulast%3DYeh%26aufirst%3DH.%26aulast%3DSoghomonyan%26aufirst%3DS.%26aulast%3DVolgin%26aufirst%3DA.%26aulast%3DAlauddin%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DW.%26aulast%3DGelovani%26aufirst%3DJ.%26atitle%3DNon-invasive%2520imaging%2520of%2520histone%2520deacetylase%2520activity%2520in%2520human%2520breast%2520carcinoma%2520xenografts%2520in%2520rats%2520using%2520positron%2520emission%2520tomography%2520%2528PET%2529%2520with%2520%255B18F%255D-FAHA%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2007%26volume%3D48%26spage%3D34P" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelovani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R. S.</span></span> <span> </span><span class="NLM_article-title">A simplified kinetic model for rat glioma with [18F] FAHA</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1182</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=1182&author=J.+W.+Kuoauthor=K.+H.+Suauthor=C.+Y.+Wuauthor=C.+H.+Hoauthor=H.+E.+Wangauthor=J.+Gelovaniauthor=R.+S.+Liu&title=A+simplified+kinetic+model+for+rat+glioma+with+%5B18F%5D+FAHA"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKuo%26aufirst%3DJ.%2BW.%26aulast%3DSu%26aufirst%3DK.%2BH.%26aulast%3DWu%26aufirst%3DC.%2BY.%26aulast%3DHo%26aufirst%3DC.%2BH.%26aulast%3DWang%26aufirst%3DH.%2BE.%26aulast%3DGelovani%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DR.%2BS.%26atitle%3DA%2520simplified%2520kinetic%2520model%2520for%2520rat%2520glioma%2520with%2520%255B18F%255D%2520FAHA%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2011%26volume%3D52%26spage%3D1182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruvilla, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galitovskiy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grando, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, J.</span></span> <span> </span><span class="NLM_article-title">Targeting histone deacetylase in lung cancer for early diagnosis: (18)F-FAHA PET/CT imaging of NNK-treated A/J mice model</span>. <i>Am. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">332</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=24982818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1egtLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=324-332&author=W.+Tangauthor=S.+A.+Kuruvillaauthor=V.+Galitovskiyauthor=M.+L.+Panauthor=S.+A.+Grandoauthor=J.+Mukherjee&title=Targeting+histone+deacetylase+in+lung+cancer+for+early+diagnosis%3A+%2818%29F-FAHA+PET%2FCT+imaging+of+NNK-treated+A%2FJ+mice+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone deacetylase in lung cancer for early diagnosis: 18F-FAHA PET/CT imaging of NNK-treated A/J mice model</span></div><div class="casAuthors">Tang, Wayland; Kuruvilla, Sharon A.; Galitovskiy, Valentin; Pan, Min-Liang; Grando, Sergei A.; Mukherjee, Jogeshwar</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">324-332, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">AJNMAU</span>;
        ISSN:<span class="NLM_cas:issn">2160-8407</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Elevated levels of histone deacetylases (HDACs) have been indicated in the development of some cancers.  HDAC has been imaged using 18F-FAHA and may serve as a marker to study epigenetics.  We report evaluation of 18F-FAHA as a probe in the early diagnosis of lung cancer using 18F-FAHA PET/CT studies of A/J mice treated with NNK.  18F-FAHA radiosynthesis was carried out in specific activity of ∼2 Ci/μmol.  A/J mice were divided into 2 groups: 1. Controls; 2. NNK treatment group with NNK (100 mg/kg, i.p., weekly for 4 wks).  Mice were injected 100-200 μCi i.v. 18F-FAHA and then scanned in Inveon PET/CT under anesthesia using 2.0% isoflurane.  Midbrain, cerebellum and brainstem uptake of 18F-FAHA was displaced by the known HDAC inhibitor, suberanilohydroxamic acid (SAHA) with less than 10% activity remaining.  CT revealed presence of lung nodules in 8- to 10-mo old NNK mice while control mice were free of tumors.  Little uptake of 18F-FAHA was obsd. in the control mice lungs while significant 18F-FAHA uptake occurred in the lungs of NNK-treated mice with tumor/nontumor >2.0.  Ex vivo scans of the excised NNK and control mice lungs confirmed presence of extensive amts. of lung nodules seen by CT and confirmed by 18F-FAHA in the NNK mice with tumor/nontumor >6.0.  Our preliminary imaging studies with A/J mice lung cancer model suggest 18F-FAHA PET may allow the study of epigenetic mechanisms involved in NNK-induced tumorigenesis in the lungs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo82GHnkDkE37Vg90H21EOLACvtfcHk0ljks0by9agigg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1egtLnM&md5=1753d4a4d07bd13b3971315af3f865cb</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DW.%26aulast%3DKuruvilla%26aufirst%3DS.%2BA.%26aulast%3DGalitovskiy%26aufirst%3DV.%26aulast%3DPan%26aufirst%3DM.%2BL.%26aulast%3DGrando%26aufirst%3DS.%2BA.%26aulast%3DMukherjee%26aufirst%3DJ.%26atitle%3DTargeting%2520histone%2520deacetylase%2520in%2520lung%2520cancer%2520for%2520early%2520diagnosis%253A%2520%252818%2529F-FAHA%2520PET%252FCT%2520imaging%2520of%2520NNK-treated%2520A%252FJ%2520mice%2520model%26jtitle%3DAm.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2014%26volume%3D4%26spage%3D324%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendricks, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keliher, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissleder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span> <span> </span><span class="NLM_article-title">In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5576</span>– <span class="NLM_lpage">5582</span>, <span class="refDoi"> DOI: 10.1021/jm200620f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200620f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptVSltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5576-5582&author=J.+A.+Hendricksauthor=E.+J.+Keliherauthor=B.+Marinelliauthor=T.+Reinerauthor=R.+Weisslederauthor=R.+Mazitschek&title=In+vivo+PET+imaging+of+histone+deacetylases+by+18F-suberoylanilide+hydroxamic+acid+%2818F-SAHA%29&doi=10.1021%2Fjm200620f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo PET Imaging of Histone Deacetylases by 18F-Suberoylanilide Hydroxamic Acid (18F-SAHA)</span></div><div class="casAuthors">Hendricks, J. Adam; Keliher, Edmund J.; Marinelli, Brett; Reiner, Thomas; Weissleder, Ralph; Mazitschek, Ralph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5576-5582</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are a group of enzymes that modulate gene expression and cell state by deacetylation of both histone and non-histone proteins.  A variety of HDAC inhibitors (HDACi) have already undergone clin. testing in cancer.  Real-time in vivo imaging of HDACs and their inhibition would be invaluable; however, the development of appropriate imaging agents has remained a major challenge.  Here, we describe the development and evaluation of 18F-suberoylanilide hydroxamic acid (18F-SAHA 1a), a close analog of the most clin. relevant HDAC inhibitor suberoylanilide hydroxamic acid (SAHA).  We demonstrate that 1a has near identical biochem. activity profiles to that of SAHA and report findings from pharmacokinetic studies.  Using a murine ovarian cancer model, we likewise show that HDAC inhibitor target binding efficacy can be quantitated within 24 h of administration.  1A thus represents the first 18F-positron emission tomog. (PET) HDAC imaging agent, which also exhibits low nanomolar potency and is pharmacol. analogous to a clin. relevant HDAC inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF0PVTT66Za7Vg90H21EOLACvtfcHk0ljks0by9agigg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptVSltbc%253D&md5=7226170eed911cb862935a5377367e07</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm200620f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200620f%26sid%3Dliteratum%253Aachs%26aulast%3DHendricks%26aufirst%3DJ.%2BA.%26aulast%3DKeliher%26aufirst%3DE.%2BJ.%26aulast%3DMarinelli%26aufirst%3DB.%26aulast%3DReiner%26aufirst%3DT.%26aulast%3DWeissleder%26aufirst%3DR.%26aulast%3DMazitschek%26aufirst%3DR.%26atitle%3DIn%2520vivo%2520PET%2520imaging%2520of%2520histone%2520deacetylases%2520by%252018F-suberoylanilide%2520hydroxamic%2520acid%2520%252818F-SAHA%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5576%26epage%3D5582%26doi%3D10.1021%2Fjm200620f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Novel (64)Cu-labeled CUDC-101 for in vivo PET imaging of histone deacetylases</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">858</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1021/ml400191z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400191z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOltr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=858-862&author=Q.+Mengauthor=F.+Liauthor=S.+Jiangauthor=Z.+Li&title=Novel+%2864%29Cu-labeled+CUDC-101+for+in+vivo+PET+imaging+of+histone+deacetylases&doi=10.1021%2Fml400191z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 64Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases</span></div><div class="casAuthors">Meng, Qingqing; Li, Feng; Jiang, Sheng; Li, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">858-862</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the design, synthesis, and biol. evaluation of a 64Cu-labeled histone deacetylase (HDAC) imaging probe, which was obtained by introduction of metal chelator through click reaction of HDAC inhibitor CUDC-101 and then radiolabeled with 64Cu.  The resulting 64Cu-labeled compd. 7 ([64Cu]7) was identified as a positron emission tomog. (PET) imaging probe to noninvasively visualize HDAC expression in vivo.  Cell based competitive assay established the specific binding of [64Cu]7 to HDACs.  Biodistribution and small-animal microPET/CT studies further showed that [64Cu]7 had high tumor to background ratio in the MDA-MB-231 xenograft model, a triple-neg. breast cancer with high expression of HDACs.  To our knowledge, [64Cu]7 thus represents the first 64Cu-labeled PET HDAC imaging probe, which exhibits nanomolar range binding affinity and capability to imaging HDAC expression in triple-neg. breast cancer in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv0IUScAfOG7Vg90H21EOLACvtfcHk0lgcVv5jn3RhLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOltr7M&md5=9d54dfd040f23252bb474047b97b542b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fml400191z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400191z%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DNovel%2520%252864%2529Cu-labeled%2520CUDC-101%2520for%2520in%2520vivo%2520PET%2520imaging%2520of%2520histone%2520deacetylases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D858%26epage%3D862%26doi%3D10.1021%2Fml400191z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">An HDAC-targeted imaging probe LBH589-Cy5.5 for tumor detection and therapy evaluation</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2469</span>– <span class="NLM_lpage">2476</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00167</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00167" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptlOhu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=2469-2476&author=Q.+Mengauthor=Z.+Liuauthor=F.+Liauthor=J.+Maauthor=H.+Wangauthor=Y.+Huanauthor=Z.+Li&title=An+HDAC-targeted+imaging+probe+LBH589-Cy5.5+for+tumor+detection+and+therapy+evaluation&doi=10.1021%2Facs.molpharmaceut.5b00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">An HDAC-Targeted Imaging Probe LBH589-Cy5.5 for Tumor Detection and Therapy Evaluation</span></div><div class="casAuthors">Meng, Qingqing; Liu, Zhiyi; Li, Feng; Ma, Jianjun; Wang, He; Huan, Yi; Li, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2469-2476</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are overexpressed in various cancers.  In vivo imaging to measure the expression and functions of HDACs in tumor plays an important role for tumor diagnosis and HDAC-targeted therapy evaluation.  The development of stable and highly sensitive HDAC targeting probe is highly desirable.  Near-IR (NIR) fluorescence optical imaging is a powerful technol. for visualizing disease at the mol. level in vivo with high sensitivity and no ionizing radiation.  We report here the design, synthesis, and bioactivity evaluation of LBH589-Cy5.5 for in vivo NIR fluorescence imaging of HDACs.  The IC50 value of the resulting NIR probe to HDACs was detd. to be 9.6 nM.  In vitro fluorescence microscopic studies using a triple-neg. breast cancer cell line, MDA-MB-231, established the binding specificity of LBH589-Cy5.5 to HDACs.  An in vivo imaging study performed in MDA-MB-231 tumor xenografts demonstrated accumulation of the probe in tumor with good contrast from 2 h to 48 h postinjection.  Furthermore, the fluorescent signal of LBH589-Cy5.5 in tumor was successfully blocked by coinjection of nonfluorescent LBH589 with the probe.  In a following therapy evaluation study, the administration of SAHA, a clin. used HDAC inhibitor, decreased LBH589-Cy5.5 accumulation in tumor, demonstrating the potential application of LBH589-Cy5.5 for evaluating therapeutic response of HDAC inhibitors in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ-peJSyPe8LVg90H21EOLACvtfcHk0lgcVv5jn3RhLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptlOhu7c%253D&md5=e65d0ec36cad4b2302a288747aef110f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00167%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DAn%2520HDAC-targeted%2520imaging%2520probe%2520LBH589-Cy5.5%2520for%2520tumor%2520detection%2520and%2520therapy%2520evaluation%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D2469%26epage%3D2476%26doi%3D10.1021%2Facs.molpharmaceut.5b00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span> <span> </span><span class="NLM_article-title">Development of a novel histone deacetylase-targeted near-infrared probe for hepatocellular carcinoma imaging and fluorescence image-guided surgery</span>. <i>Mol. Imaging Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">476</span>– <span class="NLM_lpage">485</span>, <span class="refDoi"> DOI: 10.1007/s11307-019-01389-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1007%2Fs11307-019-01389-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=31228075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Kqt7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2020&pages=476-485&author=C.+Tangauthor=Y.+Duauthor=Q.+Liangauthor=Z.+Chengauthor=J.+Tian&title=Development+of+a+novel+histone+deacetylase-targeted+near-infrared+probe+for+hepatocellular+carcinoma+imaging+and+fluorescence+image-guided+surgery&doi=10.1007%2Fs11307-019-01389-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery</span></div><div class="casAuthors">Tang, Chu; Du, Yang; Liang, Qian; Cheng, Zhen; Tian, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Imaging and Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">476-485</span>CODEN:
                <span class="NLM_cas:coden">MIBOCZ</span>;
        ISSN:<span class="NLM_cas:issn">1860-2002</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Hepatocellular carcinoma (HCC) is a common cancer worldwide, and complete surgical resection of diseased tissue is a reliable strategy to cure cancer.  Fluorescence image-guided surgery is a promising tool for surgeons to identify and remove malignant lesions.  While non-targeted fluorescent dyes have been used for HCC diagnosis and resection, insufficient specificity and false pos. uptake from inflammatory tissue result in a high recurrence rate or excessive excision of healthy liver tissue.  To circumvent these problems, we focused on developing novel tumor-specific targeting probe to selectively illuminate cancer region during surgery.  Given overexpression of histone deacetylases (HDACs) in HCC and many other cancers, HDAC-targeted imaging has been emerged as a promising tool for tumor detection.  Procedures: Recently, high expression of HDACs, in particular HDAC6, has been obsd. in tumor samples of HCC patient, and a few HDAC inhibitors, including FDA-approved suberoylanilide hydroxamic acid (SAHA), display potent antitumor effect on HCC.  Correspondingly, in this study, we utilized a small mol. SAHA with the high HDAC-binding affinity as the HCC-specific targeting ligand to develop HDAC-targeted fluorescence probe for HCC detection and fluorescence image-guided resection.  Results: In in vitro imaging, SAHA was labeled with fluorescein isothiocyanate (FITC) to evaluate targeting property, and the imaging results demonstrated that FITC-SAHA was specific uptake by HCC Bel-7402 cells.  In in vivo imaging, near IR fluorescence dye IRDye800CW-labeled SAHA (NIR probe IRDye800CW-SAHA) showed rapid tumor accumulation with high tumor-to-background contrast on both the s.c. and orthotopic HCC mouse tumor models.  Furthermore, the orthotopic HCC was successfully resected by the IRDye800CW-SAHA fluorescence image-guided surgery.  Moreover, IRDye800CW-SAHA showed no toxicity toward healthy tissues.  Conclusions: Our results indicate that IRDye800CW-SAHA is a clin. translatable probe for HCC detection and resection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpxgoP3K9oWbVg90H21EOLACvtfcHk0lgcVv5jn3RhLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Kqt7vI&md5=de9d96a637787deee821c607a7c5ae08</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs11307-019-01389-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11307-019-01389-4%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DQ.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DTian%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520a%2520novel%2520histone%2520deacetylase-targeted%2520near-infrared%2520probe%2520for%2520hepatocellular%2520carcinoma%2520imaging%2520and%2520fluorescence%2520image-guided%2520surgery%26jtitle%3DMol.%2520Imaging%2520Biol.%26date%3D2020%26volume%3D22%26spage%3D476%26epage%3D485%26doi%3D10.1007%2Fs11307-019-01389-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span> <span> </span><span class="NLM_article-title">Environment-sensitive fluorescent inhibitors of histone deacetylase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>, <span class="NLM_elocation-id">127128</span> <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1016%2Fj.bmcl.2020.127128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=32247729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsVSis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&author=X.+Zhouauthor=G.+Dongauthor=T.+Songauthor=G.+Wangauthor=Z.+Liauthor=X.+Qinauthor=L.+Duauthor=M.+Li&title=Environment-sensitive+fluorescent+inhibitors+of+histone+deacetylase&doi=10.1016%2Fj.bmcl.2020.127128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Environment-sensitive fluorescent inhibitors of histone deacetylase</span></div><div class="casAuthors">Zhou, Xin; Dong, Gaopan; Song, Tianjia; Wang, Guankai; Li, Zhenzhen; Qin, Xiaojun; Du, Lupei; Li, Minyong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">127128</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are proteases that can catalyze the deacetylation of histones to inhibit gene transcription.  Since mutations and/or aberrant expression of various HDACs are frequently assocd. with human diseases, particularly cancers, HDACs are important therapeutic targets for many human tumors.  However, there are still relatively few studies on HDAC small mol. fluorescent probes.  Herein, we designed and synthesized a class of environment-sensitive fluorescent inhibitors with a switch mechanism to study HDAC activity.  In vitro, the enzyme inhibition activity of compd. 6b was comparable to the pos. control drug SAHA, and it presented suitable imaging in living cells and tumor-tissue slices.  This environment-sensitive fluorescent inhibitor provides a new idea for the diagnosis and treatment of HDACs-related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKzIkMzw7F07Vg90H21EOLACvtfcHk0ljb6i0s16IDvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsVSis7k%253D&md5=3b1de86b28f8bbdebf99a87ad0d5c101</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127128%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DQin%26aufirst%3DX.%26aulast%3DDu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DM.%26atitle%3DEnvironment-sensitive%2520fluorescent%2520inhibitors%2520of%2520histone%2520deacetylase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26doi%3D10.1016%2Fj.bmcl.2020.127128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raudszus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowotny, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertzen, C. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krizsan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gockel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohlke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thieme, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span> <span> </span><span class="NLM_article-title">Fluorescent analogs of peptoid-based HDAC inhibitors: Synthesis, biological activity and cellular uptake kinetics</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>, <span class="NLM_elocation-id">115039</span> <span class="refDoi"> DOI: 10.1016/j.bmc.2019.07.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1016%2Fj.bmc.2019.07.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=31420257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyltbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&author=R.+Raudszusauthor=R.+Nowotnyauthor=C.+G.+W.+Gertzenauthor=A.+Sch%C3%B6lerauthor=A.+Krizsanauthor=I.+Gockelauthor=H.+Kalwaauthor=H.+Gohlkeauthor=R.+Thiemeauthor=F.+K.+Hansen&title=Fluorescent+analogs+of+peptoid-based+HDAC+inhibitors%3A+Synthesis%2C+biological+activity+and+cellular+uptake+kinetics&doi=10.1016%2Fj.bmc.2019.07.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescent analogs of peptoid-based HDAC inhibitors: Synthesis, biological activity and cellular uptake kinetics</span></div><div class="casAuthors">Raudszus, Rick; Nowotny, Robert; Gertzen, Christoph G. W.; Schoeler, Andrea; Krizsan, Andor; Gockel, Ines; Kalwa, Hermann; Gohlke, Holger; Thieme, Rene; Hansen, Finn K.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">115039</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Fluorescent tagging of bioactive mols. is a powerful tool to study cellular uptake kinetics and is considered as an attractive alternative to radioligands.  In this study, we developed fluorescent histone deacetylase (HDAC) inhibitors and investigated their biol. activity and cellular uptake kinetics.  Our approach was to introduce a dansyl group as a fluorophore in the solvent-exposed cap region of the HDAC inhibitor pharmacophore model.  Three novel fluorescent HDAC inhibitors were synthesized utilizing efficient submonomer protocols followed by the introduction of a hydroxamic acid or 2-aminoanilide moiety as zinc-binding group.  All compds. were tested for their inhibition of selected HDAC isoforms, and docking studies were subsequently performed to rationalize the obsd. selectivity profiles.  All HDAC inhibitors were further screened in proliferation assays in the esophageal adenocarcinoma cell lines OE33 and OE19.  Compd. I, 6-((N-(2-(benzylamino)-2-oxoethyl)-5-(dimethylamino)naphthalene)-1-sulfonamido)-N-hydroxyhexanamide, displayed the highest HDAC inhibitory capacity as well as the strongest anti-proliferative activity.  Fluorescence microscopy studies revealed that compd. I showed the fastest uptake kinetic and reached the highest abs. fluorescence intensity of all compds.  Hence, the rapid and increased cellular uptake of I might contribute to its potent anti-proliferative properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqML3cNtCXbvrVg90H21EOLACvtfcHk0ljb6i0s16IDvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyltbvJ&md5=7b944f5251e7e738edc203b33b2a9a2c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.07.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.07.055%26sid%3Dliteratum%253Aachs%26aulast%3DRaudszus%26aufirst%3DR.%26aulast%3DNowotny%26aufirst%3DR.%26aulast%3DGertzen%26aufirst%3DC.%2BG.%2BW.%26aulast%3DSch%25C3%25B6ler%26aufirst%3DA.%26aulast%3DKrizsan%26aufirst%3DA.%26aulast%3DGockel%26aufirst%3DI.%26aulast%3DKalwa%26aufirst%3DH.%26aulast%3DGohlke%26aufirst%3DH.%26aulast%3DThieme%26aufirst%3DR.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26atitle%3DFluorescent%2520analogs%2520of%2520peptoid-based%2520HDAC%2520inhibitors%253A%2520Synthesis%252C%2520biological%2520activity%2520and%2520cellular%2520uptake%2520kinetics%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26doi%3D10.1016%2Fj.bmc.2019.07.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wey, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span> <span> </span><span class="NLM_article-title">In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7999</span>– <span class="NLM_lpage">8009</span>, <span class="refDoi"> DOI: 10.1021/jm500872p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500872p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFWjsbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7999-8009&author=C.+Wangauthor=F.+A.+Schroederauthor=H.-Y.+Weyauthor=R.+Borraauthor=F.+F.+Wagnerauthor=S.+Reisauthor=S.+W.+Kimauthor=E.+B.+Holsonauthor=S.+J.+Haggartyauthor=J.+M.+Hooker&title=In+vivo+imaging+of+histone+deacetylases+%28HDACs%29+in+the+central+nervous+system+and+major+peripheral+organs&doi=10.1021%2Fjm500872p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs</span></div><div class="casAuthors">Wang, Changning; Schroeder, Frederick A.; Wey, Hsiao-Ying; Borra, Ronald; Wagner, Florence F.; Reis, Surya; Kim, Sung Won; Holson, Edward B.; Haggarty, Stephen J.; Hooker, Jacob M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7999-8009</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epigenetic enzymes are now targeted to treat the underlying gene expression dysregulation that contribute to disease pathogenesis.  Histone deacetylases (HDACs) have shown broad potential in treatments against cancer and emerging data supports their targeting in the context of cardiovascular disease and central nervous system dysfunction.  Development of a mol. agent for non-invasive imaging to elucidate the distribution and functional roles of HDACs in humans will accelerate medical research and drug discovery in this domain.  Herein, we describe the synthesis and validation of an HDAC imaging agent, [11C]6.  Our imaging results demonstrate that this probe has high specificity, good selectivity, and appropriate kinetics and distribution for imaging HDACs in the brain, heart, kidney, pancreas, and spleen.  Our findings support the translational potential for [11C]6 for human epigenetic imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoehb3pUmjZo7Vg90H21EOLACvtfcHk0ljb6i0s16IDvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFWjsbrF&md5=18db553fdee12a680743b8b34e34e337</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm500872p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500872p%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSchroeder%26aufirst%3DF.%2BA.%26aulast%3DWey%26aufirst%3DH.-Y.%26aulast%3DBorra%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DReis%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26atitle%3DIn%2520vivo%2520imaging%2520of%2520histone%2520deacetylases%2520%2528HDACs%2529%2520in%2520the%2520central%2520nervous%2520system%2520and%2520major%2520peripheral%2520organs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7999%26epage%3D8009%26doi%3D10.1021%2Fjm500872p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strebl, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Placzek, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wey, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de
Bittner, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelamegam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span> <span> </span><span class="NLM_article-title">Development of a fluorinated class-I HDAC radiotracer reveals key chemical determinants of brain penetrance</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00297</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00297" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVWrt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=528-533&author=M.+G.+Streblauthor=C.+Wangauthor=F.+A.+Schroederauthor=M.+S.+Placzekauthor=H.-Y.+Weyauthor=G.+C.+Van+de%0ABittnerauthor=R.+Neelamegamauthor=J.+M.+Hooker&title=Development+of+a+fluorinated+class-I+HDAC+radiotracer+reveals+key+chemical+determinants+of+brain+penetrance&doi=10.1021%2Facschemneuro.5b00297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Fluorinated Class-I HDAC Radiotracer Reveals Key Chemical Determinants of Brain Penetrance</span></div><div class="casAuthors">Strebl, Martin G.; Wang, Changning; Schroeder, Frederick A.; Placzek, Michael S.; Wey, Hsiao-Ying; Van de Bittner, Genevieve C.; Neelamegam, Ramesh; Hooker, Jacob M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-533</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite major efforts, our knowledge about many brain diseases remains remarkably limited.  Epigenetic dysregulation has been one of the few leads toward identifying the causes and potential treatments of psychiatric disease over the past decade.  A new positron emission tomog. radiotracer, [11C]Martinostat, has enabled the study of histone deacetylase in living human subjects.  A unique property of [11C]Martinostat is its profound brain penetrance, a feature that is challenging to engineer intentionally.  In order to understand detg. factors for the high brain-uptake of Martinostat, a series of compds. was evaluated in rodents and nonhuman primates.  The study revealed the major structural contributors to brain uptake, as well as a more clin. relevant fluorinated HDAC radiotracer with comparable behavior to Martinostat, yet longer half-life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi_QJv9S699LVg90H21EOLACvtfcHk0ljPqI-IqfKNNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVWrt7rJ&md5=391511376aa9d1a2125dce1ac7a1a849</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00297%26sid%3Dliteratum%253Aachs%26aulast%3DStrebl%26aufirst%3DM.%2BG.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSchroeder%26aufirst%3DF.%2BA.%26aulast%3DPlaczek%26aufirst%3DM.%2BS.%26aulast%3DWey%26aufirst%3DH.-Y.%26aulast%3DVan%2Bde%2BBittner%26aufirst%3DG.%2BC.%26aulast%3DNeelamegam%26aufirst%3DR.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26atitle%3DDevelopment%2520of%2520a%2520fluorinated%2520class-I%2520HDAC%2520radiotracer%2520reveals%2520key%2520chemical%2520determinants%2520of%2520brain%2520penetrance%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D528%26epage%3D533%26doi%3D10.1021%2Facschemneuro.5b00297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strebl, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chindavong, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span> <span> </span><span class="NLM_article-title">HDAC6 brain mapping with [(18)F]bavarostat enabled by a Ru-mediated deoxyfluorination</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1006</span>– <span class="NLM_lpage">1014</span>, <span class="refDoi"> DOI: 10.1021/acscentsci.7b00274</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.7b00274" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVaqsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=1006-1014&author=M.+G.+Streblauthor=A.+J.+Campbellauthor=W.-N.+Zhaoauthor=F.+A.+Schroederauthor=M.+M.+Rileyauthor=P.+S.+Chindavongauthor=T.+M.+Morinauthor=S.+J.+Haggartyauthor=F.+F.+Wagnerauthor=T.+Ritterauthor=J.+M.+Hooker&title=HDAC6+brain+mapping+with+%5B%2818%29F%5Dbavarostat+enabled+by+a+Ru-mediated+deoxyfluorination&doi=10.1021%2Facscentsci.7b00274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 Brain Mapping with [18F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination</span></div><div class="casAuthors">Strebl, Martin G.; Campbell, Arthur J.; Zhao, Wen-Ning; Schroeder, Frederick A.; Riley, Misha M.; Chindavong, Peter S.; Morin, Thomas M.; Haggarty, Stephen J.; Wagner, Florence F.; Ritter, Tobias; Hooker, Jacob M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1006-1014</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) function and dysregulation have been implicated in the etiol. of certain cancers and more recently in central nervous system (CNS) disorders including Rett syndrome, Alzheimer's and Parkinson's diseases, and major depressive disorder.  HDAC6-selective inhibitors have therapeutic potential, but in the CNS drug space the development of highly brain penetrant HDAC inhibitors has been a persistent challenge.  Moreover, no tool exists to directly characterize HDAC6 and its related biol. in the living human brain.  Here, we report a highly brain penetrant HDAC6 inhibitor, Bavarostat, that exhibits excellent HDAC6 selectivity (>80-fold over all other Zn-contg. HDAC paralogues), modulates tubulin acetylation selectively over histone acetylation, and has excellent brain penetrance.  We further demonstrate that Bavarostat can be radiolabeled with 18F by deoxyfluorination through in situ formation of a ruthenium π-complex of the corresponding phenol precursor: the only method currently suitable for synthesis of [18F]Bavarostat.  Finally, by using [18F]Bavarostat in a series of rodent and nonhuman primate imaging expts., we demonstrate its utility for mapping HDAC6 in the living brain, which sets the stage for first-in-human neurochem. imaging of this important target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmXyZxgRQnAbVg90H21EOLACvtfcHk0ljPqI-IqfKNNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVaqsLjK&md5=269c6b99919bd156272afc8ad3502146</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.7b00274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.7b00274%26sid%3Dliteratum%253Aachs%26aulast%3DStrebl%26aufirst%3DM.%2BG.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DW.-N.%26aulast%3DSchroeder%26aufirst%3DF.%2BA.%26aulast%3DRiley%26aufirst%3DM.%2BM.%26aulast%3DChindavong%26aufirst%3DP.%2BS.%26aulast%3DMorin%26aufirst%3DT.%2BM.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DRitter%26aufirst%3DT.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26atitle%3DHDAC6%2520brain%2520mapping%2520with%2520%255B%252818%2529F%255Dbavarostat%2520enabled%2520by%2520a%2520Ru-mediated%2520deoxyfluorination%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2017%26volume%3D3%26spage%3D1006%26epage%3D1014%26doi%3D10.1021%2Facscentsci.7b00274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. H.</span></span> <span> </span><span class="NLM_article-title">Activatable fluorescence probe via self-immolative intramolecular cyclization for histone deacetylase imaging in live cells and tissues</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">5534</span>– <span class="NLM_lpage">5539</span>, <span class="refDoi"> DOI: 10.1021/acs.analchem.8b00709</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.analchem.8b00709" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVals7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2018&pages=5534-5539&author=X.+Liuauthor=M.+Xiangauthor=Z.+Tongauthor=F.+Luoauthor=W.+Chenauthor=F.+Liuauthor=F.+Wangauthor=R.+Q.+Yuauthor=J.+H.+Jiang&title=Activatable+fluorescence+probe+via+self-immolative+intramolecular+cyclization+for+histone+deacetylase+imaging+in+live+cells+and+tissues&doi=10.1021%2Facs.analchem.8b00709"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Activatable Fluorescence Probe via Self-Immolative Intramolecular Cyclization for Histone Deacetylase Imaging in Live Cells and Tissues</span></div><div class="casAuthors">Liu, Xianjun; Xiang, Meihao; Tong, Zongxuan; Luo, Fengyan; Chen, Wen; Liu, Feng; Wang, Fenglin; Yu, Ru-Qin; Jiang, Jian-Hui</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Chemistry (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5534-5539</span>CODEN:
                <span class="NLM_cas:coden">ANCHAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2700</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) play essential roles in transcription regulation and are valuable theranostic targets.  However, there are no activatable fluorescent probes for imaging of HDAC activity in live cells.  Here, the authors develop for the first time a novel activatable two-photon fluorescence probe that enables in situ imaging of HDAC activity in living cells and tissues.  The probe is designed by conjugating an acetyl-lysine mimic substrate to a masked aldehyde-contg. fluorophore via a cyanoester linker.  Upon deacetylation by HDAC, the probe undergoes a rapid self-immolative intramol. cyclization reaction, producing a cyanohydrin intermediate that is spontaneously rapidly decompd. into the highly fluorescent aldehyde-contg. two-photon fluorophore.  The probe is shown to exhibit high sensitivity, high specificity, and fast response for HDAC detection in vitro.  Imaging studies reveal that the probe is able to directly visualize and monitor HDAC activity in living cells.  Moreover, the probe is demonstrated to have the capability of two-photon imaging of HDAC activity in deep tissue slices up to 130 μm.  This activatable fluorescent probe affords a useful tool for evaluating HDAC activity and screening HDAC-targeting drugs in both live cell and tissue assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOWxYXI_ybmbVg90H21EOLACvtfcHk0ljPqI-IqfKNNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVals7Y%253D&md5=477d1e0c92d60364063300bbc848b1ea</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.analchem.8b00709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.analchem.8b00709%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DR.%2BQ.%26aulast%3DJiang%26aufirst%3DJ.%2BH.%26atitle%3DActivatable%2520fluorescence%2520probe%2520via%2520self-immolative%2520intramolecular%2520cyclization%2520for%2520histone%2520deacetylase%2520imaging%2520in%2520live%2520cells%2520and%2520tissues%26jtitle%3DAnal.%2520Chem.%26date%3D2018%26volume%3D90%26spage%3D5534%26epage%3D5539%26doi%3D10.1021%2Facs.analchem.8b00709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rooker, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buccella, D.</span></span> <span> </span><span class="NLM_article-title">Real-time detection of histone deacetylase activity with a small molecule fluorescent and spectrophotometric probe</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">6456</span>– <span class="NLM_lpage">6461</span>, <span class="refDoi"> DOI: 10.1039/C5SC02704G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1039%2FC5SC02704G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=30090264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KltrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6456-6461&author=D.+R.+Rookerauthor=D.+Buccella&title=Real-time+detection+of+histone+deacetylase+activity+with+a+small+molecule+fluorescent+and+spectrophotometric+probe&doi=10.1039%2FC5SC02704G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Real-time detection of histone deacetylase activity with a small molecule fluorescent and spectrophotometric probe</span></div><div class="casAuthors">Rooker, Debra R.; Buccella, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6456-6461</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are central players in transcription regulation and important targets in cancer treatment.  Activity assays are crit. tools for the study of the function and regulation of these enzymes, as well as for the screening of potential inhibitors.  We report a small-mol. probe for single-step, continuous detection of deacetylase activity based on an acetyl-lysine mimic functionalized with an amine-reactive fluorophore, designed to undergo rapid intramol. imine formation upon deacetylation.  The probe exhibits a bathochromic shift in the absorption spectrum and changes in fluorescence emission intensity that enable unprecedented real-time detection of HDAC activity of purified enzymes or in cell lyzates, and offers a means to evaluate HDAC inhibitors via simple spectrophotometric or fluorescence readings without the need of addnl. reagents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVPpn45jTFbrVg90H21EOLACvtfcHk0lgzPtMQSFWpHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KltrzP&md5=0da2de420ded32981463744d7aa6b0a5</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1039%2FC5SC02704G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5SC02704G%26sid%3Dliteratum%253Aachs%26aulast%3DRooker%26aufirst%3DD.%2BR.%26aulast%3DBuccella%26aufirst%3DD.%26atitle%3DReal-time%2520detection%2520of%2520histone%2520deacetylase%2520activity%2520with%2520a%2520small%2520molecule%2520fluorescent%2520and%2520spectrophotometric%2520probe%26jtitle%3DChem.%2520Sci.%26date%3D2015%26volume%3D6%26spage%3D6456%26epage%3D6461%26doi%3D10.1039%2FC5SC02704G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Fluorescent probes for single-step detection and proteomic profiling of histone deacetylases</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">15596</span>– <span class="NLM_lpage">15604</span>, <span class="refDoi"> DOI: 10.1021/jacs.6b07334</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.6b07334" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslygt73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=15596-15604&author=Y.+Xieauthor=J.+Geauthor=H.+Leiauthor=B.+Pengauthor=H.+Zhangauthor=D.+Wangauthor=S.+Panauthor=G.+Chenauthor=L.+Chenauthor=Y.+Wangauthor=Q.+Haoauthor=S.+Q.+Yaoauthor=H.+Sun&title=Fluorescent+probes+for+single-step+detection+and+proteomic+profiling+of+histone+deacetylases&doi=10.1021%2Fjacs.6b07334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescent Probes for Single-Step Detection and Proteomic Profiling of Histone Deacetylases</span></div><div class="casAuthors">Xie, Yusheng; Ge, Jingyan; Lei, Haipeng; Peng, Bo; Zhang, Huatang; Wang, Danyang; Pan, Sijun; Chen, Ganchao; Chen, Lanfang; Wang, Yi; Hao, Quan; Yao, Shao Q.; Sun, Hongyan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">15596-15604</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HDACs play important roles in regulating various physiol. and pathol. processes.  Developing fluorescent probes capable of detecting HDAC activity can help further elucidate the roles of HDACs in biol.  In this study, the authors first developed a set of activity-based fluorescent probes by incorporating Kac residue and O-NBD group.  Upon enzymic removal of the acetyl group in Kac residue, the released free amine reacted intramolecularly with the O-NBD moiety, resulting in turn-on of fluorescence.  These designed probes are capable of detecting HDAC activity in a continuous fashion, thereby eliminating the extra step of fluorescence development.  Remarkably, the amt. of turn-on fluorescence can be as high as 50-fold, which is superior to the existing one-step HDAC fluorescent probes.  Inhibition expts. further proved that the probes can serve as useful tools for screening HDAC inhibitors.  Building on these results, the authors moved on and designed a dual-purpose fluorescent probe by introducing a diazirine photo-crosslinker into the probe.  The resulting probe was not only capable of reporting enzymic activity, but also able to directly identify and capture the protein targets from complex cellular environment.  By combining fluorometric method and in-gel fluorescence scanning technique, the authors found that epigenetic readers and erasers can be readily identified and differentiated using a single probe.  This is not achievable with traditional photoaffinity probes.  In light of the prominent properties and the diverse functions of this newly developed probe, the authors envision that it can provide a robust tool for functional anal. of HDACs and facilitate future drug discovery in epigenetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7OzMsFAUigLVg90H21EOLACvtfcHk0lgzPtMQSFWpHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslygt73K&md5=2b56fc33a5c83eff399a500d6f4ee24c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjacs.6b07334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.6b07334%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DY.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DLei%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DQ.%26aulast%3DYao%26aufirst%3DS.%2BQ.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DFluorescent%2520probes%2520for%2520single-step%2520detection%2520and%2520proteomic%2520profiling%2520of%2520histone%2520deacetylases%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2016%26volume%3D138%26spage%3D15596%26epage%3D15604%26doi%3D10.1021%2Fjacs.6b07334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, K.</span></span> <span> </span><span class="NLM_article-title">Development of a fluorogenic probe with a transesterification switch for detection of histone deacetylase activity</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">14310</span>– <span class="NLM_lpage">14313</span>, <span class="refDoi"> DOI: 10.1021/ja306045j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja306045j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1CisrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=14310-14313&author=R.+Babaauthor=Y.+Horiauthor=S.+Mizukamiauthor=K.+Kikuchi&title=Development+of+a+fluorogenic+probe+with+a+transesterification+switch+for+detection+of+histone+deacetylase+activity&doi=10.1021%2Fja306045j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Fluorogenic Probe with a Transesterification Switch for Detection of Histone Deacetylase Activity</span></div><div class="casAuthors">Baba, Reisuke; Hori, Yuichiro; Mizukami, Shin; Kikuchi, Kazuya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">14310-14313</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are key enzymic regulators of many cellular processes such as gene expression, cell cycle, and tumorigenesis.  These enzymes are attractive targets for drug development.  However, very few simple methods for monitoring HDAC activity have been reported.  Here, we have developed a fluorogenic probe, K4(Ac)-CCB, which consists of the histone H3 peptide contg. acetyl-Lys and a coumarin fluorophore with a carbonate ester.  By the simple addn. of the probe to a HDAC soln., enzyme activity was clearly detected through spontaneous intramol. transesterification, which renders the probe fluorescent.  In addn., K4(Ac)-CCB can be applied to the evaluation of HDAC inhibitor activity.  This is the first report to demonstrate the monitoring of HDAC activity by using a one-step procedure.  Thus, our novel fluorogenic probe will provide a powerful tool for epigenetic research and the discovery of HDAC-targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcvX_lNo7MQrVg90H21EOLACvtfcHk0lgzPtMQSFWpHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1CisrbK&md5=c355835940280a678c38ae9e7e3b740c</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fja306045j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja306045j%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DR.%26aulast%3DHori%26aufirst%3DY.%26aulast%3DMizukami%26aufirst%3DS.%26aulast%3DKikuchi%26aufirst%3DK.%26atitle%3DDevelopment%2520of%2520a%2520fluorogenic%2520probe%2520with%2520a%2520transesterification%2520switch%2520for%2520detection%2520of%2520histone%2520deacetylase%2520activity%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D14310%26epage%3D14313%26doi%3D10.1021%2Fja306045j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, C.</span></span> <span> </span><span class="NLM_article-title">A review of NIR dyes in cancer targeting and imaging</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">7127</span>– <span class="NLM_lpage">7138</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2011.06.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1016%2Fj.biomaterials.2011.06.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=21724249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFWhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=7127-7138&author=S.+Luoauthor=E.+Zhangauthor=Y.+Suauthor=T.+Chengauthor=C.+Shi&title=A+review+of+NIR+dyes+in+cancer+targeting+and+imaging&doi=10.1016%2Fj.biomaterials.2011.06.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A review of NIR dyes in cancer targeting and imaging</span></div><div class="casAuthors">Luo, Shenglin; Zhang, Erlong; Su, Yongping; Cheng, Tianmin; Shi, Chunmeng</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">7127-7138</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of multifunctional agents for simultaneous tumor targeting and near IR (NIR) fluorescence imaging is expected to have significant impact on future personalized oncol. owing to the very low tissue autofluorescence and high tissue penetration depth in the NIR spectrum window.  Cancer NIR mol. imaging relies greatly on the development of stable, highly specific and sensitive mol. probes.  Org. dyes have shown promising clin. implications as non-targeting agents for optical imaging in which indocyanine green has long been implemented in clin. use.  Recently, significant progress has been made on the development of unique NIR dyes with tumor targeting properties.  Current ongoing design strategies have overcome some of the limitations of conventional NIR org. dyes, such as poor hydrophilicity and photostability, low quantum yield, insufficient stability in biol. system, low detection sensitivity, etc.  This potential is further realized with the use of these NIR dyes or NIR dye-encapsulated nanoparticles by conjugation with tumor specific ligands (such as small mols., peptides, proteins and antibodies) for tumor targeted imaging.  Very recently, natively multifunctional NIR dyes that can preferentially accumulate in tumor cells without the need of chem. conjugation to tumor targeting ligands have been developed and these dyes have shown unique optical and pharmaceutical properties for biomedical imaging with superior signal-to-background contrast index.  The main focus of this article is to provide a concise overview of newly developed NIR dyes and their potential applications in cancer targeting and imaging.  The development of future multifunctional agents by combining targeting, imaging and even therapeutic routes will also be discussed.  We believe these newly developed multifunctional NIR dyes will broaden current concept of tumor targeted imaging and hold promise to make an important contribution to the diagnosis and therapeutics for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJJQph7DjLr7Vg90H21EOLACvtfcHk0lincyHBEXvh-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFWhtbs%253D&md5=733be27dd9858f9a6ca73f70fabd77c1</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2011.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2011.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DC.%26atitle%3DA%2520review%2520of%2520NIR%2520dyes%2520in%2520cancer%2520targeting%2520and%2520imaging%26jtitle%3DBiomaterials%26date%3D2011%26volume%3D32%26spage%3D7127%26epage%3D7138%26doi%3D10.1016%2Fj.biomaterials.2011.06.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luker, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luker, K. E.</span></span> <span> </span><span class="NLM_article-title">Optical imaging: current applications and future directions. Journal of nuclear medicine: official publication</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.2967/jnumed.107.045799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.2967%2Fjnumed.107.045799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=18077528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FgtFansw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=1-4&author=G.+D.+Lukerauthor=K.+E.+Luker&title=Optical+imaging%3A+current+applications+and+future+directions.+Journal+of+nuclear+medicine%3A+official+publication&doi=10.2967%2Fjnumed.107.045799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Optical imaging: current applications and future directions</span></div><div class="casAuthors">Luker Gary D; Luker Kathryn E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-4</span>
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    </div><div class="casAbstract">Optical techniques, such as bioluminescence and fluorescence, are emerging as powerful new modalities for molecular imaging in disease and therapy.  Combining innovative molecular biology and chemistry, researchers have developed optical methods for imaging a variety of cellular and molecular processes in vivo, including protein interactions, protein degradation, and protease activity.  Whereas optical imaging has been used primarily for research in small-animal models, there are several areas in which optical molecular imaging will translate to clinical medicine.  In this review, we summarize recent advances in optical techniques for molecular imaging and the potential impact for clinical medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRB-hcTAkUpcY3yKPtYViAGfW6udTcc2ebWRHt61xcm0rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FgtFansw%253D%253D&md5=2d3a834b25e8a7e27e9e22fe83d5e7c5</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.107.045799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.107.045799%26sid%3Dliteratum%253Aachs%26aulast%3DLuker%26aufirst%3DG.%2BD.%26aulast%3DLuker%26aufirst%3DK.%2BE.%26atitle%3DOptical%2520imaging%253A%2520current%2520applications%2520and%2520future%2520directions.%2520Journal%2520of%2520nuclear%2520medicine%253A%2520official%2520publication%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2008%26volume%3D49%26spage%3D1%26epage%3D4%26doi%3D10.2967%2Fjnumed.107.045799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hilderbrand, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissleder, R.</span></span> <span> </span><span class="NLM_article-title">Near-infrared fluorescence: application to in vivo molecular imaging</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2009.09.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1016%2Fj.cbpa.2009.09.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=19879798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12qtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=71-79&author=S.+A.+Hilderbrandauthor=R.+Weissleder&title=Near-infrared+fluorescence%3A+application+to+in+vivo+molecular+imaging&doi=10.1016%2Fj.cbpa.2009.09.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Near-infrared fluorescence: application to in vivo molecular imaging</span></div><div class="casAuthors">Hilderbrand, Scott A.; Weissleder, Ralph</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-79</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Mol. imaging often relies on the use of targeted and activatable reporters to quantitate and visualize targets, biol. processes, and cells in vivo.  The use of optical probes with near-IR fluorescence allows for improved photon penetration through tissue and minimizes the effects of tissue autofluorescence.  There are several parameters that define the effectiveness of imaging agents in vivo.  These factors include probe targeting, activation, pharmacokinetics, biocompatibility, and photophysics.  Recent advances in our understanding of these variables as they pertain to the application of optical reporters for in vivo imaging are discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0P_3P78Hzk7Vg90H21EOLACvtfcHk0lincyHBEXvh-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12qtLw%253D&md5=cddcdb0a8da0e53181146c49ebda16db</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2009.09.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2009.09.029%26sid%3Dliteratum%253Aachs%26aulast%3DHilderbrand%26aufirst%3DS.%2BA.%26aulast%3DWeissleder%26aufirst%3DR.%26atitle%3DNear-infrared%2520fluorescence%253A%2520application%2520to%2520in%2520vivo%2520molecular%2520imaging%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D71%26epage%3D79%26doi%3D10.1016%2Fj.cbpa.2009.09.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel class I histone deacetylase inhibitors with promising in vitro and in vivo antitumor activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7672</span>– <span class="NLM_lpage">7680</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01044</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01044" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCgurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7672-7680&author=Y.+Yaoauthor=Z.+Tuauthor=C.+Liaoauthor=Z.+Wangauthor=S.+Liauthor=H.+Yaoauthor=Z.+Liauthor=S.+Jiang&title=Discovery+of+novel+class+I+histone+deacetylase+inhibitors+with+promising+in+vitro+and+in+vivo+antitumor+activities&doi=10.1021%2Facs.jmedchem.5b01044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities</span></div><div class="casAuthors">Yao, Yiwu; Tu, Zhengchao; Liao, Chenzhong; Wang, Zhen; Li, Shang; Yao, Hequan; Li, Zheng; Jiang, Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7672-7680</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A successful structure-based design of novel cyclic depsipeptides that selectively target class I HDAC isoforms is described.  Compd. I [R = H] an IC50 of 2.78 nM for binding to the HDAC1 protein, and the prodrugs I [R = Me(CH2)6C(O)] and I [R = MeC(O)] also exhibit promising antiproliferative activities in the nanomolar range against various cancer cell lines.  Compds. I [R = Me(CH2)6C(O)] and I [R = MeC(O)] show more than 20-fold selectivity toward human cancer cells over human normal cells in comparison with romidepsin (FK228), demonstrating low probability of toxic side effects.  In addn., compd. I [R = MeC(O)] exhibits excellent in vivo anticancer activities in a human prostate carcinoma (Du145) xenograft model with no obsd. toxicity.  Thus, prodrug I [R = MeC(O)] has therapeutic potential as a new class of anticancer agent for further clin. translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaKRpLDZwVPrVg90H21EOLACvtfcHk0lincyHBEXvh-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCgurnI&md5=3069fbc43dc2cc5ead040bad2021cae3</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01044%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520novel%2520class%2520I%2520histone%2520deacetylase%2520inhibitors%2520with%2520promising%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7672%26epage%3D7680%26doi%3D10.1021%2Facs.jmedchem.5b01044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.4155/fmc-2019-0290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.4155%2Ffmc-2019-0290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=31782319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsVOgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=311-323&author=K.+Zhangauthor=Y.+Yaoauthor=Z.+Tuauthor=C.+Liaoauthor=Z.+Wangauthor=Y.+Qiuauthor=D.+Chenauthor=D.+J.+Hamiltonauthor=Z.+Liauthor=S.+Jiang&title=Discovery+of+class+I+histone+deacetylase+inhibitors+based+on+romidpesin+with+promising+selectivity+for+cancer+cells&doi=10.4155%2Ffmc-2019-0290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells</span></div><div class="casAuthors">Zhang, Kuojun; Yao, Yiwu; Tu, Zhengchao; Liao, Chenzhong; Wang, Zhen; Qiu, Yatao; Chen, Dong; Hamilton, Dale J.; Li, Zheng; Jiang, Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-323</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Aim: Class I histone deacetylases (HDACs) are considered to be promising anticancer targets, but selective inhibition of class I HDAC isoforms remains a challenge.  Methods & results: Previously, we obtained a selective class I HDAC inhibitor 9 based on a macrocyclic HDAC inhibitor Romidpesin.  As our continuous efforts, a library of novel cyclicdepsipeptides based on 9 was established using a convergent synthesis strategy.  The most active compds. 10, 16 and 19 selectively inhibit class I HDACs and exhibit promising nanomolar antiproliferative activities against several cancer cell lines with excellent selectivity toward cancer cells over normal cells.  Besides, compd. 10 demonstrates excellent antitumor effects in human prostate carcinoma PC3 xenograft models with no obsd. toxicity.  Conclusion: These cyclicdepsipeptides show great therapeutic potential as novel anticancer agents for clin. translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaIqsiQZpfsbVg90H21EOLACvtfcHk0ljOboKnsoA6wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsVOgsb0%253D&md5=750a2e0bd4bae72953d823f1a6730b4c</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2019-0290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2019-0290%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHamilton%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520class%2520I%2520histone%2520deacetylase%2520inhibitors%2520based%2520on%2520romidpesin%2520with%2520promising%2520selectivity%2520for%2520cancer%2520cells%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2020%26volume%3D12%26spage%3D311%26epage%3D323%26doi%3D10.4155%2Ffmc-2019-0290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Estrela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obrador, E.</span></span> <span> </span><span class="NLM_article-title">Glutathione in cancer biology and therapy</span>. <i>Crit. Rev. Clin. Lab. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1080/10408360500523878</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1080%2F10408360500523878" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=16517421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFCkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2006&pages=143-181&author=J.+M.+Estrelaauthor=A.+Ortegaauthor=E.+Obrador&title=Glutathione+in+cancer+biology+and+therapy&doi=10.1080%2F10408360500523878"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Glutathione in Cancer Biology and Therapy</span></div><div class="casAuthors">Estrela, Jose; Ortega, Angel; Obrador, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Clinical Laboratory Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-181</span>CODEN:
                <span class="NLM_cas:coden">CRCLBH</span>;
        ISSN:<span class="NLM_cas:issn">1040-8363</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  The glutathione (GSH) content of cancer cells is particularly relevant in regulating mutagenic mechanisms, DNA synthesis, growth, and multidrug and radiation resistance.  In malignant tumors, as compared with normal tissues, that resistance assocs. in most cases with higher GSH levels within these cancer cells.  Thus, approaches to cancer treatment based on modulation of GSH should control possible growth-assocd. changes in GSH content and synthesis in these cells.  Despite the potential benefits for cancer therapy of a selective GSH-depleting strategy, such a methodol. has remained elusive up to now.Metastatic spread, not primary tumor burden, is the leading cause of cancer death.  For patient prognosis to improve, new systemic therapies capable of effectively inhibiting the outgrowth of seeded tumor cells are needed.  Interaction of metastatic cells with the vascular endothelium activates local release of proinflammatory cytokines, which act as signals promoting cancer cell adhesion, extravasation, and proliferation.  Recent work shows that a high percentage of metastatic cells with high GSH levels survive the combined nitrosative and oxidative stresses elicited by the vascular endothelium and possibly by macrophages and granulocytes. -Glutamyl transpeptidase overexpression and an inter-organ flow of GSH (where the liver plays a central role), by increasing cysteine availability for tumor GSH synthesis, function in combination as a metastatic-growth promoting mechanism.  The present review focuses on an anal. of links among GSH, adaptive responses to stress, mol. mechanisms of invasive cancer cell survival and death, and sensitization of metastatic cells to therapy.  Exptl. evidence shows that acceleration of GSH efflux facilitates selective GSH depletion in metastatic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPRmAf3JYiLbVg90H21EOLACvtfcHk0ljOboKnsoA6wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFCkurg%253D&md5=dbc8ffc50e29bf01e69ebd643dca0f11</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1080%2F10408360500523878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10408360500523878%26sid%3Dliteratum%253Aachs%26aulast%3DEstrela%26aufirst%3DJ.%2BM.%26aulast%3DOrtega%26aufirst%3DA.%26aulast%3DObrador%26aufirst%3DE.%26atitle%3DGlutathione%2520in%2520cancer%2520biology%2520and%2520therapy%26jtitle%3DCrit.%2520Rev.%2520Clin.%2520Lab.%2520Sci.%26date%3D2006%26volume%3D43%26spage%3D143%26epage%3D181%26doi%3D10.1080%2F10408360500523878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiseman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creighton, D. J.</span></span> <span> </span><span class="NLM_article-title">N-(2-hydroxypropyl)methacrylamide copolymers of a glutathione (GSH)-activated glyoxalase I inhibitor and DNA alkylating agent: Synthesis, reaction kinetics with GSH, and in vitro antitumor activities</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.1021/bc0499634</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc0499634" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlWksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=598-607&author=Z.-B.+Zhengauthor=G.+Zhuauthor=H.+Takauthor=E.+Josephauthor=J.+L.+Eisemanauthor=D.+J.+Creighton&title=N-%282-hydroxypropyl%29methacrylamide+copolymers+of+a+glutathione+%28GSH%29-activated+glyoxalase+I+inhibitor+and+DNA+alkylating+agent%3A+Synthesis%2C+reaction+kinetics+with+GSH%2C+and+in+vitro+antitumor+activities&doi=10.1021%2Fbc0499634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">N-(2-Hydroxypropyl)methacrylamide copolymers of a glutathione (GSH)-activated glyoxalase I inhibitor and DNA alkylating agent: synthesis, reaction kinetics with GSH, and in vitro antitumor activities</span></div><div class="casAuthors">Zheng, Zhe-Bin; Zhu, Guozhang; Tak, Heekyung; Joseph, Erin; Eiseman, Julie L.; Creighton, Donald J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">598-607</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The incorporation of anticancer prodrugs into polyacrylamide conjugates has been shown to improve tumor targeting via the so-called "enhanced permeability and retention" effect.  This strategy has now been expanded to include two different classes of glutathione (GSH)-activated antitumor agents prepd. by radical polymn. of N-(2-hydroxypropyl)methacrylamide (HPMA) with 2-methacryloyloxy-methyl-2-cyclohexenone (7) and/or with S-(N-4-chlorophenyl-N-hydroxycarbamoyl-thioethyl)methacrylamide (8), followed by treatment with 3-chloroperoxybenzoic acid, to give the HPMA copolymers of 7 and the 8-sulfoxide, resp.  In aq.-buffered soln. at pH 6.5, GSH reacts rapidly with poly-HPMA-8-sulfoxide (k ≈ 2.3 mM-1 min-1) to give S-(N-4-chlorophenyl-N-hydroxycarbamoyl)glutathione (1), a tight-binding transition state analog inhibitor of the antitumor target enzyme glyoxalase I (Ki = 46 nM), or with poly-HPMA-7 (k ≈ 0.02 mM-1 min-1) to give the electrophilic antitumor agent 3-glutathio-2-methylenecyclohexenone (4).  Indeed, B16 melanotic melanoma in culture is inhibited by poly-HPMA-8-sulfoxide and by poly-HPMA-7 with IC50 values of 168 ± 8 and 284 ± 5 μM, resp.  These values are significantly greater than those of the unpolymd. prodrugs suggesting that the cytotoxicity of the polymer prodrugs might be limited by slow cellular uptake via pinocytosis.  This prodrug strategy should be applicable to a range of different GSH-based antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovRm2e-n7wtrVg90H21EOLACvtfcHk0ljOboKnsoA6wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlWksbs%253D&md5=3c1884e0169065a83217df1fe000c727</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fbc0499634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0499634%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DZ.-B.%26aulast%3DZhu%26aufirst%3DG.%26aulast%3DTak%26aufirst%3DH.%26aulast%3DJoseph%26aufirst%3DE.%26aulast%3DEiseman%26aufirst%3DJ.%2BL.%26aulast%3DCreighton%26aufirst%3DD.%2BJ.%26atitle%3DN-%25282-hydroxypropyl%2529methacrylamide%2520copolymers%2520of%2520a%2520glutathione%2520%2528GSH%2529-activated%2520glyoxalase%2520I%2520inhibitor%2520and%2520DNA%2520alkylating%2520agent%253A%2520Synthesis%252C%2520reaction%2520kinetics%2520with%2520GSH%252C%2520and%2520in%2520vitro%2520antitumor%2520activities%26jtitle%3DBioconjugate%2520Chem.%26date%3D2005%26volume%3D16%26spage%3D598%26epage%3D607%26doi%3D10.1021%2Fbc0499634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Millard, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celardo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordiyenko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwabe, J. W.</span></span> <span> </span><span class="NLM_article-title">Class I HDACs share a common mechanism of regulation by inositol phosphates</span>. <i>Mol. Cell.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2013.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1016%2Fj.molcel.2013.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=23791785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVygu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2013&pages=57-67&author=C.+J.+Millardauthor=P.+J.+Watsonauthor=I.+Celardoauthor=Y.+Gordiyenkoauthor=S.+M.+Cowleyauthor=C.+V.+Robinsonauthor=L.+Fairallauthor=J.+W.+Schwabe&title=Class+I+HDACs+share+a+common+mechanism+of+regulation+by+inositol+phosphates&doi=10.1016%2Fj.molcel.2013.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates</span></div><div class="casAuthors">Millard, Christopher J.; Watson, Peter J.; Celardo, Ivana; Gordiyenko, Yuliya; Cowley, Shaun M.; Robinson, Carol V.; Fairall, Louise; Schwabe, John W. R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-67</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Class I histone deacetylases (HDAC1, HDAC2, and HDAC3) are recruited by cognate corepressor proteins into specific transcriptional repression complexes that target HDAC activity to chromatin resulting in chromatin condensation and transcriptional silencing.  The authors previously reported the structure of HDAC3 in complex with the SMRT corepressor.  This structure revealed inositol-tetraphosphate [Ins(1,4,5,6)P4] at the interface of the two proteins.  It was previously unclear whether the role of Ins(1,4,5,6)P4 is to act as a structural cofactor or a regulator of HDAC3 activity.  Here the authors report the structure of HDAC1 in complex with MTA1 from the NuRD complex.  The ELM2-SANT domains from MTA1 wrap completely around HDAC1 occupying both sides of the active site such that the adjacent BAH domain is ideally positioned to recruit nucleosomes to the active site of the enzyme.  Functional assays of both the HDAC1 and HDAC3 complexes reveal that Ins(1,4,5,6)P4 is a bona fide conserved regulator of class I HDAC complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYPhL0103LkLVg90H21EOLACvtfcHk0lha-fXRLtMEpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVygu74%253D&md5=05a4267bf965b5a6217873217044ef2a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2013.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2013.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DMillard%26aufirst%3DC.%2BJ.%26aulast%3DWatson%26aufirst%3DP.%2BJ.%26aulast%3DCelardo%26aufirst%3DI.%26aulast%3DGordiyenko%26aufirst%3DY.%26aulast%3DCowley%26aufirst%3DS.%2BM.%26aulast%3DRobinson%26aufirst%3DC.%2BV.%26aulast%3DFairall%26aufirst%3DL.%26aulast%3DSchwabe%26aufirst%3DJ.%2BW.%26atitle%3DClass%2520I%2520HDACs%2520share%2520a%2520common%2520mechanism%2520of%2520regulation%2520by%2520inositol%2520phosphates%26jtitle%3DMol.%2520Cell.%26date%3D2013%26volume%3D51%26spage%3D57%26epage%3D67%26doi%3D10.1016%2Fj.molcel.2013.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wegener, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirsching, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riester, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwienhorst, A.</span></span> <span> </span><span class="NLM_article-title">A fluorogenic histone deacetylase assay well suited for high-throughput activity screening</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/S1074-5521(02)00305-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1016%2FS1074-5521%2802%2900305-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=12573699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1Skuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=61-68&author=D.+Wegenerauthor=F.+Wirschingauthor=D.+Riesterauthor=A.+Schwienhorst&title=A+fluorogenic+histone+deacetylase+assay+well+suited+for+high-throughput+activity+screening&doi=10.1016%2FS1074-5521%2802%2900305-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A Fluorogenic Histone Deacetylase Assay Well Suited for High-Throughput Activity Screening</span></div><div class="casAuthors">Wegener, Dennis; Wirsching, Frank; Riester, Daniel; Schwienhorst, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-68</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are important enzymes for the transcriptional regulation of gene expression in eukaryotic cells.  Recent findings suggest that HDACs could be key targets for chemotherapeutic intervention in malignant diseases.  A convenient and sensitive fluorogenic assay for HDAC activity would therefore expedite studies of HDAC in transcriptional regulation and in vitro screening for drug discovery.  In this study, novel fluorogenic substrates of HDACs were synthesized with an ε-acetylated lysyl moiety and an adjacent MCA moiety at the C terminus of the peptide chain.  Upon deacetylation of the acetylated lysyl moiety, mols. became substrates for trypsin, which released highly fluorescent AMC mols. in a subsequent step of the assay.  The fluorescence increased in direct proportion to the amt. of deacetylated substrate mols., i.e., HDAC activity.  The nonisotopic, homogeneous assay is well suited for high-throughput HDAC inhibitor screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5ogyqEBSC3bVg90H21EOLACvtfcHk0lha-fXRLtMEpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1Skuw%253D%253D&md5=eea350d8066f6ebd773ba50cc0211fdc</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2802%2900305-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252802%252900305-8%26sid%3Dliteratum%253Aachs%26aulast%3DWegener%26aufirst%3DD.%26aulast%3DWirsching%26aufirst%3DF.%26aulast%3DRiester%26aufirst%3DD.%26aulast%3DSchwienhorst%26aufirst%3DA.%26atitle%3DA%2520fluorogenic%2520histone%2520deacetylase%2520assay%2520well%2520suited%2520for%2520high-throughput%2520activity%2520screening%26jtitle%3DChem.%2520Biol.%26date%3D2003%26volume%3D10%26spage%3D61%26epage%3D68%26doi%3D10.1016%2FS1074-5521%2802%2900305-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foulkes, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span> <span> </span><span class="NLM_article-title">Triple-negative breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1938</span>– <span class="NLM_lpage">1948</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1001389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1056%2FNEJMra1001389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=21067385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1938-1948&author=W.+D.+Foulkesauthor=I.+E.+Smithauthor=J.+S.+Reis-Filho&title=Triple-negative+breast+cancer&doi=10.1056%2FNEJMra1001389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer</span></div><div class="casAuthors">Foulkes, William D.; Smith, Ian E.; Reis-Filho, Jorge S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1938-1948</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiN8P8IsovvLVg90H21EOLACvtfcHk0lha-fXRLtMEpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P&md5=641fe4726e6a7118208aa6b3502c9df6</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1001389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1001389%26sid%3Dliteratum%253Aachs%26aulast%3DFoulkes%26aufirst%3DW.%2BD.%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26atitle%3DTriple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1938%26epage%3D1948%26doi%3D10.1056%2FNEJMra1001389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Ning</span>, <span class="hlFld-ContribAuthor ">Xiong  Rui</span>, <span class="hlFld-ContribAuthor ">Wang  Bo</span>, <span class="hlFld-ContribAuthor ">Geng  Qing</span>. </span><span class="cited-content_cbyCitation_article-title">The critical roles of histone deacetylase 3 in the pathogenesis of solid organ injury. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2021,</strong> <em>12 </em>
                                    (8)
                                     <a href="https://doi.org/10.1038/s41419-021-04019-6" title="DOI URL">https://doi.org/10.1038/s41419-021-04019-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41419-021-04019-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41419-021-04019-6%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DThe%252Bcritical%252Broles%252Bof%252Bhistone%252Bdeacetylase%252B3%252Bin%252Bthe%252Bpathogenesis%252Bof%252Bsolid%252Borgan%252Binjury%26aulast%3DNing%26aufirst%3DLi%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selected HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Selected HDAC imaging agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0003.jpeg jm0c02161_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure-based design of class I HDACi. (A) Chemical structures of compounds <b>19</b> and <b>20</b>. (B) Overlay of docking poses of <b>19</b> and <b>20</b> thiols to HDAC1 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX">4BKX</a>). The <b>19</b>-thiol is shown in green and the <b>20</b>-thiol in violet. Zn<sup>2+</sup> is shown in indigo. The yellow arrow indicates the thiol moiety of <b>19</b> and <b>20</b> thiols. The green arrow indicates the valine of <b>19</b>-thiol, and the violet arrow indicates the lysine of <b>20</b>-thiol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0011.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Targeting Moiety <b>20</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Conjugate <b>20-</b>Cy5.5</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Concentration-dependent inhibition of HDAC enzyme activity by <b>20-Cy5.5</b>. Each point is a mean ± SD of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Imaging of <b>20</b>-Cy5.5 binding to HDACs in MDA-MB-231 cells by confocal laser microscopy at 600× magnification. The cells were incubated with <b>20</b>-Cy5.5 alone (imaging group) or pretreated with excess amount (∼100×) of unlabeled <b>20</b> (blocking group). Blue indicates DAPI-stained nuclei, and red indicates NIR fluorescence of <b>20</b>-Cy5.5. The scale bar represents 10 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Imaging of <b>20</b>-Cy5.5 binding to HDACs in the MDA-MB-231 xenograft model. (A) NIR images of mice treated with the probe <b>20</b>-Cy5.5 (imaging group) alone or in the presence of unlabeled <b>20</b> (blocking group) at different time points. The white arrows indicate the tumors. (B) <i>In vivo</i> imaging for therapeutic response evaluation of HDACi at different time points. The mice were treated with SAHA (15 mg/kg, 3 days) followed by <b>20</b>-Cy5.5 imaging studies. The white arrows indicate the tumors. (C) Region of interest (ROI) study of tumor to normal tissue ratio of the probe <b>20</b>-Cy5.5. Each point is a mean ± SD of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0009.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Biodistribution of <b>20</b>-Cy5.5 in the MDA-MB-231 xenograft model. (A) <i>Ex vivo</i> NIR images of organs collected from imaging, blocking, and SAHA-treated groups at 48 h pi. (B) Quantitative analysis of epifluorescence in the imaging group compared to the blocking and SAHA-treated groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/medium/jm0c02161_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0010.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <i>Ex vivo</i> NIR fluorescence imaging with <b>20</b>-Cy5.5 for metastatic MDA-MB-231 xenograft tumors. (A) NIR imaging of lungs harvested from the mice treated with <b>20</b>-Cy5.5 at 24 h pi. NIR signals (red) were colocalized with metastatic tumor cells in the lung (green), but normal lung did not show any NIR signals or green fluorescence. The scale bar represents 1 cm. (B) Quantification of accumulation of <b>20</b>-Cy5.5 in normal and metastatic lungs. Error bars represent SD of triplicate measurements for ROI in lungs and background tissues. (C) IHC staining for HDAC1 in metastatic lungs and H&E staining for the physiological changes of metastatic lungs. The images were acquired by a 40× objective lens.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02161/20210331/images/large/jm0c02161_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02161&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77244" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77244" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 53 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gradishar, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balassanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burstein, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elias, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrar, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isakoff, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcom, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Regan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzberg, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitapati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soliman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somlo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shead, D. A.</span></span> <span> </span><span class="NLM_article-title">Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology</span>. <i>J. Natl. Compr. Cancer Network</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">310</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.6004/jnccn.2018.0012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.6004%2Fjnccn.2018.0012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=29523670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A280%3ADC%252BC1MrpsFyjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=310-320&author=W.+J.+Gradisharauthor=B.+O.+Andersonauthor=R.+Balassanianauthor=S.+L.+Blairauthor=H.+J.+Bursteinauthor=A.+Cyrauthor=A.+D.+Eliasauthor=W.+B.+Farrarauthor=A.+Foreroauthor=S.+H.+Giordanoauthor=M.+P.+Goetzauthor=L.+J.+Goldsteinauthor=S.+J.+Isakoffauthor=J.+Lyonsauthor=P.+K.+Marcomauthor=I.+A.+Mayerauthor=B.+McCormickauthor=M.+S.+Moranauthor=R.+M.+O%E2%80%99Reganauthor=S.+A.+Patelauthor=L.+J.+Pierceauthor=E.+C.+Reedauthor=K.+E.+Salernoauthor=L.+S.+Schwartzbergauthor=A.+Sitapatiauthor=K.+L.+Smithauthor=M.+L.+Smithauthor=H.+Solimanauthor=G.+Somloauthor=M.+L.+Telliauthor=J.+H.+Wardauthor=R.+Kumarauthor=D.+A.+Shead&title=Breast+cancer%2C+version+4.2017%2C+NCCN+clinical+practice+guidelines+in+oncology&doi=10.6004%2Fjnccn.2018.0012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology</span></div><div class="casAuthors">Gradishar William J; Anderson Benjamin O; Balassanian Ron; Blair Sarah L; Burstein Harold J; Cyr Amy; Elias Anthony D; Farrar William B; Forero Andres; Giordano Sharon H; Goetz Matthew P; Goldstein Lori J; Isakoff Steven J; Lyons Janice; Marcom P Kelly; Mayer Ingrid A; McCormick Beryl; Moran Meena S; O'Regan Ruth M; Patel Sameer A; Pierce Lori J; Reed Elizabeth C; Salerno Kilian E; Schwartzberg Lee S; Sitapati Amy; Smith Karen Lisa; Smith Mary Lou; Soliman Hatem; Somlo George; Telli Melinda L; Ward John H; Kumar Rashmi; Shead Dorothy A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Comprehensive Cancer Network : JNCCN</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">310-320</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of neoplastic lesions in the breast ducts.  The goal for management of DCIS is to prevent the development of invasive breast cancer.  This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAACZdsi8QiVm8bhe6roZYfW6udTcc2eY0ymHjDcIcuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrpsFyjug%253D%253D&md5=7d3686a5eefb430f13fea8565b05cc7e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.6004%2Fjnccn.2018.0012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.6004%252Fjnccn.2018.0012%26sid%3Dliteratum%253Aachs%26aulast%3DGradishar%26aufirst%3DW.%2BJ.%26aulast%3DAnderson%26aufirst%3DB.%2BO.%26aulast%3DBalassanian%26aufirst%3DR.%26aulast%3DBlair%26aufirst%3DS.%2BL.%26aulast%3DBurstein%26aufirst%3DH.%2BJ.%26aulast%3DCyr%26aufirst%3DA.%26aulast%3DElias%26aufirst%3DA.%2BD.%26aulast%3DFarrar%26aufirst%3DW.%2BB.%26aulast%3DForero%26aufirst%3DA.%26aulast%3DGiordano%26aufirst%3DS.%2BH.%26aulast%3DGoetz%26aufirst%3DM.%2BP.%26aulast%3DGoldstein%26aufirst%3DL.%2BJ.%26aulast%3DIsakoff%26aufirst%3DS.%2BJ.%26aulast%3DLyons%26aufirst%3DJ.%26aulast%3DMarcom%26aufirst%3DP.%2BK.%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DMcCormick%26aufirst%3DB.%26aulast%3DMoran%26aufirst%3DM.%2BS.%26aulast%3DO%25E2%2580%2599Regan%26aufirst%3DR.%2BM.%26aulast%3DPatel%26aufirst%3DS.%2BA.%26aulast%3DPierce%26aufirst%3DL.%2BJ.%26aulast%3DReed%26aufirst%3DE.%2BC.%26aulast%3DSalerno%26aufirst%3DK.%2BE.%26aulast%3DSchwartzberg%26aufirst%3DL.%2BS.%26aulast%3DSitapati%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DK.%2BL.%26aulast%3DSmith%26aufirst%3DM.%2BL.%26aulast%3DSoliman%26aufirst%3DH.%26aulast%3DSomlo%26aufirst%3DG.%26aulast%3DTelli%26aufirst%3DM.%2BL.%26aulast%3DWard%26aufirst%3DJ.%2BH.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DShead%26aufirst%3DD.%2BA.%26atitle%3DBreast%2520cancer%252C%2520version%25204.2017%252C%2520NCCN%2520clinical%2520practice%2520guidelines%2520in%2520oncology%26jtitle%3DJ.%2520Natl.%2520Compr.%2520Cancer%2520Network%26date%3D2018%26volume%3D16%26spage%3D310%26epage%3D320%26doi%3D10.6004%2Fjnccn.2018.0012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertucci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervera, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esterni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermitte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, D.</span></span> <span> </span><span class="NLM_article-title">How basal are triple-negative breast cancers?</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1002/ijc.23518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1002%2Fijc.23518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=18398844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtlantbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2008&pages=236-240&author=F.+Bertucciauthor=P.+Finettiauthor=N.+Cerveraauthor=B.+Esterniauthor=F.+Hermitteauthor=P.+Viensauthor=D.+Birnbaum&title=How+basal+are+triple-negative+breast+cancers%3F&doi=10.1002%2Fijc.23518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">How basal are triple-negative breast cancers?</span></div><div class="casAuthors">Bertucci, Francois; Finetti, Pascal; Cervera, Nathalie; Esterni, Benjamin; Hermitte, Fabienne; Viens, Patrice; Birnbaum, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">236-240</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The basal mol. subtype of breast cancer (BC) is defined by the mRNA expression pattern of an intrinsic ∼500-gene set.  It is the most homogeneous subtype in transcriptional terms, and one of the most aggressive in prognostic terms.  Clin. trials testing new systemic therapeutic strategies have been launched in basal BCs.  Although no proof of evidence has yet been reported, basal tumors are currently assimilated to and selected as triple-neg. (TN) BCs in these trials because of their frequent immunohistochem. (IHC) negativity for hormone and ERBB2 receptors.  Here, we have assessed the degree of correlation and of homogeneity of the TN phenotype (IHC-based definition) and the basal subtype (gene expression-based definition).  We analyzed 172 TN BCs defined by gene expression profile as basal (123 cases) and nonbasal (49 cases).  Conversely, 160 tumors were defined as basal by their gene expression profile and included 123 TN and 37 non-TN samples.  Uni- and multivariate analyses revealed that TN BCs represent a more heterogeneous group than basal BCs, including basal and nonbasal tumors very different both at the histoclin. and mol. level, notably for mRNA expression of mols. targeted by specific therapies under evaluation in clin. trials.  These results call for caution in the interpretation of ongoing trials and selection of patients in future trials.  They also warrant the identification of mol. markers for basal BCs more clin. applicable than gene expression profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxVpoZP512JLVg90H21EOLACvtfcHk0lgmiEuKFJddoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtlantbg%253D&md5=6ca7cc86ff3ec14c508fe11e3226ca8a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fijc.23518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.23518%26sid%3Dliteratum%253Aachs%26aulast%3DBertucci%26aufirst%3DF.%26aulast%3DFinetti%26aufirst%3DP.%26aulast%3DCervera%26aufirst%3DN.%26aulast%3DEsterni%26aufirst%3DB.%26aulast%3DHermitte%26aufirst%3DF.%26aulast%3DViens%26aufirst%3DP.%26aulast%3DBirnbaum%26aufirst%3DD.%26atitle%3DHow%2520basal%2520are%2520triple-negative%2520breast%2520cancers%253F%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2008%26volume%3D123%26spage%3D236%26epage%3D240%26doi%3D10.1002%2Fijc.23518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fahad
Ullah, M.</span></span> <span> </span><span class="NLM_article-title">Breast Cancer: Current perspectives on the disease status</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1152</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1007/978-3-030-20301-6_4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1007%2F978-3-030-20301-6_4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=31456179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvFSrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1152&publication_year=2019&pages=51-64&author=M.+Fahad%0AUllah&title=Breast+Cancer%3A+Current+perspectives+on+the+disease+status&doi=10.1007%2F978-3-030-20301-6_4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Breast Cancer: Current Perspectives on the Disease Status</span></div><div class="casAuthors">Fahad Ullah, Mohammad</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1152</span>
        (<span class="NLM_cas:issue">Breast Cancer Metastasis and Drug Resistance</span>),
    <span class="NLM_cas:pages">51-64</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Breast cancer is the most frequently diagnosed cancer in women and ranks second among causes for cancer related death in women.  Evidence in literature has shown that the past and ongoing research has an enormous implication in improving the clin. outcome in breast cancer.  This has been attributed to the progress made in the realm of screening, diagnosis and therapeutic strategies engaged in breast cancer management.  However, poor prognosis in TNBC and drug resistance presents major inhibitions which are also current challenges for contg. the disease.  Similarly, a focal point of concern is the rising rate of breast cancer incidence and mortality among the population of under developed world.  In this chapter, an overview of the current practices for the diagnosis and treatment of breast cancer and assocd. impediments has been provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtaZOdy8Tx97Vg90H21EOLACvtfcHk0lgmiEuKFJddoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvFSrt7k%253D&md5=bc1efba9b3a0478f10a1df8b89b4d2ac</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2F978-3-030-20301-6_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-030-20301-6_4%26sid%3Dliteratum%253Aachs%26aulast%3DFahad%2BUllah%26aufirst%3DM.%26atitle%3DBreast%2520Cancer%253A%2520Current%2520perspectives%2520on%2520the%2520disease%2520status%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2019%26volume%3D1152%26spage%3D51%26epage%3D64%26doi%3D10.1007%2F978-3-030-20301-6_4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garrido-Castro, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, N. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyak, K.</span></span> <span> </span><span class="NLM_article-title">Insights into molecular classifications of triple-negative breast cancer: Improving patient selection for treatment</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">176</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-1177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1158%2F2159-8290.CD-18-1177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=30679171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlGrsbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=176-198&author=A.+C.+Garrido-Castroauthor=N.+U.+Linauthor=K.+Polyak&title=Insights+into+molecular+classifications+of+triple-negative+breast+cancer%3A+Improving+patient+selection+for+treatment&doi=10.1158%2F2159-8290.CD-18-1177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment</span></div><div class="casAuthors">Garrido-Castro, Ana C.; Lin, Nancy U.; Polyak, Kornelia</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">176-198</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) remains the most challenging breast cancer subtype to treat.  To date, therapies directed to specific mol. targets have rarely achieved clin. meaningful improvements in outcomes of patients with TNBC, and chemotherapy remains the std. of care.  Here, we seek to review the most recent efforts to classify TNBC based on the comprehensive profiling of tumors for cellular compn. and mol. features.  Technol. advances allow for tumor characterization at ever-increasing depth, generating data that, if integrated with clin.-pathol. features, may help improve risk stratification of patients, guide treatment decisions and surveillance, and help identify new targets for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb4mfay-pxrbVg90H21EOLACvtfcHk0li-oOrmykqT1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlGrsbbJ&md5=823d8658319e5d9d19cdae93b776c4b4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-1177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-1177%26sid%3Dliteratum%253Aachs%26aulast%3DGarrido-Castro%26aufirst%3DA.%2BC.%26aulast%3DLin%26aufirst%3DN.%2BU.%26aulast%3DPolyak%26aufirst%3DK.%26atitle%3DInsights%2520into%2520molecular%2520classifications%2520of%2520triple-negative%2520breast%2520cancer%253A%2520Improving%2520patient%2520selection%2520for%2520treatment%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26spage%3D176%26epage%3D198%26doi%3D10.1158%2F2159-8290.CD-18-1177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianni, L.</span></span> <span> </span><span class="NLM_article-title">Triple-negative breast cancer: an unmet medical need</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2011-S1-01</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1634%2Ftheoncologist.2011-S1-01" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=21278435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A280%3ADC%252BC3M7nslaiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=1-11&author=C.+A.+Hudisauthor=L.+Gianni&title=Triple-negative+breast+cancer%3A+an+unmet+medical+need&doi=10.1634%2Ftheoncologist.2011-S1-01"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer: an unmet medical need</span></div><div class="casAuthors">Hudis Clifford A; Gianni Luca</div><div class="citationInfo"><span class="NLM_cas:title">The oncologist</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16 Suppl 1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer, characterized by tumors that do not express estrogen receptor (ER), progesterone receptor (PR), or HER-2 genes, represents an important clinical challenge because these cancers do not respond to endocrine therapy or other available targeted agents.  The metastatic potential in triple-negative breast cancer is similar to that of other breast cancer subtypes, but these tumors are associated with a shorter median time to relapse and death.  One important goal is therefore the identification of prognostic factors and markers to reliably select high and low risk subsets of patients with triple-negative disease for different treatment approaches of subtypes with differential responsiveness to specific agents.  However, a reliable prognostic marker has been elusive, and markers have been inconsistently useful.  For example, epidermal growth factor receptor (EGFR) has been studied, but there is still a lack of agreement on a standard assay or cutoff for EGFR expression levels with respect to prognosis.  Similarly, because triple-negative status is sometimes used as a surrogate for basal-like breast cancer, specific basal markers have been explored.  Indeed, trials designed to accrue patients with basal-like breast cancer using ER/PR and HER-2 negativity may provide only an approximation of the triple-negative population and are sometimes reanalyzed using more specific indicators like CK 5/6, EGFR status, and others, again marred by discordances.  Chemotherapy remains the mainstay of treatment of triple-negative breast cancer, but important limitations still need to be overcome in the next few years if any significant clinical strides are to be made.  Current treatment strategies for triple-negative disease include anthracyclines, taxanes, ixabepilone, platinum agents, and biologic agents.  More recently, EGFR inhibition has been proposed as a therapeutic mechanism in triple-negative breast cancer, again with mixed results.  Agents that target poly(ADP-ribose) polymerase and androgen receptors have also been proposed in these patients or subsets of them, and ongoing trials should result in definitive guidance with respect to the value of these agents in triple-negative disease.  Triple-negative breast cancer is clearly a distinct clinical subtype, from the perspective of both ER and HER-2 expression, but further subclassification is needed.  At present, there is not a clear, proven effective single agent that targets a defining vulnerability in triple-negative breast cancer.  This article will review the clinical problem of triple-negative disease, potential prognostic factors, demonstrated efficacy of currently available therapeutic options, and new potential therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOPZpUZEYLnfx2phytoz6_fW6udTcc2eZCHmaB1KLot7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7nslaiuw%253D%253D&md5=9a57cf464e3da0253820b7828c5bc76e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2011-S1-01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2011-S1-01%26sid%3Dliteratum%253Aachs%26aulast%3DHudis%26aufirst%3DC.%2BA.%26aulast%3DGianni%26aufirst%3DL.%26atitle%3DTriple-negative%2520breast%2520cancer%253A%2520an%2520unmet%2520medical%2520need%26jtitle%3DOncologist%26date%3D2011%26volume%3D16%26spage%3D1%26epage%3D11%26doi%3D10.1634%2Ftheoncologist.2011-S1-01" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haberland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. N.</span></span> <span> </span><span class="NLM_article-title">The many roles of histone deacetylases in development and physiology: implications for disease and therapy</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1038/nrg2485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1038%2Fnrg2485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=19065135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWis7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=32-42&author=M.+Haberlandauthor=R.+L.+Montgomeryauthor=E.+N.+Olson&title=The+many+roles+of+histone+deacetylases+in+development+and+physiology%3A+implications+for+disease+and+therapy&doi=10.1038%2Fnrg2485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The many roles of histone deacetylases in development and physiology: implications for disease and therapy</span></div><div class="casAuthors">Haberland, Michael; Montgomery, Rusty L.; Olson, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The expression of many histone deacetylase (HDAC) isoforms in eukaryotic cells raises questions regarding their specificity and the programs of gene expression that they control.  HDAC knockout mice are a powerful tool for addressing these questions and have revealed that individual HDACs have specific functions in development and disease.  Histone deacetylases (HDACs) are part of a vast family of enzymes that have crucial roles in numerous biol. processes, largely through their repressive influence on transcription.  The expression of many HDAC isoforms in eukaryotic cells raises questions about their possible specificity or redundancy, and whether they control global or specific programs of gene expression.  Recent analyses of HDAC knockout mice have revealed highly specific functions of individual HDACs in development and disease.  Mutant mice lacking individual HDACs are a powerful tool for defining the functions of HDACs in vivo and the mol. targets of HDAC inhibitors in disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMWcIo3mrsM7Vg90H21EOLACvtfcHk0li-oOrmykqT1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWis7bI&md5=0678d8655e86994cd4f0174c1e9d0eb1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrg2485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg2485%26sid%3Dliteratum%253Aachs%26aulast%3DHaberland%26aufirst%3DM.%26aulast%3DMontgomery%26aufirst%3DR.%2BL.%26aulast%3DOlson%26aufirst%3DE.%2BN.%26atitle%3DThe%2520many%2520roles%2520of%2520histone%2520deacetylases%2520in%2520development%2520and%2520physiology%253A%2520implications%2520for%2520disease%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2009%26volume%3D10%26spage%3D32%26epage%3D42%26doi%3D10.1038%2Fnrg2485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruijter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gennip, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kuilenburg, A. B.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases (HDACs): characterization of the classical HDAC family</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1042/bj20021321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1042%2Fbj20021321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=12429021" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2003&pages=737-749&author=A.+J.+Ruijterauthor=A.+H.+van+Gennipauthor=H.+N.+Caronauthor=S.+Kempauthor=A.+B.+van+Kuilenburg&title=Histone+deacetylases+%28HDACs%29%3A+characterization+of+the+classical+HDAC+family&doi=10.1042%2Fbj20021321"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1042%2Fbj20021321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj20021321%26sid%3Dliteratum%253Aachs%26aulast%3DRuijter%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2BGennip%26aufirst%3DA.%2BH.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26aulast%3DKemp%26aufirst%3DS.%26aulast%3Dvan%2BKuilenburg%26aufirst%3DA.%2BB.%26atitle%3DHistone%2520deacetylases%2520%2528HDACs%2529%253A%2520characterization%2520of%2520the%2520classical%2520HDAC%2520family%26jtitle%3DBiochem.%2520J.%26date%3D2003%26volume%3D370%26spage%3D737%26epage%3D749%26doi%3D10.1042%2Fbj20021321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bountra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span> <span> </span><span class="NLM_article-title">Epigenetic protein families: a new frontier for drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1038/nrd3674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1038%2Fnrd3674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=22498752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFWjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=384-400&author=C.+H.+Arrowsmithauthor=C.+Bountraauthor=P.+V.+Fishauthor=K.+Leeauthor=M.+Schapira&title=Epigenetic+protein+families%3A+a+new+frontier+for+drug+discovery&doi=10.1038%2Fnrd3674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic protein families: a new frontier for drug discovery</span></div><div class="casAuthors">Arrowsmith, Cheryl H.; Bountra, Chas; Fish, Paul V.; Lee, Kevin; Schapira, Matthieu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">384-400</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic regulation of gene expression is a dynamic and reversible process that establishes normal cellular phenotypes but also contributes to human diseases.  At the mol. level, epigenetic regulation involves hierarchical covalent modification of DNA and the proteins that package DNA, such as histones.  Here, we review the key protein families that mediate epigenetic signalling through the acetylation and methylation of histones, including histone deacetylases, protein methyltransferases, lysine demethylases, bromodomain-contg. proteins and proteins that bind to methylated histones.  These protein families are emerging as druggable classes of enzymes and druggable classes of protein-protein interaction domains.  In this article, we discuss the known links with disease, basic mol. mechanisms of action and recent progress in the pharmacol. modulation of each class of proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcD99eCigNtLVg90H21EOLACvtfcHk0lgfg9mNb60x8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFWjsbs%253D&md5=eb82034466a43107aa74a18ccf6d29f5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd3674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3674%26sid%3Dliteratum%253Aachs%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DFish%26aufirst%3DP.%2BV.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DSchapira%26aufirst%3DM.%26atitle%3DEpigenetic%2520protein%2520families%253A%2520a%2520new%2520frontier%2520for%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D384%26epage%3D400%26doi%3D10.1038%2Fnrd3674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weichert, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roske, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niesporek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noske, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckendahl, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gekeler, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denkert, C.</span></span> <span> </span><span class="NLM_article-title">Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1669</span>– <span class="NLM_lpage">1677</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-0990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1158%2F1078-0432.CCR-07-0990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=18347167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtlejt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1669-1677&author=W.+Weichertauthor=A.+Roskeauthor=S.+Niesporekauthor=A.+Noskeauthor=A.+C.+Buckendahlauthor=M.+Dietelauthor=V.+Gekelerauthor=M.+Boehmauthor=T.+Beckersauthor=C.+Denkert&title=Class+I+histone+deacetylase+expression+has+independent+prognostic+impact+in+human+colorectal+cancer%3A+specific+role+of+class+I+histone+deacetylases+in+vitro+and+in+vivo&doi=10.1158%2F1078-0432.CCR-07-0990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo</span></div><div class="casAuthors">Weichert, Wilko; Roeske, Annika; Niesporek, Silvia; Noske, Aurelia; Buckendahl, Ann-Christin; Dietel, Manfred; Gekeler, Volker; Boehm, Markus; Beckers, Thomas; Denkert, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1669-1677</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Recently, several studies reported a strong functional link between histone deacetylases (HDAC) and the development of tumors of the large intestine.  However, despite the importance of these mols., comparably little is known on expression patterns and functions of specific HDAC isoforms in colorectal cancer.  Exptl. Design: We characterized class I HDAC isoform expression patterns in a cohort of 140 colorectal carcinomas by immunohistochem.  In addn., effects of HDAC inhibition by valproic acid and suberoylanilide hydroxamic acid, and specific HDAC isoform knockdown by short interfering RNA, were investigated in a cell culture model.  RESULTS: We found class I HDACs highly expressed in a subset of colorectal carcinomas with positivity for HDAC1 in 36.4%, HDAC2 in 57.9%, and HDAC3 in 72.9% of cases.  Expression was significantly enhanced in strongly proliferating (P = 0.002), dedifferentiated (P = 0.022) tumors.  High HDAC expression levels implicated significantly reduced patient survival (P = 0.001), with HDAC2 expression being an independent survival prognosticator (hazard ratio, 2.6; P = 0.03).  Short interfering RNA-based inhibition of HDAC1 and HDAC2 but not HDAC3 suppressed growth of colon cancer cells in vitro, although to a lesser extent than chem. HDAC inhibitors did.  CONCLUSIONS: The strong prognostic impact of HDAC isoforms in colorectal cancer, the interactions of HDACs with tumor cell proliferation and differentiation in vivo, and our finding that HDACs are differentially expressed in colorectal tumors suggest that the evaluation of HDAC expression in clin. trials for HDAC inhibitors might help to identify a patient subgroup who will exceptionally profit from such a treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQAUfNzjDakrVg90H21EOLACvtfcHk0lgfg9mNb60x8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtlejt7o%253D&md5=f54611c0b65fe4cd8a0cfea3ea143126</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0990%26sid%3Dliteratum%253Aachs%26aulast%3DWeichert%26aufirst%3DW.%26aulast%3DRoske%26aufirst%3DA.%26aulast%3DNiesporek%26aufirst%3DS.%26aulast%3DNoske%26aufirst%3DA.%26aulast%3DBuckendahl%26aufirst%3DA.%2BC.%26aulast%3DDietel%26aufirst%3DM.%26aulast%3DGekeler%26aufirst%3DV.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DBeckers%26aufirst%3DT.%26aulast%3DDenkert%26aufirst%3DC.%26atitle%3DClass%2520I%2520histone%2520deacetylase%2520expression%2520has%2520independent%2520prognostic%2520impact%2520in%2520human%2520colorectal%2520cancer%253A%2520specific%2520role%2520of%2520class%2520I%2520histone%2520deacetylases%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D1669%26epage%3D1677%26doi%3D10.1158%2F1078-0432.CCR-07-0990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinkerneil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deenen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohrer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arent, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niegisch, G.</span></span> <span> </span><span class="NLM_article-title">Inhibition of class I histone deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1158%2F1535-7163.MCT-15-0618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=26772204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVWrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=299-312&author=M.+Pinkerneilauthor=M.+J.+Hoffmannauthor=R.+Deenenauthor=K.+Kohrerauthor=T.+Arentauthor=W.+A.+Schulzauthor=G.+Niegisch&title=Inhibition+of+class+I+histone+deacetylases+1+and+2+promotes+urothelial+carcinoma+cell+death+by+various+mechanisms&doi=10.1158%2F1535-7163.MCT-15-0618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms</span></div><div class="casAuthors">Pinkerneil, Maria; Hoffmann, Michele J.; Deenen, Rene'e; Kohrer, Karl; Arent, Tanja; Schulz, Wolfgang A.; Niegisch, Gunter</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">299-312</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Class I histone deacetylases HDAC1 and HDAC2 contribute to cell proliferation and are commonly upregulated in urothelial carcinoma.  To evaluate whether specific inhibition of these enzymes might serve as an appropriate therapy for urothelial carcinoma, siRNA-mediated knockdown and specific pharmacol. inhibition of HDAC1 and HDAC2 were applied in urothelial carcinoma cell lines (UCC) with distinct HDAC1 and HDAC2 expression profiles.  HDACs and response marker proteins were followed by Western blotting and qRT-PCR.  Effects of class I HDAC suppression on UCCs were analyzed by viability, colony forming, and caspase-3/7 assays; flow cytometry, senescence and lactate dehydrogenase cytotoxicity assays; and immunofluorescence staining.  Whereas single knockdowns of HDAC1 or HDAC2 were impeded by compensatory upregulation of the other isoenzyme, efficient double knockdown of HDAC1 and HDAC2 reduced proliferation by up to 80% and induced apoptosis-like cell death in all UCCs.  Clonogenic growth was cell line- and HDAC-dependently reduced, with double knockdown of HDAC1 and HDAC2 being usually most efficient.  Class I HDAC-specific inhibitors, esp. the more specific HDAC1/2 inhibitors romidepsin and givinostat, significantly reduced proliferation of all UCCs (IC50, 3.36 nmol/L-4.59 μmol/L).  Romidepsin and givinostat also significantly inhibited clonogenic growth of UCCs, with minor effects on nontumorigenic controls.  Intriguingly, these compds. induced primarily S-phase disturbances and nonapoptotic cell death in UCCs.  Thus, although both ways of inhibiting HDAC1/2 share mechanisms and efficaciously inhibit cell proliferation, their modes of action differ substantially.  Regardless, combined inhibition of HDAC1/2 appears to represent a promising strategy for urothelial carcinoma therapy.  Mol Cancer Ther; 15(2); 299-312. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW8MT_AwmqpLVg90H21EOLACvtfcHk0lgfg9mNb60x8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVWrs7o%253D&md5=5be8f0be83930ac9aa564a9afd42d2c5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0618%26sid%3Dliteratum%253Aachs%26aulast%3DPinkerneil%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%2BJ.%26aulast%3DDeenen%26aufirst%3DR.%26aulast%3DKohrer%26aufirst%3DK.%26aulast%3DArent%26aufirst%3DT.%26aulast%3DSchulz%26aufirst%3DW.%2BA.%26aulast%3DNiegisch%26aufirst%3DG.%26atitle%3DInhibition%2520of%2520class%2520I%2520histone%2520deacetylases%25201%2520and%25202%2520promotes%2520urothelial%2520carcinoma%2520cell%2520death%2520by%2520various%2520mechanisms%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D299%26epage%3D312%26doi%3D10.1158%2F1535-7163.MCT-15-0618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buurman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gürlevik, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäffer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandbothe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreipe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegelberger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kühnel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skawran, B.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">811</span>– <span class="NLM_lpage">820</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2012.05.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1053%2Fj.gastro.2012.05.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=22641068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1KktLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2012&pages=811-820&author=R.+Buurmanauthor=E.+G%C3%BCrlevikauthor=V.+Sch%C3%A4fferauthor=M.+Eilersauthor=M.+Sandbotheauthor=H.+Kreipeauthor=L.+Wilkensauthor=B.+Schlegelbergerauthor=F.+K%C3%BChnelauthor=B.+Skawran&title=Histone+deacetylases+activate+hepatocyte+growth+factor+signaling+by+repressing+microRNA-449+in+hepatocellular+carcinoma+cells&doi=10.1053%2Fj.gastro.2012.05.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylases Activate Hepatocyte Growth Factor Signaling by Repressing MicroRNA-449 in Hepatocellular Carcinoma Cells</span></div><div class="casAuthors">Buurman, Reena; Guerlevik, Engin; Schaeffer, Vera; Eilers, Marlies; Sandbothe, Maria; Kreipe, Hans; Wilkens, Ludwig; Schlegelberger, Brigitte; Kuehnel, Florian; Skawran, Britta</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">811-820.e15</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Histone deacetylation regulates chromatin remodeling and transcriptional down-regulation of specific genomic regions; it is altered in many types of cancer cells.  We searched for microRNAs (miRs) that are affected by histone deacetylation and investigated the effects in hepatocellular carcinoma (HCC) cells.  HCC cell lines (HepG2, HLE, HLF, and Huh7) and immortalized liver cell lines (THLE-2 and THLE-3) were incubated with the histone deacetylase inhibitor trichostatin A.  Differentially expressed mRNAs (mRNAs) and miRs were identified by expression profiling.  Small interfering RNAs were used to reduce levels of histone deacetylases (HDAC)1-3, and HCC cell lines were transfected with miR-449.  We evaluated growth of xenograft tumors from modified cells in nude mice.  Cells were analyzed by immunoblot and luciferase reporter assays.  We analyzed HCC samples from 23 patients.  HDAC1-3 were up-regulated in HCC samples from patients.  In cell lines, inhibition of HDAC significantly increased levels of hsa-miR-449a. c-MET mRNA, which encodes the receptor tyrosine kinase for hepatocyte growth factor, is a target of miR-449.  Incubation of HCC cells with trichostatin A or transfection with miR-449 reduced expression of c-MET and phosphorylation of extracellular signal-regulated kinases 1 and 2 (downstream effectors of c-MET), increased apoptosis, and reduced proliferation.  Huh-7 cells transfected with miR-449 formed tumors more slowly in mice than cells expressing control miRs.  HCC samples from patients had lower levels of miR-449 and higher levels of c-MET than human ref.  In HCC cells, up-regulation of HDAC1-3 reduces expression of miR-449. miR-449 binds c-MET mRNA to reduce its levels, promoting apoptosis and reducing proliferation of liver cells.  Expression of miR-449 slows growth of HCC xenograft tumors in mice; this miR might function as a tumor suppressor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5f9Klj5wOXbVg90H21EOLACvtfcHk0ljDe0adjcK4KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1KktLnN&md5=19eb1f004c418205ed713eb9cb47ba85</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2012.05.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2012.05.033%26sid%3Dliteratum%253Aachs%26aulast%3DBuurman%26aufirst%3DR.%26aulast%3DG%25C3%25BCrlevik%26aufirst%3DE.%26aulast%3DSch%25C3%25A4ffer%26aufirst%3DV.%26aulast%3DEilers%26aufirst%3DM.%26aulast%3DSandbothe%26aufirst%3DM.%26aulast%3DKreipe%26aufirst%3DH.%26aulast%3DWilkens%26aufirst%3DL.%26aulast%3DSchlegelberger%26aufirst%3DB.%26aulast%3DK%25C3%25BChnel%26aufirst%3DF.%26aulast%3DSkawran%26aufirst%3DB.%26atitle%3DHistone%2520deacetylases%2520activate%2520hepatocyte%2520growth%2520factor%2520signaling%2520by%2520repressing%2520microRNA-449%2520in%2520hepatocellular%2520carcinoma%2520cells%26jtitle%3DGastroenterology%26date%3D2012%26volume%3D143%26spage%3D811%26epage%3D820%26doi%3D10.1053%2Fj.gastro.2012.05.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krusche, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulfing, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kersting, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vloet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiesel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beier, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfer, J.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1007/s10549-004-1668-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1007%2Fs10549-004-1668-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=15770522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Olur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2005&pages=15-23&author=C.+A.+Kruscheauthor=P.+Wulfingauthor=C.+Kerstingauthor=A.+Vloetauthor=W.+Bockerauthor=L.+Kieselauthor=H.+M.+Beierauthor=J.+Alfer&title=Histone+deacetylase-1+and+-3+protein+expression+in+human+breast+cancer%3A+a+tissue+microarray+analysis&doi=10.1007%2Fs10549-004-1668-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis</span></div><div class="casAuthors">Krusche, Claudia A.; Wuelfing, Pia; Kersting, Christian; Vloet, Anne; Boecker, Werner; Kiesel, Ludwig; Beier, Henning M.; Alfer, Joachim</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-23</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Impaired histone acetylation was recognized to be involved in carcinogenesis.  Furthermore, histone deacetylase (HDAC) inhibitors induce differentiation of breast cancer cells and inhibit tumor growth.  These results prompted us to study HDAC-1 and -3 expression in breast tumors to establish their potential therapeutic and prognostic significance.  HDAC-1 und HDAC-3 protein expression was analyzed immunohistochem. on a tissue microarray (TMA) contg. 600 core biopsies from 200 patients.  HDAC-1 and -3 expression was correlated to steroid hormone receptor-, Her2/neu- and proliferation status of tumors as well as to overall and disease free survival.  Moderate or strong nuclear immunoreactivity for HDAC-1 was obsd. in 39.8% and for HDAC-3 in 43.9% of breast carcinomas.  HDAC-1 and -3 expression correlated significantly with estrogen and progesterone receptor expression (both p< 0.001).  HDAC-1 expression predicted significantly better disease free survival (DFS: p=0.044), in particular, in patients with small tumors of all differentiation types (DFS: p=0.016).  Multivariate anal. demonstrated that HDAC-1 is an independent prognostic marker.  Our data suggest that evaluation of HDAC-1 protein expression enables a more precise assessment of the prognosis of breast cancer patients.  Thus, HDAC-1 expression anal. might be clin. useful to facilitate an individual, risk-directed, adjuvant systemic therapy in breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppl5Ppi20BRbVg90H21EOLACvtfcHk0ljDe0adjcK4KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Olur0%253D&md5=848683aeb8064462b3e269c00db0ce86</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs10549-004-1668-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-004-1668-2%26sid%3Dliteratum%253Aachs%26aulast%3DKrusche%26aufirst%3DC.%2BA.%26aulast%3DWulfing%26aufirst%3DP.%26aulast%3DKersting%26aufirst%3DC.%26aulast%3DVloet%26aufirst%3DA.%26aulast%3DBocker%26aufirst%3DW.%26aulast%3DKiesel%26aufirst%3DL.%26aulast%3DBeier%26aufirst%3DH.%2BM.%26aulast%3DAlfer%26aufirst%3DJ.%26atitle%3DHistone%2520deacetylase-1%2520and%2520-3%2520protein%2520expression%2520in%2520human%2520breast%2520cancer%253A%2520a%2520tissue%2520microarray%2520analysis%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2005%26volume%3D90%26spage%3D15%26epage%3D23%26doi%3D10.1007%2Fs10549-004-1668-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, H.</span></span> <span> </span><span class="NLM_article-title">Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1007/s10549-005-6001-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1007%2Fs10549-005-6001-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=16172792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVyltbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=11-16&author=Z.+Zhangauthor=H.+Yamashitaauthor=T.+Toyamaauthor=H.+Sugiuraauthor=Y.+Andoauthor=K.+Mitaauthor=M.+Hamaguchiauthor=Y.+Haraauthor=S.+Kobayashiauthor=H.+Iwase&title=Quantitation+of+HDAC1+mRNA+expression+in+invasive+carcinoma+of+the+breast*&doi=10.1007%2Fs10549-005-6001-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast</span></div><div class="casAuthors">Zhang, Zhenhuan; Yamashita, Hiroko; Toyama, Tatsuya; Sugiura, Hiroshi; Ando, Yoshiaki; Mita, Keiko; Hamaguchi, Maho; Hara, Yasuo; Kobayashi, Shunzo; Iwase, Hirotaka</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-16</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Estrogen is well-established as a mitogenic factor implicated in the tumorigenesis and progression of breast cancer via its binding to the estrogen receptor α (ERα).  Recent data indicate that chromatin inactivation mediated by histone deacetylation (HDAC) and DNA methylation is a crit. component of ERα silencing in human breast cancer cells.  The aim of this study was to det. the expression of the HDAC1 gene in malignant human breast tissue and to correlate our observations with available clin. information.  In the present study, the level of expression of HDAC1 mRNA was assessed by LightCycler-based quant. real-time reverse transcriptase (RT)-PCR anal. in 162 cases of invasive carcinoma of the breast.  Assocns. between HDAC1 mRNA expression and different clinicopathol. factors were sought.  It was found that HDAC1 mRNA was expressed at significantly higher levels in tumors from patients over 50 years of age and in those tumors without axillary lymph node involvement, that are less than 2 cm, that are of a non-high histol. grade, that are HER2 neg. and that are ERα/PgR pos.  Patients with tumors displaying high levels of HDAC1 mRNA expression tended to have a better prognosis in terms of both disease-free and overall survival.  However, univariate and multivariate anal. did not show HDAC1 mRNA expression level to be an independent prognostic factor for either disease-free or overall survival.  These results imply that HDAC1 mRNA expression could have potential as an endocrine response marker and may have prognostic implications for breast cancer progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXQ0D466PdgrVg90H21EOLACvtfcHk0ljDe0adjcK4KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVyltbjK&md5=2481b26970c84afab7b464d6769014da</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs10549-005-6001-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-005-6001-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DYamashita%26aufirst%3DH.%26aulast%3DToyama%26aufirst%3DT.%26aulast%3DSugiura%26aufirst%3DH.%26aulast%3DAndo%26aufirst%3DY.%26aulast%3DMita%26aufirst%3DK.%26aulast%3DHamaguchi%26aufirst%3DM.%26aulast%3DHara%26aufirst%3DY.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DIwase%26aufirst%3DH.%26atitle%3DQuantitation%2520of%2520HDAC1%2520mRNA%2520expression%2520in%2520invasive%2520carcinoma%2520of%2520the%2520breast%252A%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2005%26volume%3D94%26spage%3D11%26epage%3D16%26doi%3D10.1007%2Fs10549-005-6001-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gau, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, G.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1007/s10549-013-2784-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1007%2Fs10549-013-2784-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=24305977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFKgtbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2014&pages=99-111&author=P.+Shahauthor=Y.+Gauauthor=G.+Sabnis&title=Histone+deacetylase+inhibitor+entinostat+reverses+epithelial+to+mesenchymal+transition+of+breast+cancer+cells+by+reversing+the+repression+of+E-cadherin&doi=10.1007%2Fs10549-013-2784-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin</span></div><div class="casAuthors">Shah, Preeti; Gau, Yael; Sabnis, Gauri</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-111</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Loss of ERα in breast cancer correlates with poor prognosis, increased recurrence rates, and higher incidence of metastasis.  Epigenetic silencing of E-cadherin (loss of which is assocd. with more invasive phenotype) is obsd. in metastatic cell lines and invasive breast cancers.  Here, we are showing that entinostat (ENT) can reverse epithelial to mesenchymal transition (EMT), which is considered to be a first step in the process of metastases formation.  Triple-neg. breast cancer cells such as MDA-MB-231 and Hs578T show a basal phenotype characterized by loss of E-cadherin expression and higher expression of mesenchymal markers such as N-cadherin and vimentin along with transcriptional repressors such as twist and snail.  When MDA-MB-231 and Hs578T cells or tumors were treated with ENT, E-cadherin transcription was increased along with redn. in N-cadherin mRNA expression.  Chromatin immunopptn. assay showed that treatment of MDA-MB-231 and Hs578T cells increased the activation of E-cadherin promoter by reducing the assocn. of twist and snail with the E-cadherin (CDH1) promoter and downregulated both the snail and twist.  ENT also inhibited cell migration in vitro.  In addn., phosphorylation of vimentin was increased, as well as remodeling of vimentin filaments.  ENT treatment also reduced formation of tubulin-based microtentacles, which help floating cells attach to other surfaces.  These findings suggest that ENT can reverse EMT and may reduce the formation of metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3qhRaYzBvB7Vg90H21EOLACvtfcHk0lhOvNHsEUT1ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFKgtbrF&md5=0ad48e48edd917a879b3dadb0743e89a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs10549-013-2784-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-013-2784-7%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DP.%26aulast%3DGau%26aufirst%3DY.%26aulast%3DSabnis%26aufirst%3DG.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520entinostat%2520reverses%2520epithelial%2520to%2520mesenchymal%2520transition%2520of%2520breast%2520cancer%2520cells%2520by%2520reversing%2520the%2520repression%2520of%2520E-cadherin%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2014%26volume%3D143%26spage%3D99%26epage%3D111%26doi%3D10.1007%2Fs10549-013-2784-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garmpis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garmpi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalampokas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalampokas, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valsami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontzoglou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiteas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitroulis, D.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases as new therapeutic targets in triple-negative breast cancer: progress and promises</span>. <i>Cancer Genomics Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.21873/CGP.20041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.21873%2FCGP.20041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=28870998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslaisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=299-313&author=N.+Garmpisauthor=D.+Christosauthor=A.+Garmpiauthor=E.+Kalampokasauthor=T.+A.+Kalampokasauthor=S.+Valsamiauthor=M.+Kontosauthor=A.+Nonniauthor=K.+Kontzoglouauthor=D.+Perreaauthor=N.+Nikiteasauthor=D.+Dimitroulis&title=Histone+deacetylases+as+new+therapeutic+targets+in+triple-negative+breast+cancer%3A+progress+and+promises&doi=10.21873%2FCGP.20041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases as new therapeutic targets in triple-negative breast cancer: progress and promises</span></div><div class="casAuthors">Garmpis, Nikolaos; Damaskos, Christos; Garmpi, Anna; Kalampokas, Emmanouil; Kalampokas, Theodoros; Spartalis, Eleftherios; Daskalopoulou, Afrodite; Valsami, Serena; Kontos, Michael; Nonni, Afroditi; Kontzoglou, Konstantinos; Perrea, Despina; Nikiteas, Nikolaos; Dimitroulis, Dimitrios</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Genomics & Proteomics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">299-313</span>CODEN:
                <span class="NLM_cas:coden">CGPAC7</span>;
        ISSN:<span class="NLM_cas:issn">1790-6245</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) lacks expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 gene.  It comprises approx. 15-20% of breast cancers (BCs).  Unfortunately, TNBC's treatment continues to be a clin. problem because of its relatively poor prognosis, its aggressiveness and the lack of targeted therapies, leaving chemotherapy as the mainstay of treatment.  It is essential to find new therapies against TNBC, in order to surpass the resistance and the invasiveness of already existing therapies.  Given the fact that epigenetic processes control both the initiation and progression of TNBC, there is an increasing interest in the mechanisms, mols. and signaling pathways that participate at the epigenetic modulation of genes expressed in carcinogenesis.  The acetylation of histone proteins provokes the transcription of genes involved in cell growth, and the expression of histone deacetylases (HDACs) is frequently up-regulated in many malignancies.  Unfortunately, in the field of BC, HDAC inhibitors have shown limited effect as single agents.  Nevertheless, their use in combination with kinase inhibitors, autophagy inhibitors, ionizing radiation, or two HDAC inhibitors together is currently being evaluated.  HDAC inhibitors such as suberoylanilidehydroxamic acid (SAHA), sodium butyrate, mocetinostat, panobinostat, entinostat, YCW1 and N-2-hydroxyphenyl-2-propylpentanamide have shown promising therapeutic outcomes against TNBC, esp. when they are used in combination with other anticancer agents.  More studies concerning HDAC inhibitors in breast carcinomas along with a more accurate understanding of the TNBC's pathobiol. are required for the possible identification of new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQvJ3B103o-rVg90H21EOLACvtfcHk0lhOvNHsEUT1ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslaisw%253D%253D&md5=05740e9bef67109a282ce4ad7399ebb5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.21873%2FCGP.20041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21873%252FCGP.20041%26sid%3Dliteratum%253Aachs%26aulast%3DGarmpis%26aufirst%3DN.%26aulast%3DChristos%26aufirst%3DD.%26aulast%3DGarmpi%26aufirst%3DA.%26aulast%3DKalampokas%26aufirst%3DE.%26aulast%3DKalampokas%26aufirst%3DT.%2BA.%26aulast%3DValsami%26aufirst%3DS.%26aulast%3DKontos%26aufirst%3DM.%26aulast%3DNonni%26aufirst%3DA.%26aulast%3DKontzoglou%26aufirst%3DK.%26aulast%3DPerrea%26aufirst%3DD.%26aulast%3DNikiteas%26aufirst%3DN.%26aulast%3DDimitroulis%26aufirst%3DD.%26atitle%3DHistone%2520deacetylases%2520as%2520new%2520therapeutic%2520targets%2520in%2520triple-negative%2520breast%2520cancer%253A%2520progress%2520and%2520promises%26jtitle%3DCancer%2520Genomics%2520Proteomics%26date%3D2017%26volume%3D14%26spage%3D299%26epage%3D313%26doi%3D10.21873%2FCGP.20041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maiti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hait, N. C.</span></span> <span> </span><span class="NLM_article-title">Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.3892/ijo.2019.4796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.3892%2Fijo.2019.4796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=31059004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1OqtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=116-130&author=A.+Maitiauthor=Q.+Qiauthor=X.+Pengauthor=L.+Yanauthor=K.+Takabeauthor=N.+C.+Hait&title=Class+I+histone+deacetylase+inhibitor+suppresses+vasculogenic+mimicry+by+enhancing+the+expression+of+tumor+suppressor+and+anti-angiogenesis+genes+in+aggressive+human+TNBC+cells&doi=10.3892%2Fijo.2019.4796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells</span></div><div class="casAuthors">Maiti, Aparna; Qi, Qianya; Peng, Xuan; Yan, Li; Takabe, Kazuaki; Hait, Nitai C.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-130</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1791-2423</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) cells form angiogenesis-independent vessel-like structures to survive, known as vasculogenic mimicry (VM), contributing to a poor prognosis for cancer patients.  Nuclear localized class I histone deacetylases (HDACs) enzymes, particularly HDACs 1, 2, 3 deacetylate chromatin histones, are overexpressed in cancers and epigenetically regulate the expression of genes involved in cancer initiation and progression.  The specific HDAC inhibitor, entinostat, has been shown to attenuate tumor progression and metastasis in TNBC.  In this study, we hypothesized that entinostat would enhance the expression of anti-angiogenic and tumor suppressor genes and would thus suppress VM structures in TNBC cells in a 3D Matrigel cell culture preclin. model.  Our data indicated that invasive triple-neg. MDA-MB-231, LM2-4 and BT-549 breast cancer cells, but not poorly invasive luminal MCF-7 cells, efficiently underwent matrix-assocd. VM formation.  Approx. 80% of TNBC cells with the stem cell phenotype potential formed vessel-like structures when mixed with Matrigel and cultured in the low attachment tissue culture plate.  The mol. mechanisms of VM formation are rather complex, while angiogenesis inhibitor genes are downregulated and pro-angiogenesis genes are upregulated in VM-forming cells.  Our data revealed that treatment of the TNBC VM phenotype cells with entinostat epigenetically led to the re-expression of the anti-angiogenic genes, serpin family F member 1 (SERPINF1) and thrombospondin 2 (THBS2), and to that of the tumor suppressor genes, phosphatase and tensin homolog (PTEN) and p21, and reduced VM structures.  We also found that treatment of the TNBC VM phenotype cells with entinostat downregulated the expression of vascular endothelial growth factor A (VEGF-A), and that of the epithelial-mesenchymal transition (EMT)-related genes, Vimentin and β-catenin.  METABIRC and TCGA breast cancer cohort mRNA expression data anal. revealed that a high expression of the anti-angiogenesis-assocd. genes, THBS2, SERPINF1 and serpin family B member 5 (SERPINB5), and of the tumor suppressor gene, PTEN, was assocd. with a better overall survival (OS) of breast cancer patients.  Taken together, the findings of this study demonstrate that HDACs 1, 2, 3 partly contribute to VM formation in TNBC cells; thus, HDACs may be an important therapeutic target for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMD7MoYG5MHbVg90H21EOLACvtfcHk0lhOvNHsEUT1ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1OqtLrM&md5=b1340b7490c73e28379ad785cb33ce14</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.3892%2Fijo.2019.4796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2019.4796%26sid%3Dliteratum%253Aachs%26aulast%3DMaiti%26aufirst%3DA.%26aulast%3DQi%26aufirst%3DQ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DTakabe%26aufirst%3DK.%26aulast%3DHait%26aufirst%3DN.%2BC.%26atitle%3DClass%2520I%2520histone%2520deacetylase%2520inhibitor%2520suppresses%2520vasculogenic%2520mimicry%2520by%2520enhancing%2520the%2520expression%2520of%2520tumor%2520suppressor%2520and%2520anti-angiogenesis%2520genes%2520in%2520aggressive%2520human%2520TNBC%2520cells%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2019%26volume%3D55%26spage%3D116%26epage%3D130%26doi%3D10.3892%2Fijo.2019.4796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanigan, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboukhatwa, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taha, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frasor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petukhov, P. A.</span></span> <span> </span><span class="NLM_article-title">Divergent JNK phosphorylation of HDAC3 in triple-negative breast cancer cells determines HDAC inhibitor binding and selectivity</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1356</span>– <span class="NLM_lpage">13676</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1016%2Fj.chembiol.2017.08.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=28943357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGnsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1356-13676&author=T.+W.+Haniganauthor=S.+M.+Aboukhatwaauthor=T.+Y.+Tahaauthor=J.+Frasorauthor=P.+A.+Petukhov&title=Divergent+JNK+phosphorylation+of+HDAC3+in+triple-negative+breast+cancer+cells+determines+HDAC+inhibitor+binding+and+selectivity&doi=10.1016%2Fj.chembiol.2017.08.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity</span></div><div class="casAuthors">Hanigan, Thomas W.; Aboukhatwa, Shaimaa M.; Taha, Taha Y.; Frasor, Jonna; Petukhov, Pavel A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1356-1367.e8</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) catalytic activity is regulated by formation of co-regulator complexes and post-translational modification.  Whether these mechanisms are transformed in cancer and how this affects the binding and selectivity of HDAC inhibitors (HDACis) is unclear.  In this study, we developed a method that identified a 3- to 16-fold increase in HDACi selectivity for HDAC3 in triple-neg. breast cancer (TNBC) cells in comparison with luminal subtypes that was not predicted by current practice measurements with recombinant proteins.  We found this increase was caused by c-Jun N-terminal kinase (JNK) phosphorylation of HDAC3, was independent of HDAC3 complex compn. or subcellular localization, and was assocd. with a 5-fold increase in HDAC3 enzymic activity.  This study points to HDAC3 and the JNK axes as targets in TNBC, highlights how HDAC phosphorylation affects HDACi binding and selectivity, and outlines a method to identify changes in individual HDAC isoforms catalytic activity, applicable to any disease state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCZU_S5SEOArVg90H21EOLACvtfcHk0ljY39kIKr6t-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGnsrfF&md5=f63d68cc73cf1175890f39b6a91301bc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DHanigan%26aufirst%3DT.%2BW.%26aulast%3DAboukhatwa%26aufirst%3DS.%2BM.%26aulast%3DTaha%26aufirst%3DT.%2BY.%26aulast%3DFrasor%26aufirst%3DJ.%26aulast%3DPetukhov%26aufirst%3DP.%2BA.%26atitle%3DDivergent%2520JNK%2520phosphorylation%2520of%2520HDAC3%2520in%2520triple-negative%2520breast%2520cancer%2520cells%2520determines%2520HDAC%2520inhibitor%2520binding%2520and%2520selectivity%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D1356%26epage%3D13676%26doi%3D10.1016%2Fj.chembiol.2017.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schech, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, G.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor entinostat inhibits tumor-initiating cells in triple-negative breast cancer cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1848</span>– <span class="NLM_lpage">1857</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1158%2F1535-7163.MCT-14-0778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=26037781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1yrs7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1848-1857&author=A.+Schechauthor=A.+Kaziauthor=S.+Yuauthor=P.+Shahauthor=G.+Sabnis&title=Histone+deacetylase+inhibitor+entinostat+inhibits+tumor-initiating+cells+in+triple-negative+breast+cancer+cells&doi=10.1158%2F1535-7163.MCT-14-0778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells</span></div><div class="casAuthors">Schech, Amanda; Kazi, Armina; Yu, Stephen; Shah, Preeti; Sabnis, Gauri</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1848-1857</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mortality following breast cancer diagnosis is mainly due to the development of distant metastasis.  To escape from the primary site, tumor cells undergo the epithelial-to-mesenchymal transition (EMT), which helps them acquire a more motile and invasive phenotype.  In our previous study, we showed that class I selective HDAC inhibitor entinostat reverses the EMT phenotype through reversal of epigenetic repression of E-cadherin.  Recent evidence suggests that a subset of cells within a breast tumor may drive the metastatic outgrowth following escape from the primary site.  These cells, termed tumor-initiating cells (TIC), represent a great threat to overall prognosis.  They are crit. in terms of drug resistance and tumor initiation at metastatic sites.  Acquisition of EMT traits has also been shown to impart TIC phenotype to the cells, making EMT a "dual-threat" for prognosis.  In the current study, we show that entinostat treatment can reduce the percentage of TIC cells from triple-neg. breast cancer (TNBC) cells.  Entinostat treatment was able to reduce the CD44high/CD24low cell population, ALDH-1 activity, as well as protein and mRNA expression of known TIC markers such as Bmi-1, Nanog, and Oct-4.  Next, we inoculated MDA-MB-231 cells transfected with firefly luciferase (231/Luc) in mammary fat pad of NSG mice.  The mice were then treated with entinostat (2.5 mg/kg/d), and tumor development and formation of metastasis were assessed by bioluminescence imaging.  Treatment with entinostat significantly reduced tumor formation at the primary site as well as lung metastasis.  As such, entinostat may help prevent development of distant metastasis.  Mol Cancer Ther; 14(8); 1848-57. 2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRu0jMR4ckFrVg90H21EOLACvtfcHk0ljY39kIKr6t-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1yrs7vF&md5=0a68c2c5bdfd03939c216a59987fc8bd</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0778%26sid%3Dliteratum%253Aachs%26aulast%3DSchech%26aufirst%3DA.%26aulast%3DKazi%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DSabnis%26aufirst%3DG.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520entinostat%2520inhibits%2520tumor-initiating%2520cells%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D1848%26epage%3D1857%26doi%3D10.1158%2F1535-7163.MCT-14-0778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terranova-Barberio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowskal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeenah Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krings, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budillon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibition potentiates immunotherapy in triple negative breast cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">114156</span>– <span class="NLM_lpage">114172</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.23169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.18632%2Foncotarget.23169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=29371976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A280%3ADC%252BC1MvksFSrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=114156-114172&author=M.+Terranova-Barberioauthor=S.+Scott+Thomasauthor=N.+Aliauthor=N.+Pawlowskalauthor=J.+Jeenah+Parkauthor=G.+Kringsauthor=M.+D.+Rosenblumauthor=A.+Budillonauthor=P.+N.+Munster&title=HDAC+inhibition+potentiates+immunotherapy+in+triple+negative+breast+cancer&doi=10.18632%2Foncotarget.23169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibition potentiates immunotherapy in triple negative breast cancer</span></div><div class="casAuthors">Terranova-Barberio Manuela; Thomas Scott; Pawlowska Nela; Park Jeenah; Munster Pamela N; Ali Niwa; Rosenblum Michael D; Krings Gregor; Budillon Alfredo</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">69</span>),
    <span class="NLM_cas:pages">114156-114172</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is significant and resistance often follows.  Immunotherapy has shown promising results in various types of cancer, including breast cancer.  Here, we investigated a new combination strategy where histone deacetylase inhibitors (HDACi) are applied with immune checkpoint inhibitors to improve immunotherapy responses in TNBC.  Testing different epigenetic modifiers, we focused on the mechanisms underlying HDACi as priming modulators of immunotherapy.  Tumor cells were co-cultured with human peripheral blood mononuclear cells (PBMCs) and flow cytometric immunophenotyping was performed to define the role of epigenetic priming in promoting tumor antigen presentation and immune cell activation.  We found that HDACi up-regulate PD-L1 mRNA and protein expression in a time-dependent manner in TNBC cells, but not in hormone responsive cells.  Focusing on TNBC, HDACi up-regulated PD-L1 and HLA-DR on tumor cells when co-cultured with PBMCs and down-regulated CD4(+) Foxp3(+) Treg in vitro.  HDACi significantly enhanced the in vivo response to PD-1/CTLA-4 blockade in the triple-negative 4T1 breast cancer mouse model, the only currently available experimental system with functional resemblance to human TNBC.  This resulted in a significant decrease in tumor growth and increased survival, associated with increased T cell tumor infiltration and a reduction in CD4(+) Foxp3(+) T cells in the tumor microenvironment.  Overall, our results suggest a novel role for HDAC inhibition in combination with immune checkpoint inhibitors and identify a promising therapeutic strategy, supporting its further clinical evaluation for TNBC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUq_R8b5qOmiSm0e6ZOaemfW6udTcc2ebcEibZk7lbAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvksFSrsw%253D%253D&md5=c9511d4998918fe6313ea5cdea6dd924</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.23169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.23169%26sid%3Dliteratum%253Aachs%26aulast%3DTerranova-Barberio%26aufirst%3DM.%26aulast%3DScott%2BThomas%26aufirst%3DS.%26aulast%3DAli%26aufirst%3DN.%26aulast%3DPawlowskal%26aufirst%3DN.%26aulast%3DJeenah%2BPark%26aufirst%3DJ.%26aulast%3DKrings%26aufirst%3DG.%26aulast%3DRosenblum%26aufirst%3DM.%2BD.%26aulast%3DBudillon%26aufirst%3DA.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DHDAC%2520inhibition%2520potentiates%2520immunotherapy%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D114156%26epage%3D114172%26doi%3D10.18632%2Foncotarget.23169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waschke, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolaver, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piscopio, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. H.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibition sensitizes PD1 blockade-resistant B-cell lymphomas.</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1318</span>– <span class="NLM_lpage">1331</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-18-0875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1158%2F2326-6066.CIR-18-0875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=31235619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGjs7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=1318-1331&author=X.+Wangauthor=B.+C.+Waschkeauthor=R.+A.+Woolaverauthor=Z.+Chenauthor=G.+Zhangauthor=A.+D.+Piscopioauthor=X.+Liuauthor=J.+H.+Wang&title=Histone+deacetylase+inhibition+sensitizes+PD1+blockade-resistant+B-cell+lymphomas.&doi=10.1158%2F2326-6066.CIR-18-0875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibition sensitizes PD1 blockade-resistant B-cell lymphomas</span></div><div class="casAuthors">Wang, Xiaoguang; Waschke, Brittany C.; Woolaver, Rachel A.; Chen, Zhangguo; Zhang, Gan; Piscopio, Anthony D.; Liu, Xuedong; Wang, Jing H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1318-1331</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PD1 blockade is effective in a subset of patients with B-cell lymphoma (e.g., classical-Hodgkin lymphomas); however, most patients do not respond to anti-PD1 therapy.  To study PD1 resistance, we used an isoform-selective histone deacetylase inhibitor (HDACi; OKI-179), and a mouse mature B-cell lymphoma, G1XP lymphoma, immunosuppressive features of which resemble those of human B-cell lymphomas, including downregulation of MHC class I and II, exhaustion of CD8+ and CD4+ tumor-infiltrating lymphocytes (TIL), and PD1-blockade resistance.  Using two lymphoma models, we show that treatment of B-cell lymphomas refractory to PD1 blockade with both OKI-179 and anti-PD1 inhibited growth; furthermore, sensitivity to single or combined treatment required tumor-derived MHC class I, and pos. correlated with MHC class II expression level.  We conclude that OKI-179 sensitizes lymphomas to PD1-blockade by enhancing tumor immunogenicity.  In addn., we found that different HDACis exhibited distinct effects on tumors and T cells, yet the same HDACi could differentially affect HLA expression on different human B-cell lymphomas.  Our study highlights the immunol. effects of HDACis on antitumor responses and suggests that optimal treatment efficacy requires personalized design and rational combination based on prognostic biomarkers (e.g., MHCs) and the individual profiles of HDACi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYLbxnb5iyHLVg90H21EOLACvtfcHk0lh4AbpxjK29wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGjs7nM&md5=c1c8a7be8c141e751de4b5c811caf6ba</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-18-0875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-18-0875%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWaschke%26aufirst%3DB.%2BC.%26aulast%3DWoolaver%26aufirst%3DR.%2BA.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DPiscopio%26aufirst%3DA.%2BD.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26atitle%3DHistone%2520deacetylase%2520inhibition%2520sensitizes%2520PD1%2520blockade-resistant%2520B-cell%2520lymphomas.%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2019%26volume%3D7%26spage%3D1318%26epage%3D1331%26doi%3D10.1158%2F2326-6066.CIR-18-0875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bieliauskas, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflum, M. K.</span></span> <span> </span><span class="NLM_article-title">Isoform-selective histone deacetylase inhibitors</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1402</span>– <span class="NLM_lpage">1413</span>, <span class="refDoi"> DOI: 10.1039/b703830p</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1039%2Fb703830p" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=18568166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFejsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2008&pages=1402-1413&author=A.+V.+Bieliauskasauthor=M.+K.+Pflum&title=Isoform-selective+histone+deacetylase+inhibitors&doi=10.1039%2Fb703830p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Isoform-selective histone deacetylase inhibitors</span></div><div class="casAuthors">Bieliauskas, Anton V.; Pflum, Mary Kay H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1402-1413</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) proteins are transcription regulators linked to cancer.  As a result, multiple small mol. HDAC inhibitors are in various phases of clin. trials as anti-cancer drugs.  The majority of HDAC inhibitors non-selectively influence the activities of eleven human HDAC isoforms, which are divided into distinct classes.  This tutorial review focuses on the recent progress toward the identification of class-selective and isoform-selective HDAC inhibitors.  The emerging trends suggest that subtle differences in the active sites of the HDAC isoforms can be exploited to dictate selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXOB_YFWaeZrVg90H21EOLACvtfcHk0lho12iv6GRnbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFejsbs%253D&md5=326e20da0623a00114f43e5c459c9920</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1039%2Fb703830p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb703830p%26sid%3Dliteratum%253Aachs%26aulast%3DBieliauskas%26aufirst%3DA.%2BV.%26aulast%3DPflum%26aufirst%3DM.%2BK.%26atitle%3DIsoform-selective%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2008%26volume%3D37%26spage%3D1402%26epage%3D1413%26doi%3D10.1039%2Fb703830p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span> <span> </span><span class="NLM_article-title">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1038/nbt1272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1038%2Fnbt1272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=17211407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=84-90&author=P.+A.+Marksauthor=R.+Breslow&title=Dimethyl+sulfoxide+to+vorinostat%3A+development+of+this+histone+deacetylase+inhibitor+as+an+anticancer+drug&doi=10.1038%2Fnbt1272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span></div><div class="casAuthors">Marks, Paul A.; Breslow, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-90</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In our quest to understand why DMSO (DMSO) can cause growth arrest and terminal differentiation of transformed cells, we followed a path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a histone deacetylase inhibitor.  SAHA reacts with and blocks the catalytic site of these enzymes.  Extensive structure-activity studies were done along the path from DMSO to SAHA.  SAHA can cause growth arrest and death of a broad variety of transformed cells both in vitro and in tumor-bearing animals at concns. not toxic to normal cells.  SAHA has many protein targets whose structure and function are altered by acetylation, including chromatin-assocd. histones, nonhistone gene transcription factors and proteins involved in regulation of cell proliferation, migration and death.  In clin. trials, SAHA has shown significant anticancer activity against both hematol. and solid tumors at doses well tolerated by patients.  A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma.  More potent analogs of SAHA have shown unacceptable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK3endE54rQ7Vg90H21EOLACvtfcHk0lho12iv6GRnbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D&md5=cc2a39d80d5d5bea0a1377bdf48a957d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnbt1272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1272%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26atitle%3DDimethyl%2520sulfoxide%2520to%2520vorinostat%253A%2520development%2520of%2520this%2520histone%2520deacetylase%2520inhibitor%2520as%2520an%2520anticancer%2520drug%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D84%26epage%3D90%26doi%3D10.1038%2Fnbt1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smolewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span> <span> </span><span class="NLM_article-title">The discovery and development of romidepsin for the treatment of T-cell lymphoma</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">859</span>– <span class="NLM_lpage">873</span>, <span class="refDoi"> DOI: 10.1080/17460441.2017.1341487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1080%2F17460441.2017.1341487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=28641053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFaksbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=859-873&author=P.+Smolewskiauthor=T.+Robak&title=The+discovery+and+development+of+romidepsin+for+the+treatment+of+T-cell+lymphoma&doi=10.1080%2F17460441.2017.1341487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and development of romidepsin for the treatment of T-cell lymphoma</span></div><div class="casAuthors">Smolewski, Piotr; Robak, Tadeusz</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">859-873</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Romidepsin is a potent and selective inhibitor of histone deacetylases (HDCAi).  It is also the only bicyclic inhibitor to undergo clin. assessment and is considered a promising drug for the treatment of T-cell lymphomas.  The cellular action of romidepsin results in enhanced histone acetylation, as well as the acetylation of other nuclear or cytoplasmic proteins, influencing cell cycle, apoptosis, and angiogenesis.  In phase II studies involving patients with relapsed or refractory of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), romidepsin produced overall response rates (ORR) of 34-35% and 25-38%, with complete response (CR) rates of 6% and 15-18%, resp.: This review summarizes the development of romidepsin, the mechanisms behind its antineoplastic action and its pharmacol.  It also covers its pharmacokinetic and pharmacodynamic properties, as well as the preclin. and clin. data on its activity in T-cell lymphoma.: Since there are only few effective therapies available for T-cell lymphomas, romidepsin is a valuable option for relapsed/refractory patients with both CTCL and PTCL.  It's also generally well tolerated, and gives potentially durable responses for patients with advanced and symptomatic disease.  Combinations of romidepsin with other antineoplastic agents may also further improve drug response and outcomes in T-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsigr0TqPjabVg90H21EOLACvtfcHk0lho12iv6GRnbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFaksbbM&md5=663c00630892ded87486e8ca6f406b13</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1080%2F17460441.2017.1341487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2017.1341487%26sid%3Dliteratum%253Aachs%26aulast%3DSmolewski%26aufirst%3DP.%26aulast%3DRobak%26aufirst%3DT.%26atitle%3DThe%2520discovery%2520and%2520development%2520of%2520romidepsin%2520for%2520the%2520treatment%2520of%2520T-cell%2520lymphoma%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2017%26volume%3D12%26spage%3D859%26epage%3D873%26doi%3D10.1080%2F17460441.2017.1341487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwitkowski, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Valle, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habtemariam, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomquist, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehrotra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlab, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminskas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2666</span>– <span class="NLM_lpage">2670</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-3119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1158%2F1078-0432.CCR-14-3119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=25802282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2666-2670&author=H.+Z.+Leeauthor=V.+E.+Kwitkowskiauthor=P.+L.+Del+Valleauthor=M.+S.+Ricciauthor=H.+Saberauthor=B.+A.+Habtemariamauthor=J.+Bullockauthor=E.+Bloomquistauthor=Y.+Li+Shenauthor=X.+H.+Chenauthor=J.+Brownauthor=N.+Mehrotraauthor=S.+Dorffauthor=R.+Charlabauthor=R.+C.+Kaneauthor=E.+Kaminskasauthor=R.+Justiceauthor=A.+T.+Farrellauthor=R.+Pazdur&title=FDA+approval%3A+Belinostat+for+the+treatment+of+patients+with+relapsed+or+refractory+peripheral+T-cell+lymphoma&doi=10.1158%2F1078-0432.CCR-14-3119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma</span></div><div class="casAuthors">Lee, Hyon-Zu; Kwitkowski, Virginia E.; Del Valle, Pedro L.; Ricci, M. Stacey; Saber, Haleh; Habtemariam, Bahru A.; Bullock, Julie; Bloomquist, Erik; Shen, Yuan Li; Chen, Xiao-Hong; Brown, Janice; Mehrotra, Nitin; Dorff, Sarah; Charlab, Rosane; Kane, Robert C.; Kaminskas, Edvardas; Justice, Robert; Farrell, Ann T.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2666-2670</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On July 3, 2014, the FDA granted accelerated approval for belinostat (Beleodaq; Spectrum Pharmaceuticals, Inc.), a histone deacetylase inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).  A single-arm, open-label, multicenter, international trial in the indicated patient population was submitted in support of the application.  Belinostat was administered i.v. at a dose of 1000 mg/m2 over 30 min once daily on days 1 to 5 of a 21-day cycle.  The primary efficacy endpoint was overall response rate (ORR) based on central radiol. readings by an independent review committee.  The ORR was 25.8% [95% confidence interval (CI), 18.3-34.6] in 120 patients that had confirmed diagnoses of PTCL by the Central Pathol. Review Group.  The complete and partial response rates were 10.8% (95% CI, 5.9-17.8) and 15.0% (95% CI, 9.1-22.7), resp.  The median duration of response, the key secondary efficacy endpoint, was 8.4 mo (95% CI, 4.5-29.4).  The most common adverse reactions (>25%) were nausea, fatigue, pyrexia, anemia, and vomiting.  Grade 3/4 toxicities (≥5.0%) included anemia, thrombocytopenia, dyspnea, neutropenia, fatigue, and pneumonia.  Belinostat is the third drug to receive accelerated approval for the treatment of relapsed or refractory PTCL.  Clin Cancer Res; 21(12); 2666-70. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1RbkvuHSk6rVg90H21EOLACvtfcHk0lguY_Ex57arnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfM&md5=c1e64c9d01d18272d25ad03001e7041a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-3119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-3119%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BZ.%26aulast%3DKwitkowski%26aufirst%3DV.%2BE.%26aulast%3DDel%2BValle%26aufirst%3DP.%2BL.%26aulast%3DRicci%26aufirst%3DM.%2BS.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DHabtemariam%26aufirst%3DB.%2BA.%26aulast%3DBullock%26aufirst%3DJ.%26aulast%3DBloomquist%26aufirst%3DE.%26aulast%3DLi%2BShen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DMehrotra%26aufirst%3DN.%26aulast%3DDorff%26aufirst%3DS.%26aulast%3DCharlab%26aufirst%3DR.%26aulast%3DKane%26aufirst%3DR.%2BC.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%253A%2520Belinostat%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520relapsed%2520or%2520refractory%2520peripheral%2520T-cell%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2666%26epage%3D2670%26doi%3D10.1158%2F1078-0432.CCR-14-3119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Veggel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamberg, P.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics and pharmacodynamics of panobinostat</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1007/s40262-017-0565-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1007%2Fs40262-017-0565-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=28667459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCrsrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=21-29&author=M.+Van%0AVeggelauthor=E.+Westermanauthor=P.+Hamberg&title=Clinical+pharmacokinetics+and+pharmacodynamics+of+panobinostat&doi=10.1007%2Fs40262-017-0565-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat</span></div><div class="casAuthors">Van Veggel, Mathilde; Westerman, Elsbeth; Hamberg, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-29</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors cause an increase in acetylation that leads to an increase in DNA transcription and accumulation of different proteins, reducing cell proliferation and inducing cell death.  Panobinostat is a first-in-line HDAC inhibitor approved for treating multiple myeloma in combination with bortezomib and dexamethasone.  It is a pan-deacetylase inhibitor and therefore inhibits not only HDAC but also other deacetylases.  The main mechanism of action of panobinostat is to inhibit HDAC, which causes cell cycle arrest and apoptosis, leading to it being an antineoplastic drug.  Pooled data of multiple-dose studies show that an oral dose of panobinostat 20 mg resulted in a max. plasma concn. (Cmax) of 21.6 ng/mL approx. 1 h after administration, while doses between 10 and 30 mg resulted in dose proportional plasma levels.  The abs. bioavailability of panobinostat is 21.4%, and it is moderately bound to plasma proteins.  Renal impairment does not influence the intrinsic pharmacokinetics of panobinostat, however hepatic impairment causes an increase in the plasma concns. of this drug.  Therefore, starting treatment at lower doses could be considered in patients with mild to moderate hepatic impairment.  Different ethnic backgrounds have an influence on the pharmacokinetics of panobinostat; however, due to major interindividual variability, no dose adjustment is recommended.  The area under the concn.-time curve of panobinostat changes significantly under cytochrome P 450 (CYP) 3A4 inhibitors, CYP3A4 and CYP2D6 inducers, and P-glycoprotein inhibitors.  Panobinostat itself is a CYP2D6 inhibitor, which influences the plasma levels of the CYP2D6 substrate dexamethasone.  The main side effects of panobinostat are diarrhea, peripheral neuropathy, asthenia and fatigue; hematol. side effects include neutropenia, thrombocytopenia, and lymphocytopenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-2XvQp0m2jLVg90H21EOLACvtfcHk0lguY_Ex57arnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCrsrnI&md5=1459e8401b5682d9ed56899da8f7b6db</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs40262-017-0565-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-017-0565-x%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BVeggel%26aufirst%3DM.%26aulast%3DWesterman%26aufirst%3DE.%26aulast%3DHamberg%26aufirst%3DP.%26atitle%3DClinical%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520panobinostat%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2018%26volume%3D57%26spage%3D21%26epage%3D29%26doi%3D10.1007%2Fs40262-017-0565-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span> <span> </span><span class="NLM_article-title">Selective histone deacetylase small molecule inhibitors: recent progress and perspectives</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">636</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1276565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1080%2F13543776.2017.1276565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=28033734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVym" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=621-636&author=H.+T.+Qinauthor=H.+Q.+Liauthor=F.+Liu&title=Selective+histone+deacetylase+small+molecule+inhibitors%3A+recent+progress+and+perspectives&doi=10.1080%2F13543776.2017.1276565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Selective histone deacetylase small molecule inhibitors: recent progress and perspectives</span></div><div class="casAuthors">Qin, Hai-Tao; Li, Huan-Qiu; Liu, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">621-636</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Since the first pan-HDAC inhibitor SAHA was approved by U.  S. FDA 10 years ago, HDACs including SIRT1-7 have received significant attention due to the fact that aberrant histone deacetylase activity has been implicated in a variety of human diseases, such as cancers, virus infection, and neurodegenerative diseases.  During the past years, a considerable achievement of development of isoform- or class-selective HDAC inhibitors has been made, yielding many drug candidates for further clin. studies, which represents a state-of-the-art technol. in the drug discovery arena.  This review covers new patents and articles about isoform- or class-selective HDAC inhibitors during the last four years, as well as the therapeutic potential of these compds.  HDACs represent one of the most promising therapeutic targets, particularly for tumor therapy though their roles in cancer are still blurry.  From 2012 to present, along with the advances of structural biol. and homol. models, lots of isoform- or class-selective HDAC inhibitors, such as hydroxamic acids and benzamides with various capping groups were found, providing a promising way to circumvent drug toxicity and side-effect issues, as well as providing chem. probes for further better understanding of the biol. process related to specific isoform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwnI5I_UhbmLVg90H21EOLACvtfcHk0lguY_Ex57arnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVym&md5=2984f0a32f64aa8d2a33174ed053da10</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1276565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1276565%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DH.%2BT.%26aulast%3DLi%26aufirst%3DH.%2BQ.%26aulast%3DLiu%26aufirst%3DF.%26atitle%3DSelective%2520histone%2520deacetylase%2520small%2520molecule%2520inhibitors%253A%2520recent%2520progress%2520and%2520perspectives%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D621%26epage%3D636%26doi%3D10.1080%2F13543776.2017.1276565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kollar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frecer, V.</span></span> <span> </span><span class="NLM_article-title">Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1472</span>– <span class="NLM_lpage">1502</span>, <span class="refDoi"> DOI: 10.2174/1381612820666141110164604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.2174%2F1381612820666141110164604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=25382430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslyhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1472-1502&author=J.+Kollarauthor=V.+Frecer&title=Selective+inhibitors+of+zinc-dependent+histone+deacetylases.+Therapeutic+targets+relevant+to+cancer&doi=10.2174%2F1381612820666141110164604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer</span></div><div class="casAuthors">Kollar, Jakub; Frecer, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1472-1502</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs), which act on acetylated histones and/or other non-histone protein substrates, represent validated epigenetic targets for the treatment of cancer and other human diseases.  The inhibition of HDAC activity was shown to induce cell cycle arrest, differentiation, apoptosis as well as a decrease in proliferation, angiogenesis, migration, and cell resistance to chemotherapy.  Targeting single HDAC isoforms with selective inhibitors will help to reveal the role of individual HDACs in cancer development or uncover further biol. consequences of protein acetylation.  This review focuses on conventional zinc-contg. HDACs.  In its first part, the biol. role of individual HDACs in various types of cancer is summarized.  In the second part, promising HDAC inhibitors showing activity both in enzymic and cell-based assays are surveyed with an emphasis on the inhibitors selective to the individual HDACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruWmnPURx9OrVg90H21EOLACvtfcHk0lguY_Ex57arnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslyhtL8%253D&md5=a9d5af3a36841338b76423db1c849468</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F1381612820666141110164604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612820666141110164604%26sid%3Dliteratum%253Aachs%26aulast%3DKollar%26aufirst%3DJ.%26aulast%3DFrecer%26aufirst%3DV.%26atitle%3DSelective%2520inhibitors%2520of%2520zinc-dependent%2520histone%2520deacetylases.%2520Therapeutic%2520targets%2520relevant%2520to%2520cancer%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2015%26volume%3D21%26spage%3D1472%26epage%3D1502%26doi%3D10.2174%2F1381612820666141110164604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishii, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhopadhyay, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soghomonyan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volgin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alauddin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelovani, J.</span></span> <span> </span><span class="NLM_article-title">Non-invasive imaging of histone deacetylase activity in human breast carcinoma xenografts in rats using positron emission tomography (PET) with [18F]-FAHA</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">34P</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=34P&author=R.+Nishiiauthor=U.+Mukhopadhyayauthor=H.+Yehauthor=S.+Soghomonyanauthor=A.+Volginauthor=M.+Alauddinauthor=W.+Tongauthor=J.+Gelovani&title=Non-invasive+imaging+of+histone+deacetylase+activity+in+human+breast+carcinoma+xenografts+in+rats+using+positron+emission+tomography+%28PET%29+with+%5B18F%5D-FAHA"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNishii%26aufirst%3DR.%26aulast%3DMukhopadhyay%26aufirst%3DU.%26aulast%3DYeh%26aufirst%3DH.%26aulast%3DSoghomonyan%26aufirst%3DS.%26aulast%3DVolgin%26aufirst%3DA.%26aulast%3DAlauddin%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DW.%26aulast%3DGelovani%26aufirst%3DJ.%26atitle%3DNon-invasive%2520imaging%2520of%2520histone%2520deacetylase%2520activity%2520in%2520human%2520breast%2520carcinoma%2520xenografts%2520in%2520rats%2520using%2520positron%2520emission%2520tomography%2520%2528PET%2529%2520with%2520%255B18F%255D-FAHA%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2007%26volume%3D48%26spage%3D34P" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelovani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R. S.</span></span> <span> </span><span class="NLM_article-title">A simplified kinetic model for rat glioma with [18F] FAHA</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1182</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=1182&author=J.+W.+Kuoauthor=K.+H.+Suauthor=C.+Y.+Wuauthor=C.+H.+Hoauthor=H.+E.+Wangauthor=J.+Gelovaniauthor=R.+S.+Liu&title=A+simplified+kinetic+model+for+rat+glioma+with+%5B18F%5D+FAHA"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKuo%26aufirst%3DJ.%2BW.%26aulast%3DSu%26aufirst%3DK.%2BH.%26aulast%3DWu%26aufirst%3DC.%2BY.%26aulast%3DHo%26aufirst%3DC.%2BH.%26aulast%3DWang%26aufirst%3DH.%2BE.%26aulast%3DGelovani%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DR.%2BS.%26atitle%3DA%2520simplified%2520kinetic%2520model%2520for%2520rat%2520glioma%2520with%2520%255B18F%255D%2520FAHA%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2011%26volume%3D52%26spage%3D1182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruvilla, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galitovskiy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grando, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, J.</span></span> <span> </span><span class="NLM_article-title">Targeting histone deacetylase in lung cancer for early diagnosis: (18)F-FAHA PET/CT imaging of NNK-treated A/J mice model</span>. <i>Am. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">332</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=24982818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1egtLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=324-332&author=W.+Tangauthor=S.+A.+Kuruvillaauthor=V.+Galitovskiyauthor=M.+L.+Panauthor=S.+A.+Grandoauthor=J.+Mukherjee&title=Targeting+histone+deacetylase+in+lung+cancer+for+early+diagnosis%3A+%2818%29F-FAHA+PET%2FCT+imaging+of+NNK-treated+A%2FJ+mice+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone deacetylase in lung cancer for early diagnosis: 18F-FAHA PET/CT imaging of NNK-treated A/J mice model</span></div><div class="casAuthors">Tang, Wayland; Kuruvilla, Sharon A.; Galitovskiy, Valentin; Pan, Min-Liang; Grando, Sergei A.; Mukherjee, Jogeshwar</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">324-332, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">AJNMAU</span>;
        ISSN:<span class="NLM_cas:issn">2160-8407</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Elevated levels of histone deacetylases (HDACs) have been indicated in the development of some cancers.  HDAC has been imaged using 18F-FAHA and may serve as a marker to study epigenetics.  We report evaluation of 18F-FAHA as a probe in the early diagnosis of lung cancer using 18F-FAHA PET/CT studies of A/J mice treated with NNK.  18F-FAHA radiosynthesis was carried out in specific activity of ∼2 Ci/μmol.  A/J mice were divided into 2 groups: 1. Controls; 2. NNK treatment group with NNK (100 mg/kg, i.p., weekly for 4 wks).  Mice were injected 100-200 μCi i.v. 18F-FAHA and then scanned in Inveon PET/CT under anesthesia using 2.0% isoflurane.  Midbrain, cerebellum and brainstem uptake of 18F-FAHA was displaced by the known HDAC inhibitor, suberanilohydroxamic acid (SAHA) with less than 10% activity remaining.  CT revealed presence of lung nodules in 8- to 10-mo old NNK mice while control mice were free of tumors.  Little uptake of 18F-FAHA was obsd. in the control mice lungs while significant 18F-FAHA uptake occurred in the lungs of NNK-treated mice with tumor/nontumor >2.0.  Ex vivo scans of the excised NNK and control mice lungs confirmed presence of extensive amts. of lung nodules seen by CT and confirmed by 18F-FAHA in the NNK mice with tumor/nontumor >6.0.  Our preliminary imaging studies with A/J mice lung cancer model suggest 18F-FAHA PET may allow the study of epigenetic mechanisms involved in NNK-induced tumorigenesis in the lungs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo82GHnkDkE37Vg90H21EOLACvtfcHk0lgH_CKQhBu2ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1egtLnM&md5=1753d4a4d07bd13b3971315af3f865cb</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DW.%26aulast%3DKuruvilla%26aufirst%3DS.%2BA.%26aulast%3DGalitovskiy%26aufirst%3DV.%26aulast%3DPan%26aufirst%3DM.%2BL.%26aulast%3DGrando%26aufirst%3DS.%2BA.%26aulast%3DMukherjee%26aufirst%3DJ.%26atitle%3DTargeting%2520histone%2520deacetylase%2520in%2520lung%2520cancer%2520for%2520early%2520diagnosis%253A%2520%252818%2529F-FAHA%2520PET%252FCT%2520imaging%2520of%2520NNK-treated%2520A%252FJ%2520mice%2520model%26jtitle%3DAm.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2014%26volume%3D4%26spage%3D324%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendricks, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keliher, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissleder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span> <span> </span><span class="NLM_article-title">In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5576</span>– <span class="NLM_lpage">5582</span>, <span class="refDoi"> DOI: 10.1021/jm200620f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200620f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptVSltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5576-5582&author=J.+A.+Hendricksauthor=E.+J.+Keliherauthor=B.+Marinelliauthor=T.+Reinerauthor=R.+Weisslederauthor=R.+Mazitschek&title=In+vivo+PET+imaging+of+histone+deacetylases+by+18F-suberoylanilide+hydroxamic+acid+%2818F-SAHA%29&doi=10.1021%2Fjm200620f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo PET Imaging of Histone Deacetylases by 18F-Suberoylanilide Hydroxamic Acid (18F-SAHA)</span></div><div class="casAuthors">Hendricks, J. Adam; Keliher, Edmund J.; Marinelli, Brett; Reiner, Thomas; Weissleder, Ralph; Mazitschek, Ralph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5576-5582</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are a group of enzymes that modulate gene expression and cell state by deacetylation of both histone and non-histone proteins.  A variety of HDAC inhibitors (HDACi) have already undergone clin. testing in cancer.  Real-time in vivo imaging of HDACs and their inhibition would be invaluable; however, the development of appropriate imaging agents has remained a major challenge.  Here, we describe the development and evaluation of 18F-suberoylanilide hydroxamic acid (18F-SAHA 1a), a close analog of the most clin. relevant HDAC inhibitor suberoylanilide hydroxamic acid (SAHA).  We demonstrate that 1a has near identical biochem. activity profiles to that of SAHA and report findings from pharmacokinetic studies.  Using a murine ovarian cancer model, we likewise show that HDAC inhibitor target binding efficacy can be quantitated within 24 h of administration.  1A thus represents the first 18F-positron emission tomog. (PET) HDAC imaging agent, which also exhibits low nanomolar potency and is pharmacol. analogous to a clin. relevant HDAC inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF0PVTT66Za7Vg90H21EOLACvtfcHk0lgH_CKQhBu2ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptVSltbc%253D&md5=7226170eed911cb862935a5377367e07</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm200620f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200620f%26sid%3Dliteratum%253Aachs%26aulast%3DHendricks%26aufirst%3DJ.%2BA.%26aulast%3DKeliher%26aufirst%3DE.%2BJ.%26aulast%3DMarinelli%26aufirst%3DB.%26aulast%3DReiner%26aufirst%3DT.%26aulast%3DWeissleder%26aufirst%3DR.%26aulast%3DMazitschek%26aufirst%3DR.%26atitle%3DIn%2520vivo%2520PET%2520imaging%2520of%2520histone%2520deacetylases%2520by%252018F-suberoylanilide%2520hydroxamic%2520acid%2520%252818F-SAHA%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5576%26epage%3D5582%26doi%3D10.1021%2Fjm200620f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Novel (64)Cu-labeled CUDC-101 for in vivo PET imaging of histone deacetylases</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">858</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1021/ml400191z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400191z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOltr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=858-862&author=Q.+Mengauthor=F.+Liauthor=S.+Jiangauthor=Z.+Li&title=Novel+%2864%29Cu-labeled+CUDC-101+for+in+vivo+PET+imaging+of+histone+deacetylases&doi=10.1021%2Fml400191z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 64Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases</span></div><div class="casAuthors">Meng, Qingqing; Li, Feng; Jiang, Sheng; Li, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">858-862</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the design, synthesis, and biol. evaluation of a 64Cu-labeled histone deacetylase (HDAC) imaging probe, which was obtained by introduction of metal chelator through click reaction of HDAC inhibitor CUDC-101 and then radiolabeled with 64Cu.  The resulting 64Cu-labeled compd. 7 ([64Cu]7) was identified as a positron emission tomog. (PET) imaging probe to noninvasively visualize HDAC expression in vivo.  Cell based competitive assay established the specific binding of [64Cu]7 to HDACs.  Biodistribution and small-animal microPET/CT studies further showed that [64Cu]7 had high tumor to background ratio in the MDA-MB-231 xenograft model, a triple-neg. breast cancer with high expression of HDACs.  To our knowledge, [64Cu]7 thus represents the first 64Cu-labeled PET HDAC imaging probe, which exhibits nanomolar range binding affinity and capability to imaging HDAC expression in triple-neg. breast cancer in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv0IUScAfOG7Vg90H21EOLACvtfcHk0lgduiP9Q60LwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOltr7M&md5=9d54dfd040f23252bb474047b97b542b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fml400191z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400191z%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DNovel%2520%252864%2529Cu-labeled%2520CUDC-101%2520for%2520in%2520vivo%2520PET%2520imaging%2520of%2520histone%2520deacetylases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D858%26epage%3D862%26doi%3D10.1021%2Fml400191z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">An HDAC-targeted imaging probe LBH589-Cy5.5 for tumor detection and therapy evaluation</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2469</span>– <span class="NLM_lpage">2476</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00167</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00167" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptlOhu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=2469-2476&author=Q.+Mengauthor=Z.+Liuauthor=F.+Liauthor=J.+Maauthor=H.+Wangauthor=Y.+Huanauthor=Z.+Li&title=An+HDAC-targeted+imaging+probe+LBH589-Cy5.5+for+tumor+detection+and+therapy+evaluation&doi=10.1021%2Facs.molpharmaceut.5b00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">An HDAC-Targeted Imaging Probe LBH589-Cy5.5 for Tumor Detection and Therapy Evaluation</span></div><div class="casAuthors">Meng, Qingqing; Liu, Zhiyi; Li, Feng; Ma, Jianjun; Wang, He; Huan, Yi; Li, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2469-2476</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are overexpressed in various cancers.  In vivo imaging to measure the expression and functions of HDACs in tumor plays an important role for tumor diagnosis and HDAC-targeted therapy evaluation.  The development of stable and highly sensitive HDAC targeting probe is highly desirable.  Near-IR (NIR) fluorescence optical imaging is a powerful technol. for visualizing disease at the mol. level in vivo with high sensitivity and no ionizing radiation.  We report here the design, synthesis, and bioactivity evaluation of LBH589-Cy5.5 for in vivo NIR fluorescence imaging of HDACs.  The IC50 value of the resulting NIR probe to HDACs was detd. to be 9.6 nM.  In vitro fluorescence microscopic studies using a triple-neg. breast cancer cell line, MDA-MB-231, established the binding specificity of LBH589-Cy5.5 to HDACs.  An in vivo imaging study performed in MDA-MB-231 tumor xenografts demonstrated accumulation of the probe in tumor with good contrast from 2 h to 48 h postinjection.  Furthermore, the fluorescent signal of LBH589-Cy5.5 in tumor was successfully blocked by coinjection of nonfluorescent LBH589 with the probe.  In a following therapy evaluation study, the administration of SAHA, a clin. used HDAC inhibitor, decreased LBH589-Cy5.5 accumulation in tumor, demonstrating the potential application of LBH589-Cy5.5 for evaluating therapeutic response of HDAC inhibitors in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ-peJSyPe8LVg90H21EOLACvtfcHk0lgduiP9Q60LwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptlOhu7c%253D&md5=e65d0ec36cad4b2302a288747aef110f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00167%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DAn%2520HDAC-targeted%2520imaging%2520probe%2520LBH589-Cy5.5%2520for%2520tumor%2520detection%2520and%2520therapy%2520evaluation%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D2469%26epage%3D2476%26doi%3D10.1021%2Facs.molpharmaceut.5b00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span> <span> </span><span class="NLM_article-title">Development of a novel histone deacetylase-targeted near-infrared probe for hepatocellular carcinoma imaging and fluorescence image-guided surgery</span>. <i>Mol. Imaging Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">476</span>– <span class="NLM_lpage">485</span>, <span class="refDoi"> DOI: 10.1007/s11307-019-01389-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1007%2Fs11307-019-01389-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=31228075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Kqt7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2020&pages=476-485&author=C.+Tangauthor=Y.+Duauthor=Q.+Liangauthor=Z.+Chengauthor=J.+Tian&title=Development+of+a+novel+histone+deacetylase-targeted+near-infrared+probe+for+hepatocellular+carcinoma+imaging+and+fluorescence+image-guided+surgery&doi=10.1007%2Fs11307-019-01389-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery</span></div><div class="casAuthors">Tang, Chu; Du, Yang; Liang, Qian; Cheng, Zhen; Tian, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Imaging and Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">476-485</span>CODEN:
                <span class="NLM_cas:coden">MIBOCZ</span>;
        ISSN:<span class="NLM_cas:issn">1860-2002</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Hepatocellular carcinoma (HCC) is a common cancer worldwide, and complete surgical resection of diseased tissue is a reliable strategy to cure cancer.  Fluorescence image-guided surgery is a promising tool for surgeons to identify and remove malignant lesions.  While non-targeted fluorescent dyes have been used for HCC diagnosis and resection, insufficient specificity and false pos. uptake from inflammatory tissue result in a high recurrence rate or excessive excision of healthy liver tissue.  To circumvent these problems, we focused on developing novel tumor-specific targeting probe to selectively illuminate cancer region during surgery.  Given overexpression of histone deacetylases (HDACs) in HCC and many other cancers, HDAC-targeted imaging has been emerged as a promising tool for tumor detection.  Procedures: Recently, high expression of HDACs, in particular HDAC6, has been obsd. in tumor samples of HCC patient, and a few HDAC inhibitors, including FDA-approved suberoylanilide hydroxamic acid (SAHA), display potent antitumor effect on HCC.  Correspondingly, in this study, we utilized a small mol. SAHA with the high HDAC-binding affinity as the HCC-specific targeting ligand to develop HDAC-targeted fluorescence probe for HCC detection and fluorescence image-guided resection.  Results: In in vitro imaging, SAHA was labeled with fluorescein isothiocyanate (FITC) to evaluate targeting property, and the imaging results demonstrated that FITC-SAHA was specific uptake by HCC Bel-7402 cells.  In in vivo imaging, near IR fluorescence dye IRDye800CW-labeled SAHA (NIR probe IRDye800CW-SAHA) showed rapid tumor accumulation with high tumor-to-background contrast on both the s.c. and orthotopic HCC mouse tumor models.  Furthermore, the orthotopic HCC was successfully resected by the IRDye800CW-SAHA fluorescence image-guided surgery.  Moreover, IRDye800CW-SAHA showed no toxicity toward healthy tissues.  Conclusions: Our results indicate that IRDye800CW-SAHA is a clin. translatable probe for HCC detection and resection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpxgoP3K9oWbVg90H21EOLACvtfcHk0lgduiP9Q60LwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Kqt7vI&md5=de9d96a637787deee821c607a7c5ae08</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs11307-019-01389-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11307-019-01389-4%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DQ.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DTian%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520a%2520novel%2520histone%2520deacetylase-targeted%2520near-infrared%2520probe%2520for%2520hepatocellular%2520carcinoma%2520imaging%2520and%2520fluorescence%2520image-guided%2520surgery%26jtitle%3DMol.%2520Imaging%2520Biol.%26date%3D2020%26volume%3D22%26spage%3D476%26epage%3D485%26doi%3D10.1007%2Fs11307-019-01389-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span> <span> </span><span class="NLM_article-title">Environment-sensitive fluorescent inhibitors of histone deacetylase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>, <span class="NLM_elocation-id">127128</span> <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1016%2Fj.bmcl.2020.127128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=32247729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsVSis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&author=X.+Zhouauthor=G.+Dongauthor=T.+Songauthor=G.+Wangauthor=Z.+Liauthor=X.+Qinauthor=L.+Duauthor=M.+Li&title=Environment-sensitive+fluorescent+inhibitors+of+histone+deacetylase&doi=10.1016%2Fj.bmcl.2020.127128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Environment-sensitive fluorescent inhibitors of histone deacetylase</span></div><div class="casAuthors">Zhou, Xin; Dong, Gaopan; Song, Tianjia; Wang, Guankai; Li, Zhenzhen; Qin, Xiaojun; Du, Lupei; Li, Minyong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">127128</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are proteases that can catalyze the deacetylation of histones to inhibit gene transcription.  Since mutations and/or aberrant expression of various HDACs are frequently assocd. with human diseases, particularly cancers, HDACs are important therapeutic targets for many human tumors.  However, there are still relatively few studies on HDAC small mol. fluorescent probes.  Herein, we designed and synthesized a class of environment-sensitive fluorescent inhibitors with a switch mechanism to study HDAC activity.  In vitro, the enzyme inhibition activity of compd. 6b was comparable to the pos. control drug SAHA, and it presented suitable imaging in living cells and tumor-tissue slices.  This environment-sensitive fluorescent inhibitor provides a new idea for the diagnosis and treatment of HDACs-related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKzIkMzw7F07Vg90H21EOLACvtfcHk0ljsqO7BXLkEKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsVSis7k%253D&md5=3b1de86b28f8bbdebf99a87ad0d5c101</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127128%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DQin%26aufirst%3DX.%26aulast%3DDu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DM.%26atitle%3DEnvironment-sensitive%2520fluorescent%2520inhibitors%2520of%2520histone%2520deacetylase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26doi%3D10.1016%2Fj.bmcl.2020.127128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raudszus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowotny, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertzen, C. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krizsan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gockel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohlke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thieme, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span> <span> </span><span class="NLM_article-title">Fluorescent analogs of peptoid-based HDAC inhibitors: Synthesis, biological activity and cellular uptake kinetics</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>, <span class="NLM_elocation-id">115039</span> <span class="refDoi"> DOI: 10.1016/j.bmc.2019.07.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1016%2Fj.bmc.2019.07.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=31420257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyltbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&author=R.+Raudszusauthor=R.+Nowotnyauthor=C.+G.+W.+Gertzenauthor=A.+Sch%C3%B6lerauthor=A.+Krizsanauthor=I.+Gockelauthor=H.+Kalwaauthor=H.+Gohlkeauthor=R.+Thiemeauthor=F.+K.+Hansen&title=Fluorescent+analogs+of+peptoid-based+HDAC+inhibitors%3A+Synthesis%2C+biological+activity+and+cellular+uptake+kinetics&doi=10.1016%2Fj.bmc.2019.07.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescent analogs of peptoid-based HDAC inhibitors: Synthesis, biological activity and cellular uptake kinetics</span></div><div class="casAuthors">Raudszus, Rick; Nowotny, Robert; Gertzen, Christoph G. W.; Schoeler, Andrea; Krizsan, Andor; Gockel, Ines; Kalwa, Hermann; Gohlke, Holger; Thieme, Rene; Hansen, Finn K.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">115039</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Fluorescent tagging of bioactive mols. is a powerful tool to study cellular uptake kinetics and is considered as an attractive alternative to radioligands.  In this study, we developed fluorescent histone deacetylase (HDAC) inhibitors and investigated their biol. activity and cellular uptake kinetics.  Our approach was to introduce a dansyl group as a fluorophore in the solvent-exposed cap region of the HDAC inhibitor pharmacophore model.  Three novel fluorescent HDAC inhibitors were synthesized utilizing efficient submonomer protocols followed by the introduction of a hydroxamic acid or 2-aminoanilide moiety as zinc-binding group.  All compds. were tested for their inhibition of selected HDAC isoforms, and docking studies were subsequently performed to rationalize the obsd. selectivity profiles.  All HDAC inhibitors were further screened in proliferation assays in the esophageal adenocarcinoma cell lines OE33 and OE19.  Compd. I, 6-((N-(2-(benzylamino)-2-oxoethyl)-5-(dimethylamino)naphthalene)-1-sulfonamido)-N-hydroxyhexanamide, displayed the highest HDAC inhibitory capacity as well as the strongest anti-proliferative activity.  Fluorescence microscopy studies revealed that compd. I showed the fastest uptake kinetic and reached the highest abs. fluorescence intensity of all compds.  Hence, the rapid and increased cellular uptake of I might contribute to its potent anti-proliferative properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqML3cNtCXbvrVg90H21EOLACvtfcHk0ljsqO7BXLkEKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyltbvJ&md5=7b944f5251e7e738edc203b33b2a9a2c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.07.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.07.055%26sid%3Dliteratum%253Aachs%26aulast%3DRaudszus%26aufirst%3DR.%26aulast%3DNowotny%26aufirst%3DR.%26aulast%3DGertzen%26aufirst%3DC.%2BG.%2BW.%26aulast%3DSch%25C3%25B6ler%26aufirst%3DA.%26aulast%3DKrizsan%26aufirst%3DA.%26aulast%3DGockel%26aufirst%3DI.%26aulast%3DKalwa%26aufirst%3DH.%26aulast%3DGohlke%26aufirst%3DH.%26aulast%3DThieme%26aufirst%3DR.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26atitle%3DFluorescent%2520analogs%2520of%2520peptoid-based%2520HDAC%2520inhibitors%253A%2520Synthesis%252C%2520biological%2520activity%2520and%2520cellular%2520uptake%2520kinetics%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26doi%3D10.1016%2Fj.bmc.2019.07.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wey, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span> <span> </span><span class="NLM_article-title">In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7999</span>– <span class="NLM_lpage">8009</span>, <span class="refDoi"> DOI: 10.1021/jm500872p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500872p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFWjsbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7999-8009&author=C.+Wangauthor=F.+A.+Schroederauthor=H.-Y.+Weyauthor=R.+Borraauthor=F.+F.+Wagnerauthor=S.+Reisauthor=S.+W.+Kimauthor=E.+B.+Holsonauthor=S.+J.+Haggartyauthor=J.+M.+Hooker&title=In+vivo+imaging+of+histone+deacetylases+%28HDACs%29+in+the+central+nervous+system+and+major+peripheral+organs&doi=10.1021%2Fjm500872p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs</span></div><div class="casAuthors">Wang, Changning; Schroeder, Frederick A.; Wey, Hsiao-Ying; Borra, Ronald; Wagner, Florence F.; Reis, Surya; Kim, Sung Won; Holson, Edward B.; Haggarty, Stephen J.; Hooker, Jacob M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7999-8009</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epigenetic enzymes are now targeted to treat the underlying gene expression dysregulation that contribute to disease pathogenesis.  Histone deacetylases (HDACs) have shown broad potential in treatments against cancer and emerging data supports their targeting in the context of cardiovascular disease and central nervous system dysfunction.  Development of a mol. agent for non-invasive imaging to elucidate the distribution and functional roles of HDACs in humans will accelerate medical research and drug discovery in this domain.  Herein, we describe the synthesis and validation of an HDAC imaging agent, [11C]6.  Our imaging results demonstrate that this probe has high specificity, good selectivity, and appropriate kinetics and distribution for imaging HDACs in the brain, heart, kidney, pancreas, and spleen.  Our findings support the translational potential for [11C]6 for human epigenetic imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoehb3pUmjZo7Vg90H21EOLACvtfcHk0ljsqO7BXLkEKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFWjsbrF&md5=18db553fdee12a680743b8b34e34e337</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm500872p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500872p%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSchroeder%26aufirst%3DF.%2BA.%26aulast%3DWey%26aufirst%3DH.-Y.%26aulast%3DBorra%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DReis%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26atitle%3DIn%2520vivo%2520imaging%2520of%2520histone%2520deacetylases%2520%2528HDACs%2529%2520in%2520the%2520central%2520nervous%2520system%2520and%2520major%2520peripheral%2520organs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7999%26epage%3D8009%26doi%3D10.1021%2Fjm500872p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strebl, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Placzek, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wey, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de
Bittner, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelamegam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span> <span> </span><span class="NLM_article-title">Development of a fluorinated class-I HDAC radiotracer reveals key chemical determinants of brain penetrance</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00297</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00297" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVWrt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=528-533&author=M.+G.+Streblauthor=C.+Wangauthor=F.+A.+Schroederauthor=M.+S.+Placzekauthor=H.-Y.+Weyauthor=G.+C.+Van+de%0ABittnerauthor=R.+Neelamegamauthor=J.+M.+Hooker&title=Development+of+a+fluorinated+class-I+HDAC+radiotracer+reveals+key+chemical+determinants+of+brain+penetrance&doi=10.1021%2Facschemneuro.5b00297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Fluorinated Class-I HDAC Radiotracer Reveals Key Chemical Determinants of Brain Penetrance</span></div><div class="casAuthors">Strebl, Martin G.; Wang, Changning; Schroeder, Frederick A.; Placzek, Michael S.; Wey, Hsiao-Ying; Van de Bittner, Genevieve C.; Neelamegam, Ramesh; Hooker, Jacob M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-533</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite major efforts, our knowledge about many brain diseases remains remarkably limited.  Epigenetic dysregulation has been one of the few leads toward identifying the causes and potential treatments of psychiatric disease over the past decade.  A new positron emission tomog. radiotracer, [11C]Martinostat, has enabled the study of histone deacetylase in living human subjects.  A unique property of [11C]Martinostat is its profound brain penetrance, a feature that is challenging to engineer intentionally.  In order to understand detg. factors for the high brain-uptake of Martinostat, a series of compds. was evaluated in rodents and nonhuman primates.  The study revealed the major structural contributors to brain uptake, as well as a more clin. relevant fluorinated HDAC radiotracer with comparable behavior to Martinostat, yet longer half-life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi_QJv9S699LVg90H21EOLACvtfcHk0lg3zX3MjuSV5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVWrt7rJ&md5=391511376aa9d1a2125dce1ac7a1a849</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00297%26sid%3Dliteratum%253Aachs%26aulast%3DStrebl%26aufirst%3DM.%2BG.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSchroeder%26aufirst%3DF.%2BA.%26aulast%3DPlaczek%26aufirst%3DM.%2BS.%26aulast%3DWey%26aufirst%3DH.-Y.%26aulast%3DVan%2Bde%2BBittner%26aufirst%3DG.%2BC.%26aulast%3DNeelamegam%26aufirst%3DR.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26atitle%3DDevelopment%2520of%2520a%2520fluorinated%2520class-I%2520HDAC%2520radiotracer%2520reveals%2520key%2520chemical%2520determinants%2520of%2520brain%2520penetrance%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D528%26epage%3D533%26doi%3D10.1021%2Facschemneuro.5b00297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strebl, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chindavong, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span> <span> </span><span class="NLM_article-title">HDAC6 brain mapping with [(18)F]bavarostat enabled by a Ru-mediated deoxyfluorination</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1006</span>– <span class="NLM_lpage">1014</span>, <span class="refDoi"> DOI: 10.1021/acscentsci.7b00274</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.7b00274" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVaqsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=1006-1014&author=M.+G.+Streblauthor=A.+J.+Campbellauthor=W.-N.+Zhaoauthor=F.+A.+Schroederauthor=M.+M.+Rileyauthor=P.+S.+Chindavongauthor=T.+M.+Morinauthor=S.+J.+Haggartyauthor=F.+F.+Wagnerauthor=T.+Ritterauthor=J.+M.+Hooker&title=HDAC6+brain+mapping+with+%5B%2818%29F%5Dbavarostat+enabled+by+a+Ru-mediated+deoxyfluorination&doi=10.1021%2Facscentsci.7b00274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 Brain Mapping with [18F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination</span></div><div class="casAuthors">Strebl, Martin G.; Campbell, Arthur J.; Zhao, Wen-Ning; Schroeder, Frederick A.; Riley, Misha M.; Chindavong, Peter S.; Morin, Thomas M.; Haggarty, Stephen J.; Wagner, Florence F.; Ritter, Tobias; Hooker, Jacob M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1006-1014</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) function and dysregulation have been implicated in the etiol. of certain cancers and more recently in central nervous system (CNS) disorders including Rett syndrome, Alzheimer's and Parkinson's diseases, and major depressive disorder.  HDAC6-selective inhibitors have therapeutic potential, but in the CNS drug space the development of highly brain penetrant HDAC inhibitors has been a persistent challenge.  Moreover, no tool exists to directly characterize HDAC6 and its related biol. in the living human brain.  Here, we report a highly brain penetrant HDAC6 inhibitor, Bavarostat, that exhibits excellent HDAC6 selectivity (>80-fold over all other Zn-contg. HDAC paralogues), modulates tubulin acetylation selectively over histone acetylation, and has excellent brain penetrance.  We further demonstrate that Bavarostat can be radiolabeled with 18F by deoxyfluorination through in situ formation of a ruthenium π-complex of the corresponding phenol precursor: the only method currently suitable for synthesis of [18F]Bavarostat.  Finally, by using [18F]Bavarostat in a series of rodent and nonhuman primate imaging expts., we demonstrate its utility for mapping HDAC6 in the living brain, which sets the stage for first-in-human neurochem. imaging of this important target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmXyZxgRQnAbVg90H21EOLACvtfcHk0lg3zX3MjuSV5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVaqsLjK&md5=269c6b99919bd156272afc8ad3502146</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.7b00274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.7b00274%26sid%3Dliteratum%253Aachs%26aulast%3DStrebl%26aufirst%3DM.%2BG.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DW.-N.%26aulast%3DSchroeder%26aufirst%3DF.%2BA.%26aulast%3DRiley%26aufirst%3DM.%2BM.%26aulast%3DChindavong%26aufirst%3DP.%2BS.%26aulast%3DMorin%26aufirst%3DT.%2BM.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DRitter%26aufirst%3DT.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26atitle%3DHDAC6%2520brain%2520mapping%2520with%2520%255B%252818%2529F%255Dbavarostat%2520enabled%2520by%2520a%2520Ru-mediated%2520deoxyfluorination%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2017%26volume%3D3%26spage%3D1006%26epage%3D1014%26doi%3D10.1021%2Facscentsci.7b00274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. H.</span></span> <span> </span><span class="NLM_article-title">Activatable fluorescence probe via self-immolative intramolecular cyclization for histone deacetylase imaging in live cells and tissues</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">5534</span>– <span class="NLM_lpage">5539</span>, <span class="refDoi"> DOI: 10.1021/acs.analchem.8b00709</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.analchem.8b00709" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVals7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2018&pages=5534-5539&author=X.+Liuauthor=M.+Xiangauthor=Z.+Tongauthor=F.+Luoauthor=W.+Chenauthor=F.+Liuauthor=F.+Wangauthor=R.+Q.+Yuauthor=J.+H.+Jiang&title=Activatable+fluorescence+probe+via+self-immolative+intramolecular+cyclization+for+histone+deacetylase+imaging+in+live+cells+and+tissues&doi=10.1021%2Facs.analchem.8b00709"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Activatable Fluorescence Probe via Self-Immolative Intramolecular Cyclization for Histone Deacetylase Imaging in Live Cells and Tissues</span></div><div class="casAuthors">Liu, Xianjun; Xiang, Meihao; Tong, Zongxuan; Luo, Fengyan; Chen, Wen; Liu, Feng; Wang, Fenglin; Yu, Ru-Qin; Jiang, Jian-Hui</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Chemistry (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5534-5539</span>CODEN:
                <span class="NLM_cas:coden">ANCHAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2700</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) play essential roles in transcription regulation and are valuable theranostic targets.  However, there are no activatable fluorescent probes for imaging of HDAC activity in live cells.  Here, the authors develop for the first time a novel activatable two-photon fluorescence probe that enables in situ imaging of HDAC activity in living cells and tissues.  The probe is designed by conjugating an acetyl-lysine mimic substrate to a masked aldehyde-contg. fluorophore via a cyanoester linker.  Upon deacetylation by HDAC, the probe undergoes a rapid self-immolative intramol. cyclization reaction, producing a cyanohydrin intermediate that is spontaneously rapidly decompd. into the highly fluorescent aldehyde-contg. two-photon fluorophore.  The probe is shown to exhibit high sensitivity, high specificity, and fast response for HDAC detection in vitro.  Imaging studies reveal that the probe is able to directly visualize and monitor HDAC activity in living cells.  Moreover, the probe is demonstrated to have the capability of two-photon imaging of HDAC activity in deep tissue slices up to 130 μm.  This activatable fluorescent probe affords a useful tool for evaluating HDAC activity and screening HDAC-targeting drugs in both live cell and tissue assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOWxYXI_ybmbVg90H21EOLACvtfcHk0lg3zX3MjuSV5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVals7Y%253D&md5=477d1e0c92d60364063300bbc848b1ea</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.analchem.8b00709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.analchem.8b00709%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DR.%2BQ.%26aulast%3DJiang%26aufirst%3DJ.%2BH.%26atitle%3DActivatable%2520fluorescence%2520probe%2520via%2520self-immolative%2520intramolecular%2520cyclization%2520for%2520histone%2520deacetylase%2520imaging%2520in%2520live%2520cells%2520and%2520tissues%26jtitle%3DAnal.%2520Chem.%26date%3D2018%26volume%3D90%26spage%3D5534%26epage%3D5539%26doi%3D10.1021%2Facs.analchem.8b00709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rooker, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buccella, D.</span></span> <span> </span><span class="NLM_article-title">Real-time detection of histone deacetylase activity with a small molecule fluorescent and spectrophotometric probe</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">6456</span>– <span class="NLM_lpage">6461</span>, <span class="refDoi"> DOI: 10.1039/C5SC02704G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1039%2FC5SC02704G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=30090264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KltrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6456-6461&author=D.+R.+Rookerauthor=D.+Buccella&title=Real-time+detection+of+histone+deacetylase+activity+with+a+small+molecule+fluorescent+and+spectrophotometric+probe&doi=10.1039%2FC5SC02704G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Real-time detection of histone deacetylase activity with a small molecule fluorescent and spectrophotometric probe</span></div><div class="casAuthors">Rooker, Debra R.; Buccella, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6456-6461</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are central players in transcription regulation and important targets in cancer treatment.  Activity assays are crit. tools for the study of the function and regulation of these enzymes, as well as for the screening of potential inhibitors.  We report a small-mol. probe for single-step, continuous detection of deacetylase activity based on an acetyl-lysine mimic functionalized with an amine-reactive fluorophore, designed to undergo rapid intramol. imine formation upon deacetylation.  The probe exhibits a bathochromic shift in the absorption spectrum and changes in fluorescence emission intensity that enable unprecedented real-time detection of HDAC activity of purified enzymes or in cell lyzates, and offers a means to evaluate HDAC inhibitors via simple spectrophotometric or fluorescence readings without the need of addnl. reagents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVPpn45jTFbrVg90H21EOLACvtfcHk0lg3zX3MjuSV5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KltrzP&md5=0da2de420ded32981463744d7aa6b0a5</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1039%2FC5SC02704G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5SC02704G%26sid%3Dliteratum%253Aachs%26aulast%3DRooker%26aufirst%3DD.%2BR.%26aulast%3DBuccella%26aufirst%3DD.%26atitle%3DReal-time%2520detection%2520of%2520histone%2520deacetylase%2520activity%2520with%2520a%2520small%2520molecule%2520fluorescent%2520and%2520spectrophotometric%2520probe%26jtitle%3DChem.%2520Sci.%26date%3D2015%26volume%3D6%26spage%3D6456%26epage%3D6461%26doi%3D10.1039%2FC5SC02704G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Fluorescent probes for single-step detection and proteomic profiling of histone deacetylases</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">15596</span>– <span class="NLM_lpage">15604</span>, <span class="refDoi"> DOI: 10.1021/jacs.6b07334</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.6b07334" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslygt73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=15596-15604&author=Y.+Xieauthor=J.+Geauthor=H.+Leiauthor=B.+Pengauthor=H.+Zhangauthor=D.+Wangauthor=S.+Panauthor=G.+Chenauthor=L.+Chenauthor=Y.+Wangauthor=Q.+Haoauthor=S.+Q.+Yaoauthor=H.+Sun&title=Fluorescent+probes+for+single-step+detection+and+proteomic+profiling+of+histone+deacetylases&doi=10.1021%2Fjacs.6b07334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescent Probes for Single-Step Detection and Proteomic Profiling of Histone Deacetylases</span></div><div class="casAuthors">Xie, Yusheng; Ge, Jingyan; Lei, Haipeng; Peng, Bo; Zhang, Huatang; Wang, Danyang; Pan, Sijun; Chen, Ganchao; Chen, Lanfang; Wang, Yi; Hao, Quan; Yao, Shao Q.; Sun, Hongyan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">15596-15604</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HDACs play important roles in regulating various physiol. and pathol. processes.  Developing fluorescent probes capable of detecting HDAC activity can help further elucidate the roles of HDACs in biol.  In this study, the authors first developed a set of activity-based fluorescent probes by incorporating Kac residue and O-NBD group.  Upon enzymic removal of the acetyl group in Kac residue, the released free amine reacted intramolecularly with the O-NBD moiety, resulting in turn-on of fluorescence.  These designed probes are capable of detecting HDAC activity in a continuous fashion, thereby eliminating the extra step of fluorescence development.  Remarkably, the amt. of turn-on fluorescence can be as high as 50-fold, which is superior to the existing one-step HDAC fluorescent probes.  Inhibition expts. further proved that the probes can serve as useful tools for screening HDAC inhibitors.  Building on these results, the authors moved on and designed a dual-purpose fluorescent probe by introducing a diazirine photo-crosslinker into the probe.  The resulting probe was not only capable of reporting enzymic activity, but also able to directly identify and capture the protein targets from complex cellular environment.  By combining fluorometric method and in-gel fluorescence scanning technique, the authors found that epigenetic readers and erasers can be readily identified and differentiated using a single probe.  This is not achievable with traditional photoaffinity probes.  In light of the prominent properties and the diverse functions of this newly developed probe, the authors envision that it can provide a robust tool for functional anal. of HDACs and facilitate future drug discovery in epigenetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7OzMsFAUigLVg90H21EOLACvtfcHk0lg0FgaWzRafFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslygt73K&md5=2b56fc33a5c83eff399a500d6f4ee24c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjacs.6b07334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.6b07334%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DY.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DLei%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DQ.%26aulast%3DYao%26aufirst%3DS.%2BQ.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DFluorescent%2520probes%2520for%2520single-step%2520detection%2520and%2520proteomic%2520profiling%2520of%2520histone%2520deacetylases%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2016%26volume%3D138%26spage%3D15596%26epage%3D15604%26doi%3D10.1021%2Fjacs.6b07334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, K.</span></span> <span> </span><span class="NLM_article-title">Development of a fluorogenic probe with a transesterification switch for detection of histone deacetylase activity</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">14310</span>– <span class="NLM_lpage">14313</span>, <span class="refDoi"> DOI: 10.1021/ja306045j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja306045j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1CisrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=14310-14313&author=R.+Babaauthor=Y.+Horiauthor=S.+Mizukamiauthor=K.+Kikuchi&title=Development+of+a+fluorogenic+probe+with+a+transesterification+switch+for+detection+of+histone+deacetylase+activity&doi=10.1021%2Fja306045j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Fluorogenic Probe with a Transesterification Switch for Detection of Histone Deacetylase Activity</span></div><div class="casAuthors">Baba, Reisuke; Hori, Yuichiro; Mizukami, Shin; Kikuchi, Kazuya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">14310-14313</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are key enzymic regulators of many cellular processes such as gene expression, cell cycle, and tumorigenesis.  These enzymes are attractive targets for drug development.  However, very few simple methods for monitoring HDAC activity have been reported.  Here, we have developed a fluorogenic probe, K4(Ac)-CCB, which consists of the histone H3 peptide contg. acetyl-Lys and a coumarin fluorophore with a carbonate ester.  By the simple addn. of the probe to a HDAC soln., enzyme activity was clearly detected through spontaneous intramol. transesterification, which renders the probe fluorescent.  In addn., K4(Ac)-CCB can be applied to the evaluation of HDAC inhibitor activity.  This is the first report to demonstrate the monitoring of HDAC activity by using a one-step procedure.  Thus, our novel fluorogenic probe will provide a powerful tool for epigenetic research and the discovery of HDAC-targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcvX_lNo7MQrVg90H21EOLACvtfcHk0lg0FgaWzRafFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1CisrbK&md5=c355835940280a678c38ae9e7e3b740c</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fja306045j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja306045j%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DR.%26aulast%3DHori%26aufirst%3DY.%26aulast%3DMizukami%26aufirst%3DS.%26aulast%3DKikuchi%26aufirst%3DK.%26atitle%3DDevelopment%2520of%2520a%2520fluorogenic%2520probe%2520with%2520a%2520transesterification%2520switch%2520for%2520detection%2520of%2520histone%2520deacetylase%2520activity%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D14310%26epage%3D14313%26doi%3D10.1021%2Fja306045j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, C.</span></span> <span> </span><span class="NLM_article-title">A review of NIR dyes in cancer targeting and imaging</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">7127</span>– <span class="NLM_lpage">7138</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2011.06.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1016%2Fj.biomaterials.2011.06.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=21724249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFWhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=7127-7138&author=S.+Luoauthor=E.+Zhangauthor=Y.+Suauthor=T.+Chengauthor=C.+Shi&title=A+review+of+NIR+dyes+in+cancer+targeting+and+imaging&doi=10.1016%2Fj.biomaterials.2011.06.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A review of NIR dyes in cancer targeting and imaging</span></div><div class="casAuthors">Luo, Shenglin; Zhang, Erlong; Su, Yongping; Cheng, Tianmin; Shi, Chunmeng</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">7127-7138</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of multifunctional agents for simultaneous tumor targeting and near IR (NIR) fluorescence imaging is expected to have significant impact on future personalized oncol. owing to the very low tissue autofluorescence and high tissue penetration depth in the NIR spectrum window.  Cancer NIR mol. imaging relies greatly on the development of stable, highly specific and sensitive mol. probes.  Org. dyes have shown promising clin. implications as non-targeting agents for optical imaging in which indocyanine green has long been implemented in clin. use.  Recently, significant progress has been made on the development of unique NIR dyes with tumor targeting properties.  Current ongoing design strategies have overcome some of the limitations of conventional NIR org. dyes, such as poor hydrophilicity and photostability, low quantum yield, insufficient stability in biol. system, low detection sensitivity, etc.  This potential is further realized with the use of these NIR dyes or NIR dye-encapsulated nanoparticles by conjugation with tumor specific ligands (such as small mols., peptides, proteins and antibodies) for tumor targeted imaging.  Very recently, natively multifunctional NIR dyes that can preferentially accumulate in tumor cells without the need of chem. conjugation to tumor targeting ligands have been developed and these dyes have shown unique optical and pharmaceutical properties for biomedical imaging with superior signal-to-background contrast index.  The main focus of this article is to provide a concise overview of newly developed NIR dyes and their potential applications in cancer targeting and imaging.  The development of future multifunctional agents by combining targeting, imaging and even therapeutic routes will also be discussed.  We believe these newly developed multifunctional NIR dyes will broaden current concept of tumor targeted imaging and hold promise to make an important contribution to the diagnosis and therapeutics for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJJQph7DjLr7Vg90H21EOLACvtfcHk0lg0FgaWzRafFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFWhtbs%253D&md5=733be27dd9858f9a6ca73f70fabd77c1</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2011.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2011.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DC.%26atitle%3DA%2520review%2520of%2520NIR%2520dyes%2520in%2520cancer%2520targeting%2520and%2520imaging%26jtitle%3DBiomaterials%26date%3D2011%26volume%3D32%26spage%3D7127%26epage%3D7138%26doi%3D10.1016%2Fj.biomaterials.2011.06.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luker, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luker, K. E.</span></span> <span> </span><span class="NLM_article-title">Optical imaging: current applications and future directions. Journal of nuclear medicine: official publication</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.2967/jnumed.107.045799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.2967%2Fjnumed.107.045799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=18077528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FgtFansw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=1-4&author=G.+D.+Lukerauthor=K.+E.+Luker&title=Optical+imaging%3A+current+applications+and+future+directions.+Journal+of+nuclear+medicine%3A+official+publication&doi=10.2967%2Fjnumed.107.045799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Optical imaging: current applications and future directions</span></div><div class="casAuthors">Luker Gary D; Luker Kathryn E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-4</span>
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    </div><div class="casAbstract">Optical techniques, such as bioluminescence and fluorescence, are emerging as powerful new modalities for molecular imaging in disease and therapy.  Combining innovative molecular biology and chemistry, researchers have developed optical methods for imaging a variety of cellular and molecular processes in vivo, including protein interactions, protein degradation, and protease activity.  Whereas optical imaging has been used primarily for research in small-animal models, there are several areas in which optical molecular imaging will translate to clinical medicine.  In this review, we summarize recent advances in optical techniques for molecular imaging and the potential impact for clinical medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRB-hcTAkUpcY3yKPtYViAGfW6udTcc2eY4QkXNeZOUfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FgtFansw%253D%253D&md5=2d3a834b25e8a7e27e9e22fe83d5e7c5</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.107.045799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.107.045799%26sid%3Dliteratum%253Aachs%26aulast%3DLuker%26aufirst%3DG.%2BD.%26aulast%3DLuker%26aufirst%3DK.%2BE.%26atitle%3DOptical%2520imaging%253A%2520current%2520applications%2520and%2520future%2520directions.%2520Journal%2520of%2520nuclear%2520medicine%253A%2520official%2520publication%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2008%26volume%3D49%26spage%3D1%26epage%3D4%26doi%3D10.2967%2Fjnumed.107.045799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hilderbrand, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissleder, R.</span></span> <span> </span><span class="NLM_article-title">Near-infrared fluorescence: application to in vivo molecular imaging</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2009.09.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1016%2Fj.cbpa.2009.09.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=19879798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12qtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=71-79&author=S.+A.+Hilderbrandauthor=R.+Weissleder&title=Near-infrared+fluorescence%3A+application+to+in+vivo+molecular+imaging&doi=10.1016%2Fj.cbpa.2009.09.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Near-infrared fluorescence: application to in vivo molecular imaging</span></div><div class="casAuthors">Hilderbrand, Scott A.; Weissleder, Ralph</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-79</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Mol. imaging often relies on the use of targeted and activatable reporters to quantitate and visualize targets, biol. processes, and cells in vivo.  The use of optical probes with near-IR fluorescence allows for improved photon penetration through tissue and minimizes the effects of tissue autofluorescence.  There are several parameters that define the effectiveness of imaging agents in vivo.  These factors include probe targeting, activation, pharmacokinetics, biocompatibility, and photophysics.  Recent advances in our understanding of these variables as they pertain to the application of optical reporters for in vivo imaging are discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0P_3P78Hzk7Vg90H21EOLACvtfcHk0ljruzqWGdeoHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12qtLw%253D&md5=cddcdb0a8da0e53181146c49ebda16db</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2009.09.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2009.09.029%26sid%3Dliteratum%253Aachs%26aulast%3DHilderbrand%26aufirst%3DS.%2BA.%26aulast%3DWeissleder%26aufirst%3DR.%26atitle%3DNear-infrared%2520fluorescence%253A%2520application%2520to%2520in%2520vivo%2520molecular%2520imaging%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D71%26epage%3D79%26doi%3D10.1016%2Fj.cbpa.2009.09.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel class I histone deacetylase inhibitors with promising in vitro and in vivo antitumor activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7672</span>– <span class="NLM_lpage">7680</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01044</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01044" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCgurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7672-7680&author=Y.+Yaoauthor=Z.+Tuauthor=C.+Liaoauthor=Z.+Wangauthor=S.+Liauthor=H.+Yaoauthor=Z.+Liauthor=S.+Jiang&title=Discovery+of+novel+class+I+histone+deacetylase+inhibitors+with+promising+in+vitro+and+in+vivo+antitumor+activities&doi=10.1021%2Facs.jmedchem.5b01044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities</span></div><div class="casAuthors">Yao, Yiwu; Tu, Zhengchao; Liao, Chenzhong; Wang, Zhen; Li, Shang; Yao, Hequan; Li, Zheng; Jiang, Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7672-7680</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A successful structure-based design of novel cyclic depsipeptides that selectively target class I HDAC isoforms is described.  Compd. I [R = H] an IC50 of 2.78 nM for binding to the HDAC1 protein, and the prodrugs I [R = Me(CH2)6C(O)] and I [R = MeC(O)] also exhibit promising antiproliferative activities in the nanomolar range against various cancer cell lines.  Compds. I [R = Me(CH2)6C(O)] and I [R = MeC(O)] show more than 20-fold selectivity toward human cancer cells over human normal cells in comparison with romidepsin (FK228), demonstrating low probability of toxic side effects.  In addn., compd. I [R = MeC(O)] exhibits excellent in vivo anticancer activities in a human prostate carcinoma (Du145) xenograft model with no obsd. toxicity.  Thus, prodrug I [R = MeC(O)] has therapeutic potential as a new class of anticancer agent for further clin. translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaKRpLDZwVPrVg90H21EOLACvtfcHk0ljruzqWGdeoHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCgurnI&md5=3069fbc43dc2cc5ead040bad2021cae3</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01044%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520novel%2520class%2520I%2520histone%2520deacetylase%2520inhibitors%2520with%2520promising%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7672%26epage%3D7680%26doi%3D10.1021%2Facs.jmedchem.5b01044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.4155/fmc-2019-0290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.4155%2Ffmc-2019-0290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=31782319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsVOgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=311-323&author=K.+Zhangauthor=Y.+Yaoauthor=Z.+Tuauthor=C.+Liaoauthor=Z.+Wangauthor=Y.+Qiuauthor=D.+Chenauthor=D.+J.+Hamiltonauthor=Z.+Liauthor=S.+Jiang&title=Discovery+of+class+I+histone+deacetylase+inhibitors+based+on+romidpesin+with+promising+selectivity+for+cancer+cells&doi=10.4155%2Ffmc-2019-0290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells</span></div><div class="casAuthors">Zhang, Kuojun; Yao, Yiwu; Tu, Zhengchao; Liao, Chenzhong; Wang, Zhen; Qiu, Yatao; Chen, Dong; Hamilton, Dale J.; Li, Zheng; Jiang, Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-323</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Aim: Class I histone deacetylases (HDACs) are considered to be promising anticancer targets, but selective inhibition of class I HDAC isoforms remains a challenge.  Methods & results: Previously, we obtained a selective class I HDAC inhibitor 9 based on a macrocyclic HDAC inhibitor Romidpesin.  As our continuous efforts, a library of novel cyclicdepsipeptides based on 9 was established using a convergent synthesis strategy.  The most active compds. 10, 16 and 19 selectively inhibit class I HDACs and exhibit promising nanomolar antiproliferative activities against several cancer cell lines with excellent selectivity toward cancer cells over normal cells.  Besides, compd. 10 demonstrates excellent antitumor effects in human prostate carcinoma PC3 xenograft models with no obsd. toxicity.  Conclusion: These cyclicdepsipeptides show great therapeutic potential as novel anticancer agents for clin. translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaIqsiQZpfsbVg90H21EOLACvtfcHk0li89HvkgSyzaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsVOgsb0%253D&md5=750a2e0bd4bae72953d823f1a6730b4c</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2019-0290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2019-0290%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHamilton%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520class%2520I%2520histone%2520deacetylase%2520inhibitors%2520based%2520on%2520romidpesin%2520with%2520promising%2520selectivity%2520for%2520cancer%2520cells%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2020%26volume%3D12%26spage%3D311%26epage%3D323%26doi%3D10.4155%2Ffmc-2019-0290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Estrela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obrador, E.</span></span> <span> </span><span class="NLM_article-title">Glutathione in cancer biology and therapy</span>. <i>Crit. Rev. Clin. Lab. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1080/10408360500523878</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1080%2F10408360500523878" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=16517421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFCkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2006&pages=143-181&author=J.+M.+Estrelaauthor=A.+Ortegaauthor=E.+Obrador&title=Glutathione+in+cancer+biology+and+therapy&doi=10.1080%2F10408360500523878"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Glutathione in Cancer Biology and Therapy</span></div><div class="casAuthors">Estrela, Jose; Ortega, Angel; Obrador, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Clinical Laboratory Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-181</span>CODEN:
                <span class="NLM_cas:coden">CRCLBH</span>;
        ISSN:<span class="NLM_cas:issn">1040-8363</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  The glutathione (GSH) content of cancer cells is particularly relevant in regulating mutagenic mechanisms, DNA synthesis, growth, and multidrug and radiation resistance.  In malignant tumors, as compared with normal tissues, that resistance assocs. in most cases with higher GSH levels within these cancer cells.  Thus, approaches to cancer treatment based on modulation of GSH should control possible growth-assocd. changes in GSH content and synthesis in these cells.  Despite the potential benefits for cancer therapy of a selective GSH-depleting strategy, such a methodol. has remained elusive up to now.Metastatic spread, not primary tumor burden, is the leading cause of cancer death.  For patient prognosis to improve, new systemic therapies capable of effectively inhibiting the outgrowth of seeded tumor cells are needed.  Interaction of metastatic cells with the vascular endothelium activates local release of proinflammatory cytokines, which act as signals promoting cancer cell adhesion, extravasation, and proliferation.  Recent work shows that a high percentage of metastatic cells with high GSH levels survive the combined nitrosative and oxidative stresses elicited by the vascular endothelium and possibly by macrophages and granulocytes. -Glutamyl transpeptidase overexpression and an inter-organ flow of GSH (where the liver plays a central role), by increasing cysteine availability for tumor GSH synthesis, function in combination as a metastatic-growth promoting mechanism.  The present review focuses on an anal. of links among GSH, adaptive responses to stress, mol. mechanisms of invasive cancer cell survival and death, and sensitization of metastatic cells to therapy.  Exptl. evidence shows that acceleration of GSH efflux facilitates selective GSH depletion in metastatic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPRmAf3JYiLbVg90H21EOLACvtfcHk0li89HvkgSyzaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFCkurg%253D&md5=dbc8ffc50e29bf01e69ebd643dca0f11</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1080%2F10408360500523878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10408360500523878%26sid%3Dliteratum%253Aachs%26aulast%3DEstrela%26aufirst%3DJ.%2BM.%26aulast%3DOrtega%26aufirst%3DA.%26aulast%3DObrador%26aufirst%3DE.%26atitle%3DGlutathione%2520in%2520cancer%2520biology%2520and%2520therapy%26jtitle%3DCrit.%2520Rev.%2520Clin.%2520Lab.%2520Sci.%26date%3D2006%26volume%3D43%26spage%3D143%26epage%3D181%26doi%3D10.1080%2F10408360500523878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiseman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creighton, D. J.</span></span> <span> </span><span class="NLM_article-title">N-(2-hydroxypropyl)methacrylamide copolymers of a glutathione (GSH)-activated glyoxalase I inhibitor and DNA alkylating agent: Synthesis, reaction kinetics with GSH, and in vitro antitumor activities</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.1021/bc0499634</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc0499634" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlWksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=598-607&author=Z.-B.+Zhengauthor=G.+Zhuauthor=H.+Takauthor=E.+Josephauthor=J.+L.+Eisemanauthor=D.+J.+Creighton&title=N-%282-hydroxypropyl%29methacrylamide+copolymers+of+a+glutathione+%28GSH%29-activated+glyoxalase+I+inhibitor+and+DNA+alkylating+agent%3A+Synthesis%2C+reaction+kinetics+with+GSH%2C+and+in+vitro+antitumor+activities&doi=10.1021%2Fbc0499634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">N-(2-Hydroxypropyl)methacrylamide copolymers of a glutathione (GSH)-activated glyoxalase I inhibitor and DNA alkylating agent: synthesis, reaction kinetics with GSH, and in vitro antitumor activities</span></div><div class="casAuthors">Zheng, Zhe-Bin; Zhu, Guozhang; Tak, Heekyung; Joseph, Erin; Eiseman, Julie L.; Creighton, Donald J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">598-607</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The incorporation of anticancer prodrugs into polyacrylamide conjugates has been shown to improve tumor targeting via the so-called "enhanced permeability and retention" effect.  This strategy has now been expanded to include two different classes of glutathione (GSH)-activated antitumor agents prepd. by radical polymn. of N-(2-hydroxypropyl)methacrylamide (HPMA) with 2-methacryloyloxy-methyl-2-cyclohexenone (7) and/or with S-(N-4-chlorophenyl-N-hydroxycarbamoyl-thioethyl)methacrylamide (8), followed by treatment with 3-chloroperoxybenzoic acid, to give the HPMA copolymers of 7 and the 8-sulfoxide, resp.  In aq.-buffered soln. at pH 6.5, GSH reacts rapidly with poly-HPMA-8-sulfoxide (k ≈ 2.3 mM-1 min-1) to give S-(N-4-chlorophenyl-N-hydroxycarbamoyl)glutathione (1), a tight-binding transition state analog inhibitor of the antitumor target enzyme glyoxalase I (Ki = 46 nM), or with poly-HPMA-7 (k ≈ 0.02 mM-1 min-1) to give the electrophilic antitumor agent 3-glutathio-2-methylenecyclohexenone (4).  Indeed, B16 melanotic melanoma in culture is inhibited by poly-HPMA-8-sulfoxide and by poly-HPMA-7 with IC50 values of 168 ± 8 and 284 ± 5 μM, resp.  These values are significantly greater than those of the unpolymd. prodrugs suggesting that the cytotoxicity of the polymer prodrugs might be limited by slow cellular uptake via pinocytosis.  This prodrug strategy should be applicable to a range of different GSH-based antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovRm2e-n7wtrVg90H21EOLACvtfcHk0li89HvkgSyzaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlWksbs%253D&md5=3c1884e0169065a83217df1fe000c727</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fbc0499634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0499634%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DZ.-B.%26aulast%3DZhu%26aufirst%3DG.%26aulast%3DTak%26aufirst%3DH.%26aulast%3DJoseph%26aufirst%3DE.%26aulast%3DEiseman%26aufirst%3DJ.%2BL.%26aulast%3DCreighton%26aufirst%3DD.%2BJ.%26atitle%3DN-%25282-hydroxypropyl%2529methacrylamide%2520copolymers%2520of%2520a%2520glutathione%2520%2528GSH%2529-activated%2520glyoxalase%2520I%2520inhibitor%2520and%2520DNA%2520alkylating%2520agent%253A%2520Synthesis%252C%2520reaction%2520kinetics%2520with%2520GSH%252C%2520and%2520in%2520vitro%2520antitumor%2520activities%26jtitle%3DBioconjugate%2520Chem.%26date%3D2005%26volume%3D16%26spage%3D598%26epage%3D607%26doi%3D10.1021%2Fbc0499634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Millard, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celardo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordiyenko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwabe, J. W.</span></span> <span> </span><span class="NLM_article-title">Class I HDACs share a common mechanism of regulation by inositol phosphates</span>. <i>Mol. Cell.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2013.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1016%2Fj.molcel.2013.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=23791785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVygu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2013&pages=57-67&author=C.+J.+Millardauthor=P.+J.+Watsonauthor=I.+Celardoauthor=Y.+Gordiyenkoauthor=S.+M.+Cowleyauthor=C.+V.+Robinsonauthor=L.+Fairallauthor=J.+W.+Schwabe&title=Class+I+HDACs+share+a+common+mechanism+of+regulation+by+inositol+phosphates&doi=10.1016%2Fj.molcel.2013.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates</span></div><div class="casAuthors">Millard, Christopher J.; Watson, Peter J.; Celardo, Ivana; Gordiyenko, Yuliya; Cowley, Shaun M.; Robinson, Carol V.; Fairall, Louise; Schwabe, John W. R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-67</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Class I histone deacetylases (HDAC1, HDAC2, and HDAC3) are recruited by cognate corepressor proteins into specific transcriptional repression complexes that target HDAC activity to chromatin resulting in chromatin condensation and transcriptional silencing.  The authors previously reported the structure of HDAC3 in complex with the SMRT corepressor.  This structure revealed inositol-tetraphosphate [Ins(1,4,5,6)P4] at the interface of the two proteins.  It was previously unclear whether the role of Ins(1,4,5,6)P4 is to act as a structural cofactor or a regulator of HDAC3 activity.  Here the authors report the structure of HDAC1 in complex with MTA1 from the NuRD complex.  The ELM2-SANT domains from MTA1 wrap completely around HDAC1 occupying both sides of the active site such that the adjacent BAH domain is ideally positioned to recruit nucleosomes to the active site of the enzyme.  Functional assays of both the HDAC1 and HDAC3 complexes reveal that Ins(1,4,5,6)P4 is a bona fide conserved regulator of class I HDAC complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYPhL0103LkLVg90H21EOLACvtfcHk0li89HvkgSyzaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVygu74%253D&md5=05a4267bf965b5a6217873217044ef2a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2013.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2013.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DMillard%26aufirst%3DC.%2BJ.%26aulast%3DWatson%26aufirst%3DP.%2BJ.%26aulast%3DCelardo%26aufirst%3DI.%26aulast%3DGordiyenko%26aufirst%3DY.%26aulast%3DCowley%26aufirst%3DS.%2BM.%26aulast%3DRobinson%26aufirst%3DC.%2BV.%26aulast%3DFairall%26aufirst%3DL.%26aulast%3DSchwabe%26aufirst%3DJ.%2BW.%26atitle%3DClass%2520I%2520HDACs%2520share%2520a%2520common%2520mechanism%2520of%2520regulation%2520by%2520inositol%2520phosphates%26jtitle%3DMol.%2520Cell.%26date%3D2013%26volume%3D51%26spage%3D57%26epage%3D67%26doi%3D10.1016%2Fj.molcel.2013.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wegener, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirsching, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riester, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwienhorst, A.</span></span> <span> </span><span class="NLM_article-title">A fluorogenic histone deacetylase assay well suited for high-throughput activity screening</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/S1074-5521(02)00305-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1016%2FS1074-5521%2802%2900305-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=12573699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1Skuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=61-68&author=D.+Wegenerauthor=F.+Wirschingauthor=D.+Riesterauthor=A.+Schwienhorst&title=A+fluorogenic+histone+deacetylase+assay+well+suited+for+high-throughput+activity+screening&doi=10.1016%2FS1074-5521%2802%2900305-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A Fluorogenic Histone Deacetylase Assay Well Suited for High-Throughput Activity Screening</span></div><div class="casAuthors">Wegener, Dennis; Wirsching, Frank; Riester, Daniel; Schwienhorst, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-68</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are important enzymes for the transcriptional regulation of gene expression in eukaryotic cells.  Recent findings suggest that HDACs could be key targets for chemotherapeutic intervention in malignant diseases.  A convenient and sensitive fluorogenic assay for HDAC activity would therefore expedite studies of HDAC in transcriptional regulation and in vitro screening for drug discovery.  In this study, novel fluorogenic substrates of HDACs were synthesized with an ε-acetylated lysyl moiety and an adjacent MCA moiety at the C terminus of the peptide chain.  Upon deacetylation of the acetylated lysyl moiety, mols. became substrates for trypsin, which released highly fluorescent AMC mols. in a subsequent step of the assay.  The fluorescence increased in direct proportion to the amt. of deacetylated substrate mols., i.e., HDAC activity.  The nonisotopic, homogeneous assay is well suited for high-throughput HDAC inhibitor screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5ogyqEBSC3bVg90H21EOLACvtfcHk0lic2Ans6YGUTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1Skuw%253D%253D&md5=eea350d8066f6ebd773ba50cc0211fdc</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2802%2900305-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252802%252900305-8%26sid%3Dliteratum%253Aachs%26aulast%3DWegener%26aufirst%3DD.%26aulast%3DWirsching%26aufirst%3DF.%26aulast%3DRiester%26aufirst%3DD.%26aulast%3DSchwienhorst%26aufirst%3DA.%26atitle%3DA%2520fluorogenic%2520histone%2520deacetylase%2520assay%2520well%2520suited%2520for%2520high-throughput%2520activity%2520screening%26jtitle%3DChem.%2520Biol.%26date%3D2003%26volume%3D10%26spage%3D61%26epage%3D68%26doi%3D10.1016%2FS1074-5521%2802%2900305-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foulkes, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span> <span> </span><span class="NLM_article-title">Triple-negative breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1938</span>– <span class="NLM_lpage">1948</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1001389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=10.1056%2FNEJMra1001389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=21067385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1938-1948&author=W.+D.+Foulkesauthor=I.+E.+Smithauthor=J.+S.+Reis-Filho&title=Triple-negative+breast+cancer&doi=10.1056%2FNEJMra1001389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer</span></div><div class="casAuthors">Foulkes, William D.; Smith, Ian E.; Reis-Filho, Jorge S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1938-1948</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiN8P8IsovvLVg90H21EOLACvtfcHk0lic2Ans6YGUTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P&md5=641fe4726e6a7118208aa6b3502c9df6</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1001389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1001389%26sid%3Dliteratum%253Aachs%26aulast%3DFoulkes%26aufirst%3DW.%2BD.%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26atitle%3DTriple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1938%26epage%3D1948%26doi%3D10.1056%2FNEJMra1001389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX','PDB','4BKX'); return false;">PDB: 4BKX</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i31"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02161">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_70748"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02161?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02161</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Chemistry and general methods; molecular modeling; HDAC inhibition assay by cyclic depsipeptides and <b>20</b>-Cy5.5; cell culture and antiproliferation assay; breast tumor xenograft and metastatic tumor model; <i>in vitro</i> fluorescence microscopic studies; <i>in vivo</i> and <i>ex vivo</i> optical imaging studies; immunohistochemistry; therapeutic evaluation study; and statistical analysis (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES formula of each tested compound and associated biochemical data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_002.csv">CSV</a>)</p></li><li><p class="inline">Compound 9 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Compound 10 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_004.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_001.pdf">jm0c02161_si_001.pdf (1.49 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_002.csv">jm0c02161_si_002.csv (0.7 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_003.pdb">jm0c02161_si_003.pdb (300.35 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02161/suppl_file/jm0c02161_si_004.pdb">jm0c02161_si_004.pdb (300.96 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02161&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-7%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02161%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02161" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67993b4dbe803cd0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
